https://www.globalkeysolutions.net/guidances/guidance-document/enforcement-priorities-for-certain-new-tobacco-products-marketed-without-premarket-authorization/8bcee99f-15bd-43bf-8746-6e6b337f5f7f 2026-05-09 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submitting-continuous-glucose-monitoring-data-in-clinical-trials/242cfeef-dde5-46f4-b50e-9669a5a75ca9 2026-05-08 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/chemistry-manufacturing-and-controls-flexibilities-for-developing-human-cellular-and-gene-therapy-products-for-a-biologics-license-application-guidance-for-industry/739ce951-2fb3-460d-bd26-98a07366db2f 2026-05-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/patient-matched-guides-for-orthopedic-implants-guidance-for-industry-and-food-and-drug-administration-staff/0052bfd6-8461-4a65-a86d-56b6854ca2bb 2026-05-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-91-vich-gl8-r-stability-testing-for-medicated-premixes-revision-1/23e6f924-de6b-4a2f-ab5c-b521774c8019 2026-04-22 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/establishing-impurity-specifications-for-antibiotics/5bb8badb-7c32-4b76-bfc9-bbb8ab55fb84 2026-04-18 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compliance-policy-regarding-premarket-and-other-requirements-for-certain-niosh-approved-air-purifying-respirators-draft-guidance-for-industry-and-food-and-drug-administration-staff/ba466fc0-9ec7-4c32-99f4-b6be8590e563 2026-04-18 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/safety-assessment-of-genome-editing-in-human-gene-therapy-products-using-next-generation-sequencing/8bd86906-9b70-4e40-ae4a-dde0c1ea99ca 2026-04-16 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bioanalytical-method-validation-for-biomarkers/dc48cea7-abd8-44db-a6fc-14b002aa59d7 2026-04-13 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/general-considerations-for-the-use-of-new-approach-methodologies-in-drug-development-draft-guidance-for-industry/090afb3a-8fce-4ac8-ac78-d208784d28ff 2026-03-19 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-devices-with-indications-associated-with-weight-loss-premarket-considerations-guidance-for-industry-and-food-and-drug-administration-staff/d5bab21e-d4b6-46f1-903b-5ef02810d145 2026-03-14 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/flavored-electronic-nicotine-delivery-systems-ends-premarket-applications-considerations-related-to-youth-risk-draft-guidance-for-industry/f43a2ce9-fe51-4df1-ae2a-72455eb9d25d 2026-03-11 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/responding-to-fda-form-483-observations-at-the-conclusion-of-a-drug-cgmp-inspection/616a1c25-5ddb-4458-88d6-d59f11231a76 2026-03-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/new-clinical-investigation-exclusivity-3-year-exclusivity-for-drug-products-questions-and-answers/19bf8380-085c-46d8-a480-d28b1c37d3de 2026-03-04 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/certification-process-for-designated-medical-gases-draft-guidance-for-industry/7af49ba2-f413-448e-a92a-863f161df336 2026-02-25 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/questions-and-answers-regarding-mandatory-cosmetics-recalls-guidance-for-industry-draft-guidance-for-industry/5fab9267-24a1-4eb3-969f-1a965a21c4b4 2026-02-25 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-real-world-evidence-to-support-regulatory-decision-making-for-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/d18b3a42-ad8b-4987-8955-ea08f4372049 2026-02-25 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-use-of-the-plausible-mechanism-framework-to-develop-individualized-therapies-that-target-specific-genetic-conditions-with-known-biological-cause/2a636aa3-3bb2-4828-83f2-b5eb7244721b 2026-02-24 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/questions-and-answers-about-requirements-for-additional-traceability-records-for-certain-foods-draft-guidance-for-industry/759b583b-4999-41da-8e7f-b7aeb7367ad2 2026-02-20 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/defining-durations-of-use-for-certain-medically-important-antimicrobial-drugs-for-food-producing-animals/73761597-11a0-487f-8c96-d52cc1bb6918 2026-02-13 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e22-general-considerations-for-patient-preference-studies/3b39fdd6-9dd0-4536-9f4d-dc3bddcc1267 2026-02-06 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/computer-software-assurance-for-production-and-quality-management-system-software-guidance-for-industry-and-food-and-drug-administration-staff/faf7c922-9ecd-4923-9bde-0981b43e60e6 2026-02-04 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cuffless-non-invasive-blood-pressure-measuring-devices-clinical-performance-testing-and-evaluation-draft-guidance-for-industry-and-food-and-drug-administration-staff/13ff4501-ce59-4262-a18d-8d3e79ad570a 2026-01-23 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-records-access-authority-for-cosmetic-products-draft-guidance-for-industry/8d135c40-7a5b-4b46-9a37-a2153689ab77 2026-01-22 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/minimal-residual-disease-and-complete-response-in-multiple-myeloma-use-as-endpoints-to-support-accelerated-approval-draft-guidance-for-industry/06f37c31-445c-4690-8220-150703bde2bd 2026-01-21 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m4qr2-the-common-technical-document-for-the-registration-of-pharmaceuticals-for-human-use-quality/99d9c6a0-e416-4075-875d-80fbbf761ac7 2026-01-21 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-bayesian-methodology-in-clinical-trials-of-drug-and-biological-products-draft-guidance-for-industry/8e9c345e-0994-47b3-8d6c-054f04ed937e 2026-01-13 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/general-wellness-policy-for-low-risk-devices-guidance-for-industry-and-food-and-drug-administration-staff/3798d098-8940-4793-bb0a-2ce3041c13ae 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/how-to-prepare-a-pre-request-for-designation-pre-rfd-guidance-for-industry/89fb560a-a61f-480a-9fe5-c7247ff0477d 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/study-data-technical-conformance-guide-technical-specifications-document/209e707c-4233-4a8a-93fd-f9203eff2aff 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/anda-submissions-amendments-and-requests-for-final-approval-to-tentatively-approved-andas-guidance-for-industry/cd346cb2-e226-4779-be3a-218d45e8d794 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-decision-support-software-guidance-for-industry-and-food-and-drug-administration-staff/7af5ae9e-47b4-4a97-bc0d-1982c42ab407 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-performance-assessment-considerations-for-computer-assisted-detection-devices-applied-to-radiology-images-and-radiology-device-data-in-premarket-notification-510k-submissions-guidance-for-industry-and-fda-staff/cba45f13-a519-4f3d-b5c9-5415b512670e 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-dermabrasion-devices-guidance-for-industry/91a77f86-f3e8-4f6f-8d6e-a54ddc91fe59 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-169-drug-substance-chemistry-manufacturing-and-controls-information/bbe20287-ea4a-4180-82db-f06cf8b71809 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-ingredients-declared-as-evaporated-cane-juice/9fdb0d4c-d641-47b2-8a5a-1a5e890428e4 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/compliance-policy-guides-index/f1ecc0d8-5856-4ec0-837f-215a185522a1 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e2bm-data-elements-for-transmission-of-individual-case-safety-reports/ee70791b-0ecd-42b4-94aa-27632314cfa8 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/questions-and-answers-about-emdr-electronic-medical-device-reporting-guidance-for-industry-user-facilities-and-fda-staff/ec55d45c-ba23-407d-959e-776337e921a3 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-on-510k-submissions-for-keratoprostheses-guidance-for-industry-and-for-fda-reviewersstaff/f9cc0274-42dd-4e68-9f13-368ab5523dd3 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/current-good-manufacturing-practice-requirements-for-combination-products-guidance-for-industry-and-fda-staff/ace9180c-ec42-40e7-9c00-fc09b45ecbc3 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/part-11-electronic-records-electronic-signatures-scope-and-application-guidance-for-industry/7aa99f30-21f3-4e1e-a9b8-2e46cdfc0ad8 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e5-ethnic-factors-in-the-acceptability-of-foreign-clinical-data/41b52855-1683-45c6-8857-0b5935cfedc3 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-device-tracking-guidance-for-industry-and-fda-staff/46409202-15d6-4d81-aaa5-edae57c9e8ea 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-document-for-powered-muscle-stimulator-510ks-guidance-for-industry-fda-reviewersstaff-and-compliance/cfd0ee3e-10da-4ceb-80bc-fd478f27183d 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/acute-bacterial-skin-and-skin-structure-infections-developing-drugs-for-treatment/ddbe2cf0-2e38-4e65-88f4-c140b1c9a825 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/liposome-drug-products-chemistry-manufacturing-and-controls-human-pharmacokinetics-and-bioavailability-and-labeling-documentation/b27b2c8a-0cb8-4775-aba0-e2a39c06fd48 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-in-electronic-format-general-considerations/09112e28-964d-4af6-8d59-7a42a1aab244 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525325-cumin-seed-adulteration-with-sand-and-grit/7a594d1a-ac29-423a-9e7d-262d1eccf48f 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585350-corn-husks-for-tamales-adulteration-with-filth/a54604b9-88f8-4897-949b-70fe2a34cc8c 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/container-and-closure-system-integrity-testing-in-lieu-of-sterility-testing-as-a-component-of-the-stability-protocol-for-sterile-products-guidance-for-industry/74ac14c8-579f-4c16-8e6c-a9f6c3bbdcdd 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/general-guidelines-for-otc-combination-products/ff4374ee-47de-427c-b40b-40730cd9599b 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/complementary-and-alternative-medicine-products-and-their-regulation-by-the-food-and-drug-administration-draft-guidance-for-industry/1f16946d-90c3-4b89-af9e-9580a5d4d9eb 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/format-and-content-of-the-human-pharmacokinetics-and-bioavailability-section-of-an-application/0fc0547b-5081-4033-af56-10b885a39a8f 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-annex-i-residue-on-ignitionsulphated-ash-general-chapter/f65942c6-240c-4569-b3fe-3018db12bfc5 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-devices-containing-materials-derived-from-animal-sources-except-for-in-vitro-diagnostic-devices-guidance-for-industry-and-food-and-drug-administration-staff/471c3590-bc19-4ba5-8fdc-05a41fdb2b6f 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-170-animal-drug-user-fees-and-fee-waivers-and-reductions/5795cb57-c70d-4451-9a36-d41c64c3233d 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guideline-for-submitting-supporting-documentation-in-drug-applications-for-the-manufacture-of-drug-products/711fae04-3dd2-45ec-a781-a15c8bffd0af 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585700-potato-chips-adulteration-with-rot/d618a19d-20a2-48cf-9e69-53b52dd954ce 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/aqueous-shunts-510k-submissions-guidance-for-industry-and-for-fda-reviewersstaff/17f37714-5103-4981-9daf-822fd5d810e3 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-173-appendix-for-the-animal-drug-sponsor-fees-under-adufa/14b5f2a8-7a0d-445f-bac6-f483fb21ecf9 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-173-animal-drug-sponsor-fees-under-the-animal-drug-user-fee-act-adufa/6beb2f98-c619-4746-bf98-be24fb8c2734 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/information-disclosure-by-manufacturers-to-assemblers-for-diagnostic-x-ray-systems-guidance-for-industry-and-fda-staff/539786d8-803c-4849-b975-345597003187 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/non-automated-sphygmomanometer-blood-pressure-cuff-guidance-version-1-guidance-for-industry/b1bff958-423b-444c-85d0-c7bb758cb6a8 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550150-apricots-canned-adulteration-with-insects/4cb8f9a4-6c1b-4365-b0d8-c293d2dda05f 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-the-submission-of-premarket-notifications-for-radionuclide-dose-calibrators-guidance-for-industry/6f0a7d64-f411-47ee-a0c7-e830bb810986 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525250-cloves-adulteration-with-stems/ef898950-5043-449f-bf43-7e55e0aa2677 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-545600-cinnamon-flavored-toothpicks/29a44ccb-a48f-42b0-82e6-066fa66e968b 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/developing-medical-imaging-drug-and-biological-products-part-1-conducting-safety-assessments/7bd6bcd1-17d8-43a5-90f7-417b39f3ebf4 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-176-vich-gl39-specifications-test-procedures-and-acceptance-criteria-for-new-veterinary-drug-substances-and-new-medicinal-products-chemical-substances/80e2677c-a05c-42ff-ac1f-a66a3cee6246 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-545500-silver-plated-hollowware-lead-contamination/f65191b7-bfe0-431f-9ae5-715741ee1a14 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/independent-consultants-for-biotechnology-clinical-trial-protocols-guidance-for-industry/5c1bd52a-26a6-498c-bb57-c7f0186d6bd4 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-the-submission-of-premarket-notifications-for-emission-computed-tomography-devices-and-accessories-spect-and-pet-and-nuclear-tomography-systems-guidance-for-industry/879ea6d9-805d-4eb5-927d-6b14a8477e8e 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/chronic-cutaneous-ulcer-and-burn-wounds-developing-products-for-treatment/2f9032c6-271c-418b-ac0a-835eff9febf9 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550270-currants-adulteration-involving-wormy-fruits/d4dfa10a-a970-49e3-9a3b-77c43b98a7b2 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-545450-pottery-ceramics-import-and-domestic-lead-contamination/723c7c40-04e8-400f-afe7-417b211cced5 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/premarket-notification-510k-submissions-for-testing-for-skin-sensitization-to-chemicals-in-natural-rubber-products-guidance-for-industry-and-fda-reviewersstaff/087c8cf4-129b-48b0-9e77-367fa3b3896e 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-export-certification-guidance-for-industry/6a6f9061-038e-4596-8220-f5f32ec2deeb 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-the-preparation-of-a-premarket-notification-application-for-a-surgical-mesh-guidance-for-industry-andor-for-fda-reviewersstaff-andor-compliance/a7ca09bf-4f01-43f3-b44b-7f175a8feb84 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/monoclonal-antibodies-used-as-reagents-in-drug-manufacturing/0b94c7da-8ce4-43bf-b6e2-89d4d67b6f23 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/emergency-use-authorization-of-medical-products-and-related-authorities-guidance-for-industry-and-other-stakeholders/c12f7bd4-cf2a-49d0-99a0-3863c15e6b5e 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/how-to-write-a-request-for-designation-rfd-guidance-for-industry/d572149c-4a2c-4f22-a261-cf79b7f8a1fa 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-166-vich-gl38-environmental-impact-assessments-eias-for-veterinary-medicinal-products-vmps-phase-ii/10588824-e41e-491b-ad4b-66ecbed2125e 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-608200-prescription-use-of-certain-injectable-animal-drugs/03fc6b44-ca9f-4d04-98b7-072b7a3cf2bf 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/shelf-life-of-medical-devices/1f8de165-791b-40a8-80ef-bb23aaa44467 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/format-and-content-of-the-clinical-and-statistical-sections-of-an-application/c1b8779c-5190-462a-b56c-64d2fb216db8 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/devices-used-to-process-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-guidance-for-industry-and-fda-staff/ab90a342-131d-4c57-bcee-19273ee6097f 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-578400-treated-grain-seed-mercury-residue/f1b6bf2e-7176-46c8-8ceb-2b30bf4893c1 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/points-to-consider-for-cervical-cytology-devices/8f2feffb-1a2d-4906-afa6-a031c5af0995 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enforcement-policy-on-marketing-otc-combination-products-cpg-7132b16/2c77f827-6c1a-4709-983c-c8314f614c3b 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fees-exceed-the-costs-waivers-under-the-prescription-drug-user-fee-act/635ddfab-1882-4949-ab8a-cbc7e467ad7f 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/integrated-summary-of-effectiveness/dceeebd6-6607-4d3c-beb9-417012c9a968 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/smallpox-variola-virus-infection-developing-drugs-for-treatment-or-prevention-guidance-for-industry/c6eb4d8b-888a-4dc5-bb4d-877f66f968fb 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/content-and-format-of-premarket-notification-510k-submissions-for-liquid-chemical-sterilantshigh-level-disinfectants-guidance-for-industry-and-fda-reviewers/cc232013-bfff-4d89-8583-8d1ed9637b68 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m4s-the-ctd-safety-appendices/21e0b200-6c21-43a7-a559-c1fb8a1ec89a 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-trial-endpoints-for-the-approval-of-cancer-drugs-and-biologics-guidance-for-industry/2ab76b05-d847-445c-b212-0047a592f760 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/concept-paper/pdufa-pilot-project-proprietary-name-review-concept-paper/c8f1f3f1-e618-4d0d-9264-921efbd1440f 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/establishment-and-operation-of-clinical-trial-data-monitoring-committees-guidance-for-clinical-trial-sponsors/47889110-d7ce-4f2a-92f8-0dabfa6effe3 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-document-for-the-preparation-of-ides-for-spinal-systems-guidance-for-industry-andor-fda-staff/53834649-62f5-4529-8bab-38ce98dfca81 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e3-structure-and-content-of-clinical-study-reports/c8d5010c-5951-4f94-9006-a41019269cd8 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/calcium-dtpa-and-zinc-dtpa-drug-products-submitting-a-new-drug-application/5abe6679-7e7c-4be3-b0bd-4f2d90bd8d10 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-the-content-of-premarket-notifications-for-penile-rigidity-implants-guidance-for-industry-and-for-fda-staff/5e304f97-143e-449e-b651-36ba826d150d 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cardiac-monitor-guidance-including-cardiotachometer-and-rate-alarm-guidance-for-industry/26ae0235-5dbf-4c77-bdb7-a543d98d17fe 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585450-greens-canned-adulteration-by-mildew/40411008-0a1b-4a34-a8ee-bf00642f16e3 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-in-electronic-format-receipt-date-guidance-for-industry/7904bfcf-d282-4a2d-8689-1483c58f11bd 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-280110-microbiological-control-requirements-licensed-anti-human-globulin-and-blood-grouping-reagents/a5cb51a9-f7e8-4fdb-91ee-ce12163f4ef5 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/using-a-centralized-irb-review-process-in-multicenter-clinical-trials-guidance-for-industry/ee43606d-42ae-49fd-904c-0cd676da114b 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/standards-for-securing-the-drug-supply-chain-standardized-numerical-identification-for-prescription-drug-packages-guidance-for-industry/7903b10d-a260-4df4-bee4-29ba22509bd9 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-280100-stability-requirements-licensed-in-vitro-diagnostic-products/6c96d1b9-e129-4eab-be6d-dba133fa1ded 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-manufacturers-seeking-marketing-clearance-of-ear-nose-and-throat-endoscope-sheaths-used-as-protective-barriers-guidance-for-industry/3d70f6f5-9903-4b48-8370-f0cb6ff64b6b 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-premarket-submissions-of-orthokeratology-rigid-gas-permeable-contact-lenses-guidance-for-industry/ae646c70-7194-4c1e-aaff-d531016973ba 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e2bm-questions-and-answers/e23757ae-eaee-4978-bd4a-8098e3f710e3 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/laser-energy-source-laser-notice-2/4939e7fe-5775-4475-bd73-cf259d14a3aa 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-study-designs-for-surgical-ablation-devices-for-treatment-of-atrial-fibrillation-guidance-for-industry-and-food-and-drug-administration-staff/f989c5df-9878-460e-b006-54728b4d7bef 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/individual-product-bioequivalence-recommendations-for-specific-products/321fabfb-8008-4b1d-856f-9a2e7d5e26b1 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/end-of-phase-2a-meetings/05202b67-ba5f-49de-b49a-1f5466adf224 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/early-development-considerations-for-innovative-combination-products-guidance-for-industry-and-fda-staff/36676b52-57e2-4ab3-8bb5-0c933692434b 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/diagnostic-ecg-guidance-including-non-alarming-st-segment-measurement-guidance-for-industry/4f4e235d-8288-44b7-9568-ab181ff0b3f2 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/antibacterial-drug-products-use-of-noninferiority-studies-to-support-approval/b2b05847-3e9e-404c-8b11-6bcb28661443 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-177-vich-gl40-test-proceduresacceptance-criteria-for-new-biotechnologicalbiological-veterinary-medicinal-products/026ff841-e6f3-4ed3-aef5-380056aa1e9d 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550450-jam-black-currant-adulteration-with-mold/e9e7ba31-5333-416a-b529-7702e349e877 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/computer-assisted-detection-devices-applied-to-radiology-images-and-radiology-device-data-premarket-notification-510k-submissions-guidance-for-industry-and-food-and-drug-administration-staff/8201b588-c213-4c45-b25e-e2450d8463c7 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/application-user-fees-for-combination-products-guidance-for-industry-and-fda-staff/5ba55571-d0a3-4fa2-91d5-a9bff4adec1a 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q3c-appendix-5/eb613fc7-8b00-4952-8353-e8ebb3cc9c77 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submission-and-resolution-of-formal-disputes-regarding-the-timeliness-of-premarket-review-of-a-combination-product-guidance-for-industry-and-fda-staff/8d93e28c-9435-4a59-a96c-53b4bb7ae048 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-submissions-in-electronic-format-postmarketing-safety-reports/4ad827be-5b2f-4a35-a05b-6c58d6dbc5ff 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/1-consolidated-annual-report-for-a-device-product-line-1-card-guidance-for-industry-and-cdrh-reviewers/16425c14-bc6e-49a8-915c-2eeaaef033d1 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-control-of-listeria-monocytogenes-in-ready-to-eat-foods/78fb1bf0-79d0-4132-8f82-fa428409b122 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q3c-tables-and-list-rev-4/603912c9-dba1-4b46-ba60-7454fec624a0 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q3c-impurities-residual-solvents_2011/b949f32c-660b-4c85-9e90-3fc9286ced2a 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-the-submission-of-premarket-notifications-for-photon-emitting-brachytherapy-sources-guidance-for-industry/eeb00240-1f41-4c21-a144-edc5c18b4095 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-178-recommended-design-and-evaluation-of-effectiveness-studies-for-swine-respiratory-disease-claims/7b91194b-471d-4c2f-813d-658071ba76a2 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-labeling-of-certain-beers-subject-to-the-labeling-jurisdiction-of-the-food-and-drug-administration/022bbd98-8abf-4b94-be97-5475c625e160 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/non-clinical-engineering-tests-and-recommended-labeling-for-intravascular-stents-and-associated-delivery-systems-guidance-for-industry-and-fda-staff/5cbc6947-584b-42ae-a6e8-d5589acdff56 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-questions-and-answers-regarding-adverse-event-reporting-and-recordkeeping-for-dietary-supplements-as-required-by-the-dietary-supplement-and-nonprescription-drug-consumer-protection-act/8c5632c8-16c0-4996-aa58-70c9a556d69d 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/process-for-handling-referrals-to-fda-under-21-cfr-5054-additional-safeguards-for-children-in-clinical-investigations-guidance-for-clinical-investigators-institutional-review-boards-and-sponsors/57b4b090-bd0e-4212-a631-6ebc41223136 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/information-sheet/evaluation-of-sex-differences-in-clinical-investigations-guidance-for-industry/92c2b117-2251-40a9-9086-3ebfed65505e 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e2f-development-safety-update-report/fce1434f-a2f0-418e-adf4-9803cbc032bd 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-on-section-216-of-the-food-and-drug-administration-modernization-act-of-1997-guidance-for-industry-and-for-fda-reviewers/0e9d60c0-b3c7-4651-a785-9107ddbc73e6 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-179-use-of-animal-clones-and-clone-progeny-for-human-food-and-animal-feed/41f5d3b1-74de-4211-bdc0-77b5020cecef 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/form-fda-3674-certifications-to-accompany-drug-biological-product-and-device-applicationssubmissions-guidance-for-sponsors-industry-researchers-investigators-and-food-and-drug-administration-staff/312246cf-5a24-407e-9152-40aff3dd539d 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-document-for-dura-substitute-devices-guidance-for-industry/e1d5a8ce-a400-4b78-9fc5-d3147a989074 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/content-of-investigational-device-exemptions-for-solutions-for-hypothermic-flushing-transport-and-storage-of-organs-for-transplantation-guidance-for-industry-and-fda-reviewers/3add142c-a8f9-485b-925d-6bd18b84c891 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-evaluation-of-antiepileptic-drugs-adults-and-children/270d4f23-2cee-4643-bcb0-8150491b581e 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compliance-with-regulations-restricting-the-sale-and-distribution-of-cigarettes-and-smokeless-tobacco-to-protect-children-and-adolescents-guidance-for-industry/7f122a8c-f0e6-4b1a-bb67-39d50dcc8231 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-on-the-testing-of-metallic-plasma-sprayed-coatings-on-orthopedic-implants-to-support-reconsideration-of-postmarket-surveillance-requirements-guidance-for-industry-and-for-fda-reviewersstaff/58b858b2-5f8b-4d3b-815e-1a26f1cf546f 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/intravascular-administration-sets-premarket-notification-submissions-510k-guidance-for-industry-and-fda-staff/687dd94a-dc01-4378-bf1b-f9fd4546e435 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-use-of-recycled-plastics-in-food-packaging-chemistry-considerations/9c8c5951-570f-4d40-a4f2-ff71708947ac 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-and-fda-staff-vocal-fold-medialization-devices-premarket-notification-510k-submissions/e1876182-0617-4cbf-90b4-830cce269aea 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/early-collaboration-meetings-under-the-fda-modernization-act-fdama-final-guidance-for-industry-and-for-cdrh-staff/fdeed1f3-00b0-4187-bf3d-80280cc10bf4 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-480300-lack-of-expiration-date-of-stability-data/3fee3909-5d6c-441a-af15-63ab5228bf60 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-data-presentations-for-orthopedic-device-applications-guidance-for-industry-and-fda-staff/b5acd4ee-cac5-446d-9a45-76683dae10e5 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/surgical-masks-premarket-notification-510k-submissions-guidance-for-industry-and-fda-staff/bd7eb9a7-9861-4f83-b6d9-2aa9042c11e4 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-policy-regarding-quantitative-labeling-of-dietary-supplements-containing-live-microbials/c18a1805-605a-4e74-818f-b08a81a7d025 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/statistical-guidance-on-reporting-results-from-studies-evaluating-diagnostic-tests-guidance-for-industry-and-fda-staff/9ab4c30d-7fe4-4a62-b46e-b16f10a19435 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-the-seafood-list-fdas-guide-to-determine-acceptable-seafood-names/47c2848a-68d3-4902-b7ce-df697c122bea 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-resorbable-adhesion-barrier-devices-for-use-in-abdominal-andor-pelvic-surgery-guidance-for-industry/b094feed-889d-4f0a-a157-882bbd110ed5 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/compliance-policy-for-certain-labeling-and-warning-statement-requirements-for-cigars-and-pipe-tobacco-guidance-for-industry/dddc072d-2030-4f77-84ae-ec086bf30681 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-devices-with-sharps-injury-prevention-features-guidance-for-industry-and-fda-staff/fe1b1e0f-2ce8-4fb9-8491-30198a55efdf 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-and-fda-staff-spinal-system-510ks/7741b13b-29da-41e1-bdad-60df446c7b43 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/role-of-hiv-drug-resistance-testing-in-antiretroviral-drug-development/b63afac3-86d1-45b1-bee0-b25944c92926 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-470100-orders-for-post-approval-record-reviews/2c1a34b9-1d69-45f1-aaeb-62f7d6ae3ce4 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/criteria-for-significant-risk-investigations-of-magnetic-resonance-diagnostic-devices-guidance-for-industry-and-food-and-drug-administration-staff/9d5e44dc-a38c-4817-93c0-e7786f404f88 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/procedures-for-handling-post-approval-studies-imposed-by-pma-order-guidance-for-industry-and-food-and-drug-administration-staff/46ba5f55-7df7-4db1-a0a3-0562b797a8f9 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m4s-the-ctd-safety/3d4fa9c6-5f48-4dc5-b89c-00dd678bc870 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/prospective-manufacturers-of-barrier-devices-used-during-oral-sex-for-std-protection/4e9d835a-e843-473d-b0b5-c29db933179e 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-mitigation-strategies-to-protect-food-against-intentional-adulteration/174e085a-483f-44da-b521-51c42bbc3591 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m4-the-ctd-efficacy-questions-and-answers/7d54ebee-7959-4925-b48e-48350bf0759b 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/acute-bacterial-sinusitis-developing-antimicrobial-drugs-for-treatment/5e420779-6391-4202-a6d4-a6ba2b0a325d 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-supplemental-questions-and-answers-regarding-food-facility-registration/cc9dde4c-1259-4a25-ab3f-4281cfb4446d 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/menstrual-tampons-and-pads-information-for-premarket-notification-submissions-510ks-guidance-for-industry-and-fda-staff/1cf32bb8-1853-4fe4-814a-59a936391791 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/needlesticks-medical-device-reporting-guidance-for-user-facilities-manufacturers-and-importers/8d24f3c8-5f71-4276-9bac-6b8a5faf894b 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/responsibilities-of-laser-light-show-projector-manufacturers-dealers-and-distributors-laser-notice-51/0f448c5e-5a9c-4118-9802-dc3ab390fe25 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/premarket-notification-510k-submissions-for-chemical-indicators-guidance-for-industry-and-fda-staff/ef44b29e-a196-4909-b62b-a28f805b7be2 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/allergic-rhinitis-developing-drug-products-for-treatment-guidance-for-industry/dcca7128-d84a-436f-83a2-e705904c701f 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-on-medical-device-patient-labeling-final-guidance-for-industry-and-fda-staff/2d0df546-e5c9-4546-a856-88c928b342fd 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/performance-standard-for-diagnostic-x-ray-systems-and-their-major-components-21cfr-102030-102031-102032-102033-small-entity-compliance-guide/25da0cdb-88f7-4421-adc2-fac6f5f588fa 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/hypnotic-drugs-clinical-evaluation/1868dcb9-1354-418c-9840-7bf1412b041f 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/street-drug-alternatives/345344ca-6b85-4f50-ab26-676bbb4cc144 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/applicability-of-the-performance-standard-for-high-intensity-mercury-vapor-discharge-lamps-21-cfr-104030/f0c6ca12-4e65-44f4-bdba-de68bb7e2759 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-the-declaration-of-certain-isolated-or-synthetic-non-digestible-carbohydrates-as-dietary-fiber-on-nutrition-and-supplement-facts-labels/b702b239-6726-4d55-a570-defa34e765f9 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/exemption-from-reporting-and-recordkeeping-requirements-for-low-power-laser-products-laser-notice-54-guidance-for-industry-and-fda-staff/8924bf17-11ed-4761-aca9-a76cce6ca70a 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-investigations-of-devices-indicated-for-the-treatment-of-urinary-incontinence-guidance-for-industry-and-fda-staff/12b5d2c6-7bf0-459d-ac2b-4b9411e82810 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/review-of-fdas-implementation-of-the-drug-export-amendments-of-1986/ac263315-7a67-481c-bd92-f824fd3c796a 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/approval-of-alternate-means-of-labeling-for-laser-products-laser-notice-53/f49b4d50-d93f-4745-bd2b-27633e593076 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e2e-pharmacovigilance-planning/89ea2b55-7e7d-4a99-9e7f-9aac73abf09b 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/all-us-condom-manufacturers-importers-and-repackagers/dbbe0b6f-eacf-48ee-9314-cd425d0edae3 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/adverse-reactions-section-of-labeling-for-human-prescription-drug-and-biological-products-content-and-format/ce6d5ce5-74d1-4dfa-b9e2-2231be5d58c1 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/addition-of-urls-to-electronic-product-labeling-guidance-for-industry-and-fda-staff/93e468e2-0261-4809-8025-dece6248f21b 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/acceptable-media-for-electronic-product-user-manuals-guidance-for-industry-and-fda-staff/89d4793a-0a3f-4029-99b8-99e361a794eb 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/allowable-excess-volume-and-labeled-vial-fill-size-in-injectable-drug-and-biological-products/23e78a60-a44a-4fe0-840f-72c23de18934 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/analytical-procedures-and-methods-validation-for-drugs-and-biologics/b63babeb-6796-4e5d-a992-7830e31b2f5a 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/an-acceptable-circular-of-information-for-the-use-of-human-blood-and-blood-components-guidance-for-industry/c3238e39-c5a0-42cd-a792-de62e9f7abf7 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/abuse-deterrent-opioids-evaluation-and-labeling/cd0f4ddf-e4fc-4694-a929-33733fb8e8db 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/processes-and-practices-applicable-to-bioresearch-monitoring-inspections-guidance-for-industry/7a35dfcf-1090-49a9-ab18-b2a5b5dfbabc 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/formal-dispute-resolution-and-administrative-hearings-of-final-administrative-orders-under-section-505g-of-the-federal-food-drug-and-cosmetic-act/29255bf9-62a0-4ada-a86d-5ccdcd460a3b 2026-01-07 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/irb-responsibilities-for-reviewing-the-qualifications-of-investigators-adequacy-of-research-sites-and-the-determination-of-whether-an-indide-is-needed-guidance-for-irbs-clinical-investigators-and-sponsors/797294db-f9b3-4c0d-b100-f6ee4b81ebae 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-questions-and-answers-regarding-the-final-rule-on-prevention-of-salmonella-enteritidis-in-shell-eggs-during-production-storage-and-transportation-layers-with-access-to-areas-outside-the-poultry-house/ea93ac30-af3d-4ee9-b918-320b21f7a976 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-action-level-for-inorganic-arsenic-in-apple-juice/4dfa2177-49b4-4c4a-99ba-8e7fb9e8df6c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/annex-13-bulk-density-and-tapped-density-of-powders-general-chapter/193844d5-b300-416d-8cd2-7a3143731d1d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/establishing-the-performance-characteristics-of-in-vitro-diagnostic-devices-for-the-detection-of-antibodies-to-borrelia-burgdorferi-guidance-for-industry-and-fda-staff/c9b388c4-7a07-4b67-9776-be87a6cfe611 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/generalspecific-intended-use-guidance-for-industry/c42b5e01-2b5c-4140-aa7a-dfbcd1beb165 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q8-q9-q10-questions-and-answers-appendix-qas-from-training-sessions-q8-q9-q10-points-to-consider/74f08aab-1b94-4f9f-8da0-2725af03d078 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-registration-of-food-facilities/c39e66f9-695f-4174-a70c-0703de38d815 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-suicidal-ideation-and-behavior-prospective-assessment-of-occurrence-in-clinical-trials/c258943d-f6d1-4ddb-b590-e1b38509aab4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-prevention-of-salmonella-enteritidis-in-shell-eggs-during-production-storage-and-transportation/fd04cafd-cf41-41d4-853d-bfa49088d334 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-questions-and-answers-regarding-the-final-rule-prevention-of-salmonella-enteritidis-in-shell-eggs-during-production-storage-and-transportation/b2dd5607-3b3c-4011-aed4-d35ca40c6e74 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/meetings-with-industry-and-investigators-on-the-research-and-development-of-tobacco-products-revised-guidance-for-industry-and-investigators/73f4985f-291c-4b92-9b49-4f2d9ba7bdde 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-device-classification-product-codes-guidance-for-industry-and-food-and-drug-administration-staff/93fc1264-3e3c-452f-bece-8eaec023dcf7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/classification-of-products-as-drugs-and-devices-and-additional-product-classification-issues-guidance-for-industry-and-fda-staff/635d5eeb-9483-433f-a569-9859c11b4052 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/industry-letter/guidance-for-industry-letter-to-firms-that-grow-harvest-sort-pack-process-or-ship-fresh-cantaloupe/10f00b57-6393-4f9f-9945-003debd26c0f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-measures-to-address-the-risk-for-contamination-by-salmonella-species-in-food-containing-a-pistachio-derived-product-as-an-ingredient/d6a73d89-6a5e-4918-9b0f-27275b56c0ec 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-635100-large-volume-parenterals-lvps-for-animal-use/fc6ac898-eb25-449d-9053-37f409e63fb6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/applications-for-premarket-review-of-new-tobacco-products-draft-guidance-for-industry/692db37e-c451-452a-8185-cb868368f59e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/blood-lancet-labeling-guidance-for-industry-and-food-and-drug-administration-staff/32f401ad-5b56-4f84-89e1-5b65fa1d4d8e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guide-pour-lindustrie-questions-et-reponses-concernant-le-registre-de-denrees-alimentaires-a-signaler-reportable-food-registry-rfr-tel-quetabli-par-le-food-and-drug-administration-amendments-act-de-2007-fdaaa-2eme-edition/e15b5d8b-ea5b-4e1e-80c1-2d7445d2fb82 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/chinese-translation-of-draft-guidance-for-industry-questions-and-answers-regarding-the-reportable-food-registry-edition-2-2007-20105/ae688524-4d1f-4b31-851d-7f8bade5274c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-providing-regulatory-submissions-in-electronic-or-paper-format-to-the-office-of-food-additive-safety/c71cf7f4-d963-446b-9ab6-4e39d3337268 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-653100-animal-grooming-aids/e9038932-e0a1-47c9-883f-da06fffd0829 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/registration-and-product-listing-for-owners-and-operators-of-domestic-tobacco-product-establishments-guidance-for-industry/8a768e6c-2730-49fd-a071-4c8de01755ba 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/general-questions-and-answers-on-the-ban-of-cigarettes-that-contain-certain-characterizing-flavors-edition-2-guidance-to-industry-and-fda-staff/ac29e2ca-f785-4bf9-9ba7-62aed2d4710c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enhancing-participation-in-clinical-trials-eligibility-criteria-enrollment-practices-and-trial-designs-guidance-for-industry/cb854ea3-a48e-47fc-aa09-ec209539e6a9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/menstrual-products-performance-testing-and-labeling-recommendations-draft-guidance-for-industry-and-food-and-drug-administration-staff/430221be-6930-4193-9f75-48e38991dcbc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postapproval-methods-to-capture-safety-and-efficacy-data-for-cell-and-gene-therapy-products-draft-guidance-for-industry/d076649d-1260-49fb-bc96-30f59be10ea0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/disseminated-coccidioidomycosis-developing-drugs-for-treatment-draft-guidance-for-industry/e0cec7f3-429f-41d0-8670-617e61df8616 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/erosive-esophagitis-developing-drugs-for-treatment-draft-guidance-for-industry/db47ebb5-eadc-4f7b-a236-ac6b016c3ec7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/study-of-sex-differences-in-the-clinical-evaluation-of-medical-products/d77c04e8-ef7b-4fbb-8b73-5fe6d3a9117f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/qtc-information-in-human-prescription-drug-and-biological-product-labeling-guidance-for-industry/84e1bfb1-3a7d-4f4f-ad99-9da85ee92408 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e6r3-good-clinical-practice-gcp/682dfcf6-82b9-407c-9ffb-89c51a0a4944 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigator-responsibilities-safety-reporting-for-investigational-drugs-and-devices-guidance-for-industry/b13fb9a0-f0aa-4b42-9091-15f8390ef696 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/sponsor-responsibilities-safety-reporting-requirements-and-safety-assessment-for-ind-and-bioavailabilitybioequivalence-studies-guidance-for-industry/de07fd31-d42a-4c2e-8af7-ae503e60bcbc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/center-for-devices-and-radiological-health-cdrh-appeals-processes-guidance-for-industry-and-food-and-drug-administration-staff/70529c89-1313-4132-a42a-4f0b2e1bb4f5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/center-for-devices-and-radiological-health-cdrh-appeals-processes-questions-and-answers-about-517a-guidance-for-industry-and-food-and-drug-administration-staff/0760caf5-5027-4b32-a213-747c43f5d018 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nepa_final_guidance/f776a722-603a-4508-bb4f-8bff8925cd2e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/newrevisedwithdrawn-guidances-2014/18621374-5530-4d93-b3a6-8e9f13bf3abc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/ecopy-program-for-medical-device-submissions-guidance-for-industry-and-food-and-drug-administration-staff/1706fd6a-d814-4646-acd6-d9d942222775 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/sample-who-certificate-for-quality-of-a-pharmaceutical-product/68cbe1fe-fd39-4c73-946b-115195e8a14e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/general-principles-of-software-validation-guidance-for-industry-and-fda-staff/e7963bfa-d95d-492f-8cb0-09d90a9c9535 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-490100-process-validation-requirements-for-drug-products-and-active-pharmaceutical-ingredients-subject-to-pre-market-approval/864a062a-ddcb-4710-b694-d588ace094c0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/promotional-labeling-and-advertising-considerations-for-prescription-biological-reference-products-biosimilar-products-and-interchangeable-biosimilar-products-questions-and-answers-guidance-for-industry/98d122b6-0f73-480f-9605-fbb17a6e6e72 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/monoclonal-antibodies-streamlined-nonclinical-safety-studies-draft-guidance-for-industry/439cec36-0e7d-4c02-88e4-7a0af7b47fa4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q3e-guideline-for-extractables-and-leachables-supporting-documentation-class-3-leachable-monographs/f8e13869-de0e-497a-9342-98fc75f65f6c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-gases-current-good-manufacturing-practice-draft-guidance-for-industry/6cc996d2-4813-44da-b318-574d8196c860 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/qe3-guideline-for-extractables-and-leachables-supporting-documentation-class-3-leachable-monographs/a1d1ebd3-2c05-423d-a1d5-6a14e887a9dc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q3e-guideline-for-extractables-and-leachables/4b0a399e-ea86-4269-bcb2-e0cf8c88b5bd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/expanded-access-to-investigational-drugs-for-treatment-use-questions-and-answers/9bb69e41-e105-4381-9ff7-898811ff1b7c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/development-of-therapeutic-protein-biosimilars-comparative-analytical-assessment-and-other-quality-related-considerations-guidance-for-industry/07142307-dadf-4c95-927c-469f261c1c58 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/alternative-tools-assessing-drug-manufacturing-facilities-identified-in-pending-applications/07863c53-b6a5-49ed-a059-f83ea441ac41 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/classification-categories-for-certain-supplements-under-bsufa-iii/66d51a68-e6a8-4e86-8097-7ddf219d36b9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/patient-focused-drug-development-selecting-developing-or-modifying-fit-for-purpose-clinical-outcome-assessments/1446031c-eaef-4950-81f7-ebe3db10d88b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-waiver-requests-for-ph-adjusters-in-generic-drug-products-intended-for-parenteral-ophthalmic-or-otic-use-guidance-for-industry/40969c10-8c6c-42cb-b3eb-03f03eb9fa38 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cross-center-master-files-where-to-submit-draft-guidance-for-industry/6a5cada6-fa5a-48b8-a90f-54033cf59459 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/program/cder-cdrh-combo-product-compliance-program/a40457d2-e1b2-4a3c-83ab-8aecd8da0221 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/operations-manual/fda-inspections-operations-management-manual-2025/6ba9b7bf-15ae-4b84-96c7-0d81d996d984 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/voluntary-labeling-indicating-whether-foods-have-or-have-not-been-derived-from-genetically-engineered-plants-guidance-for-industry/ce302474-13e1-4320-bd9b-b5118577a83a 2026-04-28 monthly 0.7 https://www.globalkeysolutions.net/guidances/preamble/21-cfr-211-preamble/c840be82-c9e9-4a22-8eee-ecd5df9dce86 2026-04-28 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/scientific-considerations-in-demonstrating-biosimilarity-to-a-reference-product-updated-recommendations-for-assessing-the-need-for-comparative-efficacy-studies-draft-guidance-for-industry/e314875c-585b-4d6e-bb97-b1b4f4edc32d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/menstrual-products-performance-testing-and-labeling-recommendations-draft-guidance-for-industry-and-food-and-drug-administration-staff/4d5ee4f9-bcfb-4ae5-a103-833694060325 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/quality-management-system-information-for-certain-premarket-submission-reviews-draft-guidance-for-industry-and-food-and-drug-administration-staff/6017369f-a44a-4101-8846-ead2d67839b2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/technical-specifications-for-submitting-clinical-trial-data-sets-for-response-assessments-for-treatments-of-acute-leukemias-guidance-for-industry-technical-specifications-document/fcae5d52-07e3-4b70-a7d3-d72bbe4ba316 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-299-dual-labeling-for-fully-approved-and-conditionally-approved-new-animal-drugs-with-a-new-world-screwworm-related-indication-guidance-for-industry/f3901b25-31a8-481c-abe2-0be5e9380650 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/symptomatic-nonerosive-gastroesophageal-reflux-disease-developing-drugs-for-treatment-draft-guidance-for-industry/a7edda76-4160-401c-a7b4-f752b268fd5d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/innovative-designs-for-clinical-trials-of-cellular-and-gene-therapy-products-in-small-populations-draft-guidance-for-industry/cd9be98c-6af4-4697-b410-093f03cd7dd5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/expedited-programs-for-regenerative-medicine-therapies-for-serious-conditions-draft-guidance-for-industry/4c570099-1582-4019-8f81-d0260a2e984c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e20-adaptive-designs-for-clinical-trials/ea1da55a-c7ba-4a8a-bf9e-cfd6180b966c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/computer-software-assurance-for-production-and-quality-system-software-guidance-for-industry-and-food-and-drug-administration-staff/3c846ce6-b6c7-4c31-b809-362db15d032f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/erosive-esophagitis-developing-drugs-for-treatment/985e94e3-4616-49e9-822e-0854256bb10e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/malaria-developing-drugs-for-treatment-draft-guidance-for-industry/3edfcacf-7736-421e-9b04-b883ec5cc173 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/consideration-of-enforcement-policies-for-in-vitro-diagnostic-tests-during-a-section-564-declared-emergency-guidance-for-industry-and-food-and-drug-administration-staff/21848893-1a28-4ffe-a5eb-e86a79546ffb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/safety-labeling-changesimplementation-of-section-505o4-of-the-fdc-act-draft-guidance-for-industry/2ed7dede-8a3f-4f38-baa2-5eec541a5edb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/clarification-of-compliance-requirements-for-certain-manufacturers-who-incorporate-certified-class-i-laser-products-into-their-products-laser-notice-42/2e442237-3c31-414f-b1e2-93fecf22f59e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/procedures-for-laboratory-testing-of-microwave-ovens/97047735-d8ec-46d5-a9ce-2f627f7a251b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/quality-control-practices-for-compliance-with-the-federal-laser-performance-standard/a617d720-50c7-4ed0-89db-aca4f9b0639c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/class-ii-and-iiia-laser-light-show-projectors-and-shows-laser-notice-40/6a7fc936-8b3f-440a-b3df-6aba6e023891 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/industry-letter/third-of-a-series-of-letters-regarding-the-implementation-of-the-act/e65f7075-0b47-4965-97da-74fe25c9bbfd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/procedures-for-field-testing-microwave-ovens/caad07df-bf6b-4e87-9bff-e611ae6a02a1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/study-of-drugs-likely-to-be-used-in-the-elderly/00cfcd92-8ac1-4307-968b-117b25f0493c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/letter-to-industry-powered-wheelchair-manufacturers-from-rmjohnson/277bd391-4826-45f8-9d5f-a9456f804238 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/user-instructions-multi-axis-workstations-laser-notice-39/4d79a0d6-82cf-4868-af00-4192a2ac7154 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clarification-of-radiation-control-regulations-for-diagnostic-x-ray-equipment-part-1/47feea8e-50d2-4ced-8d6b-c113395f92f8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clarification-of-radiation-control-regulations-for-diagnostic-x-ray-equipment-part-3/403675e4-6f1f-4779-80f8-f31d160815c6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/clarification-of-radiation-control-regulations-for-diagnostic-x-ray-equipment-part-2/3cc6bbc3-3288-4bd9-93df-ff0c3d42f197 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/beam-attenuators-and-emission-indicators-for-class-ii-and-iiia-laser-systems-laser-notice-43/5381caa5-c89a-4500-b69c-fdfa0f602525 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/industry-letter/all-holders-of-approved-variances-for-laser-light-shows-and-displays-laser-notice-46/76f289a0-7a31-4f3f-a595-0116258b178f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/effective-visual-control-of-laser-projections-laser-notice-47/bb6e400e-deb2-4956-80bd-f7a48ba57640 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/identification-labels-for-certain-class-i-laser-products-laser-notice-48/38be6ff7-c4b6-437e-925a-b2b1d26436d8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/emitted-laser-beam-as-emission-indicator-for-class-ii-and-class-iiia-laser-products-laser-notice-49/96ddd112-f7cf-4341-b51d-21d034fbf908 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/user-instruction-for-medical-products-laser-notice-44/ab0d93e3-27db-444d-bea4-426b3aba5598 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/viewing-optics-sighting-telescope-laser-notice-8/739d59be-bba8-4143-a280-a816d72dec67 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/certain-military-lasers-exempt-from-21-cfr-104010-11-laser-notice-9/712817de-7ca0-4d8b-ac73-79c79ab46fae 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/remote-interlock-connectors-laser-notice-11/51cdb989-ba40-472a-b248-53e33bf75776 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/manufacture-and-certification-of-laser-kits-laser-notice-13/417203e8-6432-4217-972c-bad707c82b2d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/lasers-manufactured-and-used-in-house-laser-notice-14/6601e90c-fee7-4437-9c04-3a34a48677dd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/warning-labels-for-dye-and-multiple-wavelength-lasers-laser-notice-16/ade813c2-3eb6-41b7-9db6-42927326a78f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/laser-light-shows-subject-to-laser-product-performance-standard-laser-notice-22/118bd600-2dd3-46e7-a61a-814d5c00f95b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/exemption-of-certain-lasers-used-by-doe-noaa-and-us-dept-of-commerce-laser-notice-25/d4edebae-a788-42ac-8c0d-e88dcdd58b29 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-laser-delivery-system-interlocks-laser-notice-34/dc5f8d05-1779-469e-a0ce-58e00d3b6ccf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/user-instruction-hazard-warnings-laser-notice-35/141ff212-42b5-4a1c-a5c2-c4318986e8b0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/walk-in-workstations-laser-notice-37/0cfd8575-0cb6-480c-910d-a529e3ec1a63 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/alternate-wording-for-caution-statement-laser-notice-30/a715b947-3351-4f3c-abf0-6b5229793235 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/real-time-premarket-approval-application-pma-supplements-guidance-for-industry-and-fda-staff/d42d9a7d-4114-4160-9763-dd442e5f7c3f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigational-medical-laser-significant-risk-device-laser-notice-31/89836767-b00c-476c-8602-3bb3c0bf5031 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-the-content-of-premarket-notifications-for-urine-drainage-bags/a26b31d1-8be1-4748-800a-cf9a559eb4da 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-oxygen-conserving-device-510k-review-73-bzd-8685905-non-continuous-ventilator-class-ii/6b6e579e-5c33-41ab-bcb6-49d9b6a72811 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/reference-guide-for-the-nonclinical-toxicity-studies-of-antivial-drugs-indicated-for-the-treatment-of-na-non-life-threatening-disease-evaluation-of-drug-toxicity-prior-to-phase-i-clinical-studies/6475f25d-20b3-4aab-b36a-be14f539fc3b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/industry-letter/supplement-to-10111984-letter-about-policies-procedures-and-implementation-of-the-act-qa-format/d3d2c846-76b2-4c5d-b3a7-21439b389e50 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-animal-products-database-data-entry-form/f30e9fd6-c81d-4570-b7a1-0cf3f7ea4495 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/format-and-content-of-the-microbiology-section-of-an-application-guidance-for-industry/ee91e4b0-e061-4cd6-ae5c-a424e72816a0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/psychoactive-drugs-in-infants-and-children-clinical-evaluation/0474cb88-76c3-4dcd-9de2-3adb6d22efec 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/oncologic-drugs-advisory-committee-discussion-on-fda-requirements-or-approval-of-new-drugs-for-treatment-of-colon-and-rectal-cancer/4902e903-ac24-437e-a3f6-69c616094804 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-the-development-of-vaginal-contraceptive-drugs-nda/274b67c2-e9a6-4c70-a492-00f91e8df6dd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/formatting-assembling-and-submitting-new-drug-and-antibiotic-applications/5c064b5e-b2cd-46ac-af3d-0df3835aa982 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-requirements-for-approval-of-drugs-to-treat-non-small-cell-lung-cancer/438d59a1-9648-4c99-b3f7-b21928a95608 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-development-and-labeling-of-anti-infective-drug-products/67f316ae-b6a3-4be9-9f04-f8ca70727735 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/general-considerations-for-the-clinical-evaluation-of-drugs/9f83d453-bc55-45a5-962d-87455db6263c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/summary-for-new-drug-and-antibiotic-applications-format-and-content-of-the-summary-for-new-drug-and-antibiotic-applications/b91d1a0d-afc8-4844-a068-b34f5da5a94b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nuclear-pharmacy-guideline-criteria-for-determining-when-to-register-as-a-drug-establishment/272dbb5d-9100-4449-80ea-9e48bd60de5f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/preparation-of-investigational-new-drug-products-human-and-animal-guidance-for-industry/4382914f-5b98-4ad4-91c1-ed6e2893e213 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/good-laboratory-practice-regulations-questions-and-answers/dce88153-5627-4e1b-a247-1e741c4bafc9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/metaproterenol-sulfate-and-albuterol-metered-dose-inhalers-in-vitro/b4a021a1-1edb-456d-a588-48acb21ffc8d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/topical-dermatologic-corticosteroids-in-vivo-bioequivalence/7ffc2692-ebeb-401d-92f6-3b735fadd8d6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/upgrading-category-iii-antiperspirants-to-category-i-43-fr-46728-46731/184d6022-1c6c-47e6-a19a-3d6c3c52a58d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/format-and-content-of-the-nonclinical-pharmacologytoxicology-section-of-an-application-guidance-for-industry/4c2b4b0e-2182-43a9-b9b0-c3c92aee26b9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/biocompatibility-testing-of-medical-devices-standards-specific-information-for-the-accreditation-scheme-for-conformity-assessment-asca-pilot-program-guidance-for-industry-accreditation-bodies-testing-laboratories-and-food-and-drug-administration-staff/f9570649-5fcb-461f-b67b-e49948ba906e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/basic-safety-and-essential-performance-of-medical-electrical-equipment-medical-electrical-systems-and-laboratory-medical-equipment-standards-specific-information-for-the-accreditation-scheme-for-conformity-assessment-asca-pilot-program-guidance-for-industry-accreditation-bodies-testing-laboratories-and-food-and-drug-administration-staff/f849c680-dd31-4f2b-ae1a-e6f8ffcf1424 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/basic-safety-and-essential-performance-of-medical-electrical-equipment-medical-electrical-systems-and-laboratory-medical-equipment-standards-specific-information-for-the-accreditation-scheme-for-conformity-assessment-asca-program-draft-guidance-for-industry-accreditation-bodies-testing-laboratories-and-food-and-drug-administration-staff/40fc3fea-136b-409c-be57-db9c38e991dc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-lot-release-protocol-submissions-to-the-center-for-biologics-evaluation-and-research-cber-in-electronic-format-guidance-for-industry/3c027394-1c01-4515-88a7-bc2f1e214d0c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/patient-focused-drug-development-methods-to-identify-what-is-important-to-patients-guidance-for-industry-food-and-drug-administration-staff-and-other-stakeholders/06de176c-365a-43ad-84f7-7aa3926833b5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/disseminated-coccidioidomycosis-developing-drugs-for-treatment/57566736-a0f1-4c1b-b09c-f05bfb8ce885 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/changes-to-an-approved-nda-or-anda-specifications-use-of-enforcement-discretion-for-compendial-changes-guidance-for-industry/1aafb7d9-76d0-4fff-8835-a361bbb77c9b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/collection-of-platelets-by-automated-methods-guidance-for-industry-and-fda-review-staff/3e3a4ad5-8406-4913-958f-aa82e587de6f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/notifying-fda-of-fatalities-related-to-blood-collection-or-transfusion-guidance-for-industry/00f8c605-19b4-4774-a558-04c89f70b1d1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-185-vich-gl43-target-animal-safety-for-veterinary-pharmaceutical-products/d942db43-d174-4bef-aa05-d4a27a1c1301 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-frequently-asked-questions-about-gras-for-substances-intended-for-use-in-human-or-animal-food/0619cd37-0b9c-4d40-bc29-69d2b0c1083c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-49-evaluating-target-animal-safety-and-effectiveness-of-antibacterial-new-animal-drugs-for-bovine-mastitis/35a39040-371d-4d01-af2e-28651bd3aa34 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-frequently-asked-questions-about-medical-foods-third-edition/43c689b8-753c-4add-825f-3b4c48553202 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-questions-and-answers-regarding-food-allergen-labeling-edition-5/94ef4071-8ef0-4d79-86e7-160953696fd7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/core-patient-reported-outcomes-in-cancer-clinical-trials-guidance-for-industry/a5111d3d-2d0d-4753-9773-d2f2a25c85fb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e6r2-good-clinical-practice-integrated-addendum-to-ich-e6r1/5fe18bca-d400-4f1d-b1fa-5d0b24388989 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/content-and-format-of-chemistry-manufacturing-and-controls-information-and-establishment-description-information-for-a-vaccine-or-related-product-guidance-for-industry/86d8898a-dfbf-4477-8b96-de5c1930be39 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/characterization-and-qualification-of-cell-substrates-and-other-biological-materials-used-in-the-production-of-viral-vaccines-for-infectious-disease-indications-guidance-for-industry/7f4ef6a5-58e5-4416-a8b1-d273185f127f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-to-reduce-the-risk-of-transfusion-transmitted-malaria-draft-guidance-for-industry/1eea49f3-76b0-45d6-81c4-4a91e8a41311 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-to-reduce-the-risk-of-transmission-of-hepatitis-c-virus-hcv-by-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-draft-guidance-for-industry/c633df96-5f83-4bc3-8f69-2096f1d81b16 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing-submission-recommendations-draft-guidance-for-industry-and-food-and-drug-administration-staff/7498efae-e618-4d5c-948d-0ce31ebc65c6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommended-followup-testing-for-an-ames-positive-drug-active-ingredient-or-metabolite-to-support-first-in-human-clinical-trials-with-healthy-subjects/ce4cb94e-e7a9-4c9d-a289-a55bc94e74c1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dental-impression-materials-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/22837680-55d2-49fb-b29d-af88582bf667 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-294-animal-food-ingredient-consultation-afic/85306026-026d-4fce-84d6-dc18952c8d4b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dental-curing-lights-premarket-notification-510k-submissions-draft-guidance-for-industry-and-food-and-drug-administration-staff/0479db14-6492-4414-b891-4485a4ba5c8e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/essential-drug-delivery-outputs-for-devices-intended-to-deliver-drugs-and-biological-products-draft-guidance-for-industry/4fd9f193-7d92-4a60-9cc8-fb2d65a0d90e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/standardized-format-for-electronic-submission-for-marketing-applications-content-for-the-planning-of-bioresearch-monitoring-bimo-inspections-for-center-of-biologics-evaluation-and-research-submissions/9135a75c-48b3-48bb-8340-09e33de8f931 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-use-of-human-and-animal-derived-materials-in-the-manufacture-of-cell-and-gene-therapy-and-tissue-engineered-medical-products/3d5c2c78-6224-49f7-8c61-e72d9219b413 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cancer-clinical-trial-eligibility-criteria-laboratory-values-draft-guidance-for-industry-irbs-and-clinical-investigators/cf0069be-0465-448a-99af-11f54aa88dfd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-285-manufacture-of-batches-in-support-of-original-nadas-anadas-and-cnadas/d6be7c32-4f76-44ec-95c4-9ac9309d861f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-new-dietary-ingredient-notification-procedures-and-timeframes-dietary-supplements/f52be4b9-64b2-4381-beaf-633dfa973c10 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/adjusting-for-covariates-in-randomized-clinical-trials-for-drugs-and-biological-products/f58b2adc-b92a-4458-b269-5346d25a8a39 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/510k-third-party-review-program-and-third-party-emergency-use-authorization-eua-review-guidance-for-industry-food-and-drug-administration-staff-and-third-party-review-organizations/1bdc19b2-0e5f-47a4-aa74-15e3e730ff5c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submitting-clinical-trial-datasets-and-documentation-for-clinical-outcome-assessments-using-item-response-theory/9895a301-585a-4b74-83a1-3b526f3ec3d3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-peptide-drug-products/1609c8ed-4d50-4235-8a00-9c63176affe8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/post-warning-letter-meetings-under-gdufa/4176915b-4275-4264-96ff-88a64a4f46e7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-registration-and-listing-of-cosmetic-product-facilities-and-products/4e200085-95f4-4755-aebf-8b12d6808163 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/formal-dispute-resolution-and-administrative-hearings-of-final-administrative-orders-under-section-505g-of-the-federal-food-drug-and-cosmetic-act/17bebcf8-b43d-4abb-89dd-98ff77692884 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/migraine-developing-drugs-for-preventive-treatment/cd739d7c-f8ed-4a37-b16f-d6f3b9550a94 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pediatric-drug-development-regulatory-considerations-complying-with-the-pediatric-research-equity-act-and-qualifying-for-pediatric-exclusivity-under-the-best-pharmaceuticals-for-children-act/c7de020f-03c0-4902-a320-07443487355d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-555400-aflatoxins-in-human-food/60acede5-b72b-4f8f-aad5-f357ca271d89 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/formal-meetings-between-the-food-and-drug-administration-and-sponsors-or-requestors-of-over-the-counter-monograph-drugs/b75646c9-df1f-4b38-a2d8-dea9f3410853 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/digital-health-technologies-for-remote-data-acquisition-in-clinical-investigations/d03b5a1b-cf30-4bed-81a8-aa883ea62d4c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/chronic-rhinosinusitis-with-nasal-polyps-developing-drugs-for-treatment-guidance-for-industry/439c0f16-253a-4864-95f1-2bc1395e5163 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-temporary-permits-for-interstate-shipment-of-experimental-packs-of-food-varying-from-the-requirements-of-definitions-and-standards-of-identity/e5cb3174-6a3d-4278-ad80-a731673f6bd0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigator-responsibilities-safety-reporting-for-investigational-drugs-and-devices-draft-guidance-for-industry/34f91048-9ac4-48e3-ac1e-4af23b426721 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-253-current-good-manufacturing-practice-for-animal-cells-tissues-and-cell-and-tissue-based-products/9f83a1f8-185e-425f-bfdc-882e095586c3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/exploratory-ind-studies-guidance-for-industry-investigators-and-reviewers/836b5809-de11-4db6-8f91-3671cf875e32 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e6r3-good-clinical-practice-annex-2/8cba2156-b613-4d5b-9a03-bb5b0bc681c1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m12-drug-interaction-studies-questions-and-answers/bc98fecb-33fe-438e-be6c-5f4d817992e9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-683100-action-levels-for-aflatoxins-in-animal-feeds/33ff4680-f087-4221-96fe-d5e08402d11d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/program/chapter-48-7348809-bioresearch-monitoring/32cb56f9-118b-4f48-b9f0-9376f28a15d0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/chemotherapy-induced-nausea-and-vomiting-developing-drugs-for-prevention-guidance-for-industry-draft-guidance-for-industry/9b036fec-744d-4fca-a565-c799357b16a9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/policy-for-evaluating-impact-of-viral-mutations-on-covid-19-tests-revised-guidance-for-test-developers-and-food-and-drug-administration-staff/91e43210-583d-46a9-919c-aab24aa0fad0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/ind-submissions-for-individualized-antisense-oligonucleotide-drug-products-administrative-and-procedural-recommendations-guidance-for-sponsor-investigators-draft-guidance-for-sponsor-investigators/002f3888-2785-46f0-a50d-016c4392f189 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/electronic-submission-template-for-medical-device-de-novo-requests-guidance-for-industry-and-food-and-drug-administration-staff/8bd49234-647d-4582-b2b5-adc2a5d75f1c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/compliance-policy-guide-cpg-sec-110650-weekly-entry-filing-guidance-for-industry-and-fda-staff/a8816af8-0022-4fe9-b58a-37473490b8e1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/premenopausal-women-with-breast-cancer-developing-drugs-for-treatment-guidance-for-industry/03f0e242-74ab-4a8e-b4b3-5d5c1d720852 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/failure-to-respond-to-an-anda-complete-response-letter-within-the-regulatory-timeframe-guidance-for-industry-guidance-for-industry/2cb79d52-2f8b-43f0-b3e6-438ef7b8a9d1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessing-covid-19-related-symptoms-in-outpatient-adult-and-adolescent-subjects-in-clinical-trials-of-drugs-and-biological-products-for-covid-19-prevention-or-treatment-guidance-for-industry/3993ff56-2b20-4679-8303-9876c6800402 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/drug-drug-interaction-assessment-for-therapeutic-proteins-guidance-for-industry-guidance-for-industry/2a0a5163-7a5f-4b3c-9eef-d94d670b6733 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-265-use-of-data-from-foreign-investigational-studies-to-support-effectiveness-of-new-animal-drugs/f6cb70ad-ba2c-4653-958c-74dd08a7f819 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/review-and-update-of-device-establishment-inspection-processes-and-standards-guidance-for-industry/41baf6cf-3349-4f8c-af1c-18313518b783 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enforcement-policy-for-certain-supplements-for-approved-premarket-approval-pma-or-humanitarian-device-exemption-hde-submissions-guidance-for-industry-and-food-and-drug-administration-staff/04d58afd-337c-4b53-abac-9b7340d35b83 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/recommendations-for-donor-screening-with-a-licensed-test-for-hiv-1-antigen-memorandum-to-all-registered-blood-establishments/b6d676b7-60c8-4606-8b58-c05a532c13f8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/recommendations-for-the-quarantine-and-disposition-of-units-from-prior-collections-from-donors-with-repeatedly-reactive-screening-tests-for-hepatitis-b-virus-hbv-hepatitis-c-virus-hcv-and-human-t-lymphotropic-virus-type-i-htlv-i/0dfc95d9-9a1a-4ce9-aca0-109d948f753c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/temporary-policy-regarding-accredited-third-party-certification-program-onsite-observation-and-certificate-duration-requirements-due-to-covid-19-guidance-for-industry/4b349f0f-560d-46dc-bd08-884c08169ecd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enforcement-policy-for-non-invasive-remote-monitoring-devices-used-to-support-patient-monitoring-guidance-for-industry-and-food-and-drug-administration-staff/6f2ee667-e678-4e6f-92d0-805b534c457f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/type-2-diabetes-mellitus-evaluating-the-safety-of-new-drugs-for-improving-glycemic-control-guidance-for-industry/8cef335d-7cb8-41c1-b77f-95a0dfb9e587 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/internetsocial-media-platforms-with-character-space-limitations-presenting-risk-and-benefit-information-for-prescription-drugs-and-medical-devices/b4147d06-9886-4255-90c9-3bc62c0c7374 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/specifications-for-preparing-and-submitting-electronic-icsrs-and-icsr-attachments/77393f14-23b3-44f2-b22c-c43dbd63161a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/biosimilars-and-interchangeable-biosimilars-licensure-for-fewer-than-all-conditions-of-use-for-which-the-reference-product-has-been-licensed-guidance-for-industry-draft-guidance-for-industry/8f893384-8971-47a4-9e54-aea227852806 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/development-of-locally-applied-corticosteroid-products-for-the-short-term-treatment-of-symptoms-associated-with-internal-or-external-hemorrhoids-guidance-for-industry-draft-guidance-for-industry/d05d2867-45e4-43f9-b2fe-8fc051d16762 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/certificates-of-confidentiality-guidance-for-sponsors-sponsor-investigators-researchers-industry-and-food-and-drug-administration-staff/2c808a5d-3858-4b85-b669-fc805457803a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/chronic-hepatitis-d-virus-infection-developing-drugs-for-treatment-guidance-for-industry/a162cb79-9621-497d-a34f-dd8e97dfa9b3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/drug-master-files-guidance-for-industry/7dfd5140-3156-43f2-bdb9-d23ad597311c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-for-medical-devices-in-electronic-format-submissions-under-section-745ab-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry-and-food-and-drug-administration-staff/fc3853a4-7287-48ef-a363-32e3dfef666c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/interpreting-sameness-of-gene-therapy-products-under-the-orphan-drug-regulations-guidance-for-industry/d27ec8e3-b338-46f1-8b89-72ee766cf16c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/interacting-with-the-fda-on-complex-innovative-trial-designs-for-drugs-and-biological-products-guidance-for-industry/915195b1-fcb7-4359-b741-f4ca3ed67b13 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cutaneous-electrodes-for-recording-purposes-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/48d2ad49-a9ca-4505-8219-90e96f78851a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pathology-peer-review-in-nonclinical-toxicology-studies-questions-and-answers/2389b45f-e333-46cf-b87b-a1e55f05c775 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-in-electronic-format-certain-human-pharmaceutical-product-applications-and-related-submissions-using-the-ectd-specifications-guidance-for-industry/f3023985-2821-4129-a059-002b98ccbb3f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compliance-policy-for-certain-compounding-of-oral-oxitriptan-5-htp-drug-products-for-patients-with-tetrahydrobiopterin-bh4-deficiency-immediately-in-effect-guidance-for-industry/d88af3f7-de54-4f46-bcc5-9dd57bf5f149 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/treatment-for-heart-failure-endpoints-for-drug-development-guidance-for-industry/3a3c4b6b-8dd2-4027-b7e6-10f7059fe28b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submission-of-plans-for-cigarette-packages-and-cigarette-advertisements-revised/f54c0f62-00c2-4287-9065-adc0e519c90e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/section-503a-bulks-list-final-rule-questions-and-answers-small-entity-compliance-guide-guidance-for-industry/8bedb0a9-b118-4dec-8101-32da6483dbba 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postapproval-pregnancy-safety-studies-guidance-for-industry/3681b74c-6d89-4847-9151-7f24bcf1a63c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/extending-expiration-dates-of-doxycycline-tablets-and-capsules-in-strategic-stockpiles-guidance-for-government-public-health-and-emergency-response-stakeholders/a217cd01-da07-4fcc-b9df-ea4c5c8aa536 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/developing-targeted-therapies-in-low-frequency-molecular-subsets-of-a-disease/becd1349-aa73-4de3-83cd-a43abfb0f98c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/technical-performance-assessment-of-quantitative-imaging-in-radiological-device-premarket-submissions-guidance-for-industry-and-food-and-drug-administration-staff/0ad9d5da-55b8-46ee-b2ab-37dd0c4b75b2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/determining-whether-to-submit-an-anda-or-a-505b2-application/c04d36f1-c78a-4aaf-8e45-6a99420cf632 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/a-risk-based-approach-to-monitoring-of-clinical-investigations-questions-and-answers-guidance-for-industry/3134187f-5a62-4b96-8e62-23b17474de42 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/smoking-cessation-and-related-indications-developing-nicotine-replacement-therapy-drug-products/bdeb89b0-5451-4478-b053-64d1decc6de0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/developing-and-submitting-proposed-draft-guidance-relating-to-patient-experience-data/49677313-1014-4cd6-be89-f28a08eb3f96 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/brief-summary-and-adequate-directions-for-use-disclosing-risk-information-in-consumer-directed-print-advertisements-and-promotional-labeling-for-prescription-drugs/47c1576a-8db7-49fb-8fcc-66e1d013145e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/presenting-risk-information-in-prescription-drug-and-medical-device-promotion/85abd709-63d2-4514-8e97-a628a63a8b2e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clarification-of-radiation-control-regulations-for-manufacturers-of-diagnostic-x-ray-equipment-guidance-for-industry-and-food-and-drug-administration-staff/9af128f7-1996-449d-9119-722799a49720 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/noncirrhotic-nonalcoholic-steatohepatitis-with-liver-fibrosis-developing-drugs-for-treatment/557c8137-5d47-4a52-ab3f-6fd88febd924 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m9-biopharmaceutics-classification-system-based-biowaivers/bf9d33a6-a7bf-4b4e-bf7a-2a88d1e6d1cf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/selection-of-the-appropriate-package-type-terms-and-recommendations-for-labeling-injectable-medical-products-packaged-in-multiple-dose-single-dose-and-single-patient-use-containers-for-human-use-guidance-for-industry/feadd78e-f706-4b5b-9845-248e50157728 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/atopic-dermatitis-timing-of-pediatric-studies-during-development-of-systemic-drugs/287c413c-cc5e-49ee-af83-9d7183bc4f4d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q3dr2-guideline-for-elemental-impurities-international-council-for-harmonisation-draft-guidance-for-industry/6c1601a1-c9c7-484c-9b10-22823aa7dcc4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-electronic-informed-consent-in-clinical-investigations-questions-and-answers-guidance-for-institutional-review-boards-investigators-and-sponsors/86634097-60db-4d53-bf74-1518a536d9df 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-deemed-to-be-a-license-provision-of-the-bpci-act-questions-and-answers-guidance-for-industry/fdd76b2b-bf3b-4f6d-9988-59d75e496a17 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/public-availability-of-lists-of-retail-consignees-to-effectuate-certain-human-and-animal-food-recalls-guidance-for-industry-and-fda-staff/66c3863f-c432-4001-91f6-beabd651424c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/placebos-and-blinding-in-randomized-controlled-cancer-clinical-trials-for-drug-and-biological-products-guidance-for-industry/f88966dd-4dae-4b98-ae6e-e21b153bfb43 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/opioid-use-disorder-endpoints-for-demonstrating-effectiveness-of-drugs-for-treatment-guidance-for-industry/88ee7ab4-2004-41c5-9b57-36cc6087d892 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-257-vich-gl57-studies-to-evaluate-the-metabolism-and-residue-kinetics-of-veterinary-drugs-in-food-producing-species-marker-residue-depletion-studies-to-establish-product-withdrawal-periods-in-aquatic-species/e5ed84ad-933b-4d48-a0de-79cb738b45a2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-development-of-dried-plasma-products-intended-for-transfusion-guidance-for-industry/c0c693ab-7392-4bad-b4c9-de122a24ced4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/oncology-therapeutic-radiopharmaceuticals-nonclinical-studies-and-labeling-recommendations-guidance-for-industry/207c1c32-d577-4283-836d-ae7bb8e1ea92 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/formal-meetings-between-the-fda-and-sponsors-or-applicants-of-bsufa-products-guidance-for-industry/8a1d80ed-d462-41f3-b1cd-7df78736a49b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/human-gene-therapy-for-rare-diseases-guidance-for-industry/1cebc8e2-7d3b-4c5f-a4c4-78d1fc112099 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/limited-population-pathway-for-antibacterial-and-antifungal-drugs-guidance-for-industry/f01d33af-ed26-4eb5-961a-03e00c90f2c7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pediatric-hiv-infection-drug-development-for-treatment/2fd110e1-e45d-44ba-8efb-87a9ba7b8d23 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q7-good-manufacturing-practice-guidance-for-active-pharmaceutical-ingredients-questions-and-answers-guidance-for-industry/1600b7d2-35c2-41f8-add1-35f8c98ddb9b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/standardization-of-data-and-documentation-practices-for-product-tracing-guidance-for-industry/d58db3d4-b065-42bd-88a6-e18fe6db0a51 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/public-warning-notification-of-recalls-under-21-cfr-part-7-subpart-c-guidance-for-industry-and-fda-staff/2ef37f26-5a8f-465a-8182-48b8e9e1613e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/systemic-antibacterial-and-antifungal-drugs-susceptibility-test-interpretive-criteria-labeling-for-ndas-and-andas/a071fec6-d1c9-41d8-bbbf-4f71788c7e7f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-dual-510k-and-clia-waiver-by-application-studies-guidance-for-industry-and-food-and-drug-administration-staff/02a7cfc8-9402-4ce9-89ca-2983b8cd9092 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigational-ivds-used-in-clinical-investigations-of-therapeutic-products-draft-guidance-for-industry-food-and-drug-administration-staff-sponsors-and-institutional-review-boards/4238dfca-183e-4815-977e-a5fc2f0a83c0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/requests-for-reconsideration-at-the-division-level-under-gdufa/57f559b5-e6c3-492b-91fd-01762f90e676 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/anda-submissions-refuse-to-receive-standards-questions-and-answers-guidance-for-industry/9263d6de-7354-4678-ba95-003ad712d3c3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/policy-clarification-and-premarket-notification-510k-submissions-for-ultrasonic-diathermy-devices-guidance-for-industry-and-food-and-drug-administration-staff/ab06388f-a3b0-4c35-a1b7-ab5befb36526 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/product-identifier-requirements-under-the-drug-supply-chain-security-act-compliance-policy-guidance-for-industry/610cbeb8-d9d2-45ae-8410-67587f5666eb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-in-demonstrating-interchangeability-with-a-reference-product-guidance-for-industry/3c6c8653-5a0c-4cb1-b776-530e73843765 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/referencing-approved-drug-products-in-anda-submissions-guidance-for-industry/a3f26b8f-0c5a-443b-b665-6fef99ae7de4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-for-industry/a65eb174-50f7-4cfb-a751-33c206aaa385 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/deciding-when-to-submit-a-510k-for-a-software-change-to-an-existing-device-guidance-for-industry-and-food-and-drug-administration-staff/303c36a0-3191-4197-bc16-584e24525d07 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-x-ray-imaging-devices-conformance-with-iec-standards-guidance-for-industry-and-food-and-drug-administration-staff/c9be6efa-524e-406c-a971-0e918a512690 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recurrent-herpes-labialis-developing-drugs-for-treatment-and-prevention/e4e0fd38-d19b-43b7-9f6b-13b91c093857 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-public-human-genetic-variant-databases-to-support-clinical-validity-for-genetic-and-genomic-based-in-vitro-diagnostics-guidance-for-stakeholders-and-food-and-drug-administration-staff/d566c877-a6de-457c-a6e7-df0e3cbbe1f9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/procedures-for-evaluating-appearance-issues-and-granting-authorizations-for-participation-in-fda-advisory-committees-draft-guidance-for-the-public-fda-advisory-committee-members-and-fda-staff/a156c1c0-e485-411d-bff1-cdd2ee684bde 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/product-labeling-for-certain-ultrasonic-surgical-aspirator-devices-guidance-for-industry-and-food-and-drug-administration-staff/329ac4bb-3703-4e49-9b11-14eaf707920c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/technical-considerations-for-additive-manufactured-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/98baa3f0-2518-4f02-a853-0147f61ef069 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-239-human-food-by-products-for-use-as-animal-food/411dc67b-5562-4701-810e-f3cacf32d44a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/hospital-and-health-system-compounding-under-section-503a-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry/e0535821-7435-45f2-b7a6-0f238fd5d3ed 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/requirements-for-transactions-with-first-responders-under-section-582-of-the-federal-food-drug-and-cosmetic-act-compliance-policy-guidance-for-industry/46d7c1a7-9368-4929-afbd-858d5ebfae9f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/design-considerations-and-pre-market-submission-recommendations-for-interoperable-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/a444df11-a94c-4951-beca-dc46d774c47b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/unique-device-identification-convenience-kits-guidance-for-industry-and-food-and-drug-administration-staff/49e66a05-5ff6-46d1-a064-3f66e6cac0a3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/sunscreen-innovation-act-withdrawal-of-a-586a-request-or-pending-request-guidance-for-industry/9140c9a3-2436-43bf-ba6d-d219dfafe717 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/sunscreen-innovation-act-section-586cc-advisory-committee-process/97993b32-7987-4792-a5b3-29e16cd2ea6b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/botanical-drug-development-guidance-for-industry/bec78068-96c3-424e-b070-7b4ecfcfc8bf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/establishing-the-performance-characteristics-of-in-vitro-diagnostic-devices-for-the-detection-or-detection-and-differentiation-of-human-papillomaviruses-guidance-for-industry-and-food-and-drug-administration-staff/e02081ea-4147-4909-8696-9b18ed3c269e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dscsa-implementation-product-tracing-requirements-for-dispensers-compliance-policy-revised-guidance-for-industry/9a8d9c28-b1b5-4f9a-8eb3-dcf23c7358e3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-232-vich-gl54-studies-to-evaluate-the-safety-of-residues-of-veterinary-drugs-in-human-food-general-approach-to-establish-an-acute-reference-dose-arfd/e28ea139-170b-4f2e-bf40-0ea296d44fb4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/alcoholism-developing-drugs-for-treatment/5dd607ce-ea00-4415-bc0a-e05b7963322b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/repackaging-of-certain-human-drug-products-by-pharmacies-and-outsourcing-facilities-guidance-for-industry/c324ad2d-8447-448c-b0ed-664984cf9ba6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/technical-performance-assessment-of-digital-pathology-whole-slide-imaging-devices-guidance-for-industry-and-food-and-drug-administration-staff/3dccc64f-9588-4e6e-a571-acd09e8f6108 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/radiation-biodosimetry-medical-countermeasure-devices-guidance-for-industry-and-food-and-drug-administration-staff/9c7e3c75-b0cc-449b-88ea-9506971780ec 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigational-enzyme-replacement-therapy-products-nonclinical-assessment-guidance-for-industry/a3c5d661-a82f-441e-9036-1639578d4fc9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pregnancy-lactation-and-reproductive-potential-labeling-for-human-prescription-drug-and-biological-products-content-and-format-draft-guidance-for-industry/6649870b-ce98-4a27-85fd-7a350c7dd276 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/anda-submissions-refuse-to-receive-for-lack-of-justification-of-impurity-limits-guidance-for-industry/29897d63-6e30-44a4-ac28-8fbd517e9e00 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-224-supplement-to-vich-gl52-supplemental-examples-for-illustrating-statistical-concepts-described-in-the-vich-in-vivo-bioequivalence-guidance-gl52/bb61941b-429e-409c-b8ce-8edfb2ecb7c4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/ind-applications-for-minimally-manipulated-unrelated-allogeneic-placentalumbilical-cord-blood-intended-for-hematopoietic-and-immunologic-reconstitution-in-patients-with-disorders-affecting-the-hematopoietic-system-guidance-for-industry-and-fda-staff/11261772-181c-4193-9a2c-ff10ff47b76a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/unique-device-identification-system-small-entity-compliance-guide-guidance-for-industry-and-food-and-drug-administration-staff/c8b98843-774d-410b-a276-7ec09b25ed58 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-100250-food-facility-registration-human-and-animal-food/d8a019c7-1d21-4e91-83be-414ddb816291 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-device-data-systems-medical-image-storage-devices-and-medical-image-communications-devices-guidance-for-industry-and-food-and-drug-administration-staff/12c2c43f-83da-46b3-84e4-d3b7216e904f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/unique-device-identification-direct-marking-of-devices-guidance-for-industry-and-food-and-drug-administration-staff/2c961788-d811-461f-b457-ae7f4bc46d83 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bioavailability-and-bioequivalence-studies-submitted-in-ndas-or-inds-general-considerations/0cbdcef4-1b6b-45e5-8563-de1bb0a4e001 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/premarket-notification-510k-submissions-for-electrosurgical-devices-for-general-surgery-guidance-for-industry-and-food-and-drug-administration-staff/92e6b261-3141-4df1-ae3c-32bb9fcfbfb3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/distribution-of-in-vitro-diagnostic-products-labeled-for-research-use-only-or-investigational-use-only-guidance-for-industry-and-fda-staff/dd8e1483-1883-474d-925f-8579c62a5379 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-nucleic-acid-tests-to-reduce-the-risk-of-transmission-of-west-nile-virus-from-living-donors-of-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-guidance-for-industry/199628b4-b340-4f78-9026-967fee9885dd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/expedited-programs-for-serious-conditions-drugs-and-biologics/d49c172d-43db-4e76-a0fd-1f51de9ecff3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/changes-to-an-approved-application-biological-products-human-blood-and-blood-components-intended-for-transfusion-or-for-further-manufacture-final-guidance/d3ff905e-6a8a-440f-bdde-3f125c0e2af2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/user-fees-and-refunds-for-premarket-approval-applications-and-device-biologics-license-applications-guidance-for-industry-and-food-and-drug-administration-staff/9eddce42-ffa7-44f9-9cb3-97a0dbdeec40 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-postmarket-periodic-safety-reports-in-the-ich-e2cr2-format-periodic-benefit-risk-evaluation-report/39cb6b72-e49f-4e02-ba0b-172f4a5701a2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/reporting-drug-sample-information-under-section-6004-of-the-affordable-care-act/324bb7a2-737c-4021-a1b4-e156ceed5ab8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/financial-disclosure-by-clinical-investigators-guidance-for-clinical-investigators-industryand-fda-staff/a2fdcaf8-673b-4e11-9017-f37e4d719af8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pediatric-information-incorporated-into-human-prescription-drug-and-biological-products-labeling-good-review-practice/b745efcc-5e41-4458-a1d9-6827d55dd3a7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-690150-labeling-and-marketing-of-dog-and-cat-food-diets-intended-to-diagnose-cure-mitigate-treat-or-prevent-diseases/d446a8af-e7bf-462b-82b7-909148b3b275 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-when-transferring-clinical-investigation-oversight-to-another-irb-guidance-for-irbs-clinical-investigators-and-sponsors/fe8296e5-3ca7-4209-9920-27aa4635ee35 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/ecopy-program-for-medical-device-submissions-guidance-for-industry-and-food-and-drug-administration-staff/8d87a1c4-b362-4f01-bdca-28f730b7f5f0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/acceptance-and-filing-reviews-for-premarket-approval-applications-pmas-guidance-for-industry-and-food-and-drug-administration-staff/52adc866-94c6-4611-9789-cabacc9e381c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/current-good-tissue-practice-cgtp-and-additional-requirements-for-manufacturers-of-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-guidance-for-industry/5197b518-94ba-4445-b2d4-cccf3c8ac0e9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/scientific-considerations-in-demonstrating-biosimilarity-to-a-reference-product/b98b0335-f4b7-4a14-88b1-7ea4d02c7e37 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-considerations-for-therapeutic-cancer-vaccines-guidance-for-industry/e0e6e4e0-a883-4f71-bf37-784e147d32d9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/availability-of-fdas-esubmitter-program-for-regulatory-submissions-from-licensed-blood-establishments-guidance-for-industry/63bf2e4e-93ca-4693-8f9c-036c97157aea 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postmarket-surveillance-under-section-522-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry-and-food-and-drug-administration-staff/f631d61d-d1a4-451d-84c0-b22c554e8218 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/applying-human-factors-and-usability-engineering-to-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/d55d40d1-e1c4-4be8-acf7-c58a58dc4e11 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-527300-microbial-contaminants-alkaline-phosphatase-activity/8d58ee38-55f2-4762-b86a-b3d8ff6e10d3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-216-chemistry-manufacturing-and-controls-cmc-information-fermentation-derived-intermediates-drug-substances-and-related-drug-products-for-veterinary-medicinal-use/d0c2c04d-d9ac-472b-81b1-52edcca39cfa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-215-target-animal-safety-effectiveness-protocol-development-submission/2946be50-57e1-485e-9751-dbc164d2900b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/residual-drug-in-transdermal-and-related-drug-delivery-systems-guidance-for-industry/54698fcf-db58-4dd4-ac3a-81992e898cae 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/cvm-gfi-201-secg-for-the-index-of-legally-marketed-unapproved-new-animal-drugs-for-minor-species/db048295-9af2-4e33-acfb-e2389a855d2b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-investigator-administrative-actions-disqualification-guidance-for-institutional-review-boards-clinical-investigators-and-sponsors/010473ad-219d-4ac4-a350-3ad80a2d42fb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/adaptive-design-clinical-trials-for-drugs-and-biologics-guidance-for-industry/97c6b6e1-4164-4fbe-8059-b0aa3fd39415 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-208-vich-gl49-studies-to-evaluate-the-metabolism-and-residue-kinetics-of-veterinary-drugs-in-food-producing-animals-validation-of-analytical-methods-used-in-residue-depletion-studies/1decc3f0-93ed-4c66-b29d-a7e81d35bffb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-nucleic-acid-tests-to-reduce-the-risk-of-transmission-of-west-nile-virus-from-donors-of-whole-blood-and-blood-components-intended-for-transfusion-guidance-for-industry/863d535f-7224-46e2-84c2-785caa4abcf3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessing-user-fees-under-the-biosimilar-user-fee-amendments-of-2022-guidance-for-industry/4fbb7da7-e7da-4ffb-a835-53f0fa1a9dda 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s6-r1-addendum-preclinical-safety-evaluation-of-biotechnology-derived-pharmaceuticals/c9774033-823e-4e54-8323-928303b9f87d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/patient-reported-outcome-measures-use-in-medical-product-development-to-support-labeling-claims-guidance-for-industry/506b29a8-b7ee-47d9-b155-79fd4d5b76e2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-information-about-pediatric-uses-of-medical-devices-guidance-for-industry-and-fda-staff/d29759e2-eeac-4df2-a513-54e7bd3cf492 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-for-the-submission-of-chemistry-manufacturing-and-controls-information-for-a-therapeutic-recombinant-dna-derived-product-or-a-monoclonal-antibody-product-for-in-vivo-use/1c78a87a-d482-4f5d-9d0e-b273649f563f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/andas-impurities-in-drug-substances-guidance-for-industry/f8f33332-d6b5-44e6-a308-aa86ea6fa74f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cellular-therapy-for-cardiac-disease-guidance-for-industry/d0a87a21-c69d-46d1-b795-8481faf21a82 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/biological-product-deviation-reporting-for-licensed-manufacturers-of-biological-products-other-than-blood-and-blood-components/6e04904d-a911-49cf-8710-0406a81665bc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-217-evaluating-the-effectiveness-of-anticoccidial-drugs-in-food-producing-animals/13c5ebd2-832b-444f-bb2f-1ae5bb928f28 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/prescription-drug-marketing-act-pdma-requirements-questions-and-answers/e1169199-071c-4b63-b38b-60b57b79d4e6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-159-vich-gl36-studies-to-evaluate-the-safety-of-residues-of-veterinary-drugs-in-human-food-general-approach-to-establish-a-microbiological-adi/cfd44eba-11ff-45b5-9630-d842b8cf08bc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-575100-pesticide-residues-in-food-and-feed-enforcement-criteria/a04717fd-d48c-44ed-ae27-bc2e57a547c2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/quality-control-practices-for-compliance-with-the-federal-mercury-vapor-lamp-performance-standard/46a67338-879a-4fbb-9bb5-5fce90300e1d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-labeling-for-human-prescription-drug-and-biological-products-content-and-format/43229708-ad02-40d3-b318-996c20552a39 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/testing-and-labeling-medical-devices-for-safety-in-the-magnetic-resonance-mr-environment-guidance-for-industry-and-food-and-drug-administration-staff/035607b0-0a83-4ff4-914b-df00d3a2038b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-192-anesthetics-for-companion-animals/2789ea64-889b-4fb7-9efe-84dac69d2857 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/industry-letter/open-door-operation-of-microwave-ovens-as-a-result-of-oven-miswiring/974ab8bc-2689-4717-baaa-4e989a3acd41 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/de-novo-classification-process-evaluation-of-automatic-class-iii-designation-guidance-for-industry-and-food-and-drug-administration-staff/c07fa6ad-91f7-456d-b51e-780b71d784f5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/repeal-of-section-507-of-the-federal-food-drug-and-cosmetic-act-_1/2e6eed29-aedc-4122-900b-0eb9b1f9aaf0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/adequate-and-appropriate-donor-screening-tests-for-hepatitis-b-hepatitis-b-surface-antigen-hbsag-assays-used-to-test-donors-of-whole-blood-and-blood-components-including-source-plasma-and-source-leukocytes-guidance-for-industry/6e1a3dc6-02e1-498b-91e1-0f50f5544d60 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pharmacogenomic-data-submissions-examples-of-voluntary-submissions-or-submissions-required-under-21-cfr-312-314-or-601/097d6c1f-5f70-4be5-acc2-a2029bde4dab 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/for-the-submission-of-chemistry-manufacturing-and-controls-and-establishment-description-information-for-human-plasma-derived-biological-products-animal-plasma-or-serum-derived-products-guidance-for-industry/84402487-bfa5-4bc3-9edf-4a7c88bac51d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/content-and-format-of-chemistry-manufacturing-and-controls-information-and-establishment-description-information-for-a-biological-in-vitro-diagnostic-product-guidance-for-industry/28d78ae4-1e11-4509-9404-577a3231fbf6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance/estimating-the-maximum-safe-starting-dose-in-initial-clinical-trials-for-therapeutics-in-adult-healthy-volunteers/a0e9555e-44bd-4cf3-bfa3-7f67f0d88a6f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/sample-formats-for-form-fda-356h_2011/1d046c26-0c90-45e2-a14f-8ce389c35cae 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/safety-testing-of-drug-metabolites/f87f3786-685f-4a28-963e-3499543cdd61 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessing-donor-suitability-and-blood-and-blood-product-safety-in-cases-of-known-or-suspected-west-nile-virus-infection-guidance-for-industry/04a8af8b-dc5e-464c-9103-5af9ec81f653 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-safety-evaluation-of-reformulated-drug-products-and-products-intended-for-administration-by-an-alternate-route/4ff25d70-5ac4-418c-a83e-79f958421f2c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/reproductive-and-developmental-toxicities-integrating-study-results-to-assess-concerns/c4a36dce-692b-4bf7-a01c-93273c8ee3e6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance/court-decisions-anda-approvals-and-180-day-exclusivity-under-the-hatch-waxman-amendments-to-the-federal-food-drug-and-cosmetic-act/4d91b564-120c-4376-be51-25fecf8aa7a3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cybersecurity-for-networked-medical-devices-containing-off-the-shelf-ots-software-guidance-for-industry/0e53f0e6-f429-403c-bcdd-999a024795d9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-570450-tree-nuts-adulteration-with-filth-involving-the-presence-of-the-organism-escherichia-coli/041bab52-1233-4af3-9608-cc14fd1119ff 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-570200-aflatoxins-in-brazil-nuts/fb743f73-3766-43d5-a47c-1e90e5bad586 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-537100-eggs-and-egg-products-frozen-adulteration-involving-decomposition/5fe94d9b-5880-4dcd-aad8-7a2ed57a874c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/appropriate-use-of-voluntary-consensus-standards-in-premarket-submissions-for-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/9e88a732-712a-4a47-90e2-8925abe66845 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/radio-frequency-wireless-technology-in-medical-devices-guidance-for-industry-and-fda-staff/a01cd2bb-faeb-44da-958b-c7ba3142c277 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525900-whole-plant-unprocessed-marjoram-unground-processed-marjoram-ground-marjoram-adulteration-by-insect-rodent-filth-mold-mammalian-excreta/be984823-62dc-43d8-ab01-1b06d457507f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-400100-drugs-human-failure-to-register/8b03ec9b-9f56-4666-92da-43df6d4900d8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585775-spinach-canned-or-frozen-adulteration-involving-insects-decomposition/018acaac-76e2-4699-b8b4-f82b9b976b96 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525150-bay-laurel-leaves-adulteration-by-insect-filth-mold-mammalian-excreta/37fbf9cb-4e6a-412b-802f-e635715dbe5f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550350-figs-fig-paste-adulteration-involving-insect-infestation-mold-dirt/aa2c1324-6871-43a5-9785-c6c0f4f9e960 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550225-cherries-brined-fresh-canned-and-frozen-adulteration-involving-rot-and-insect/ab261a49-1491-4a8c-ba67-b7bd935b2019 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-310210-blood-pressure-measurement-devices-sphygmomanometers-accuracy/ddc781a9-09e0-4db9-bf17-6e6b033eca21 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q2a-text-on-validation-of-analytical-procedures/3e742a63-75b1-4c93-a961-a710f9f035ac 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/preparing-notices-of-availability-of-investigational-medical-devices-and-for-recruiting-study-subjects-guidance-for-industry-and-fda-staff/49c8c57e-1a2a-4583-a6f1-82f8a8b39201 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/concept-paper/animal-models-essential-elements-to-address-efficacy-under-the-animal-rule-concept-paper/00cf5e8c-1e14-46d5-827f-c0bc4c1d3ee0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment-guidance-for-industry/9fb2afd0-d696-4043-9e1d-40673dcaf63a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-the-use-of-bayesian-statistics-in-medical-device-clinical-trials-pdf-version/fbeac02e-7cdc-4ed1-b4bb-6341f780d431 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-device-user-fee-and-modernization-act-of-2002-validation-data-in-premarket-notification-submissions-510ks-for-reprocessed-single-use-medical-devices-guidance-for-industry-and-fda-staff/acb7ac03-f27d-4689-a580-1296d1caf05e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550655-peaches-canned-misbranding-involving-food-standards/f2dd8ea2-279e-474f-9052-357454768ac5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q5b-quality-of-biotechnological-products-analysis-of-the-expression-construct-in-cells-used-for-production-of-r-dna-derived-protein-products/245613c2-f488-4d8f-a017-e16fbd69e2ed 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/handling-and-retention-of-bioavailability-ba-and-bioequivalence-be-testing-samples-draft-guidance-for-industry/2fcf37e3-5e20-4282-a983-136eda5bda3c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e14-clinical-evaluation-of-qtqtc-interval-prolongation-and-proarrhythmic-potential-for-non-antiarrhythmic-drugs/c83f1589-7be1-4064-93e8-eedcbfd73f95 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-development-programs-for-drugs-devices-and-biological-products-for-the-treatment-of-rheumatoid-arthritis-ra/c6678a1b-ae2a-4f48-92c5-5c50a3029502 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/frequently-asked-questions-about-the-reprocessing-and-reuse-of-single-use-devices-by-third-party-and-hospital-reprocessors-three-additional-questions-guidance-for-industry-fda-staff-third-party-and-hospital-reprocessors/79aebfa1-43e7-4304-8935-caed5d6fdf77 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency-guidance-for-submitting-hbv-resistance-data/937abe21-af65-46ce-83a8-963a0fb30d4f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/indexing-structured-product-labeling/a3bd05e5-ec29-40f1-a24b-27fe16f0c1da 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/saline-silicone-gel-and-alternative-breast-implants-guidance-for-industry-and-fda-staff/5121178c-1a3a-4504-8dfa-8440e9b3b86a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/quality-systems-approach-to-pharmaceutical-current-good-manufacturing-practice-regulations/9ed0e9b2-d08c-4cb7-b5fd-6cd0b3699b31 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigating-out-of-specification-oos-test-results-for-pharmaceutical-production-level-2-revision-guidance-for-industry/1e06deea-ceb4-4e41-b2d2-1b4611f8ccdd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/expiration-dating-and-stability-testing-of-solid-oral-dosage-form-drugs-containing-iron-guidance-for-industry/e8fd7f66-c062-4a8a-bc7b-40e37119c3cb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bioavailability-and-bioequivalence-studies-for-nasal-aerosols-and-nasal-sprays-for-local-action/c75f03a9-fe74-43cb-90de-ab8a4cbbd770 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/ind-meetings-for-human-drugs-and-biologics-chemistry-manufacturing-and-controls-information-guidance-for-industry/d36eac77-5bcf-4737-b484-0bdcaf6b5c77 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-93-vich-gl11r-impurities-in-new-veterinary-medicinal-products/5ce02165-efaa-49b1-a1bf-7cc5c320cf0f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-85-vich-gl9-good-clinical-practice/1d54554e-354f-4b8e-8af0-28277b41a7b0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-75-vich-gl5-stability-testing-photostability-testing-of-new-veterinary-drug-substances-and-medicinal-products/f51156d4-acdb-4c6d-bf5f-9ba2d99c709c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/cvm-gfi-120-veterinary-feed-directive-regulation-questions-and-answers/33777e41-11e8-4cf8-8dd0-6493b3ff2eb4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-118-mass-spectrometry-for-confirmation-of-identity-of-animal-drug-residues/48c4393e-ea9d-404d-a5ab-ae94ef57390c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-114-vich-gl21-effectiveness-of-anthelmintics-specific-recommendations-for-chickens-gallus-gallus/2c312312-2665-474b-833c-60fc61f1b30b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-109-vich-gl15-effectiveness-of-anthelmintics-specific-recommendations-for-equines/f9f205c2-a042-49f7-a15b-73ac1fde4859 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-137-analytical-methods-description-for-type-c-medicated-feeds/2581d610-79ce-492b-b696-9aa650a13339 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-152-evaluating-the-safety-of-antimicrobial-new-animal-drugs-with-regard-to-their-microbiological-effects-on-bacteria-of-human-health-concern/e4aa1a59-7022-4faf-a725-747058b8baf1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-recommendations-for-collecting-representative-samples-for-food-testing-used-as-evidence-for-release-of-certain-fish-and-fishery-products-subject-to-detention-without-physical-examination-dwpe-and-removal-of-a-foreign-manufacturers-goods-from-dwpe/19b53f04-0121-43bd-a12e-43c97f7a0fe6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-to-the-center-for-biologics-evaluation-and-research-cber-in-electronic-format-biologics-marketing-applications-guidance-for-industry/e40f855e-b668-42d8-b0d7-4fcce8341f29 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-286-vich-gl60-good-manufacturing-practice-for-active-pharmaceutical-ingredients-used-in-veterinary-medicinal-products/7f7052eb-5fa4-4d38-b174-a5a3f7b63abc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/characterization-of-metallic-coatings-andor-calcium-phosphate-coatings-on-orthopedic-devices-draft-guidance-for-industry-and-food-and-drug-administration-staff/75d15d0b-10b7-4f21-8395-0018919f5abb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/potency-assurance-for-cellular-and-gene-therapy-products/2a9b0d81-9dd5-43cf-994c-ac0df102c216 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/reformulating-drug-products-that-contain-carbomers-manufactured-with-benzene/eca61c4a-9786-4068-b4e8-00d8444874c6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/preclinical-assessment-of-investigational-cellular-and-gene-therapy-products-guidance-for-industry/e4aedc4e-81e3-4d2e-b655-2460ccf3a04e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/direct-to-consumer-prescription-drug-advertisements-presentation-of-the-major-statement-in-a-clear-conspicuous-and-neutral-manner-in-advertisements-in-television-and-radio-format-final-rule-questions-and-answers/08ff0962-be16-482b-a446-a109385d7e7a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/master-protocols-for-drug-and-biological-product-development/401e65ec-7388-4389-a95a-dc8860a1ce51 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e6r3-good-clinical-practice-gcp/bfd17ec4-cf4e-4b68-a61c-d3ae1f8a9cd1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/diabetes-mellitus-efficacy-endpoints-for-clinical-trials-investigating-antidiabetic-drugs-and-biological-products/b83095c6-9f4a-4d0e-bbb2-0e2c8a11e2f1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/generally-accepted-scientific-knowledge-in-applications-for-drug-and-biological-products-nonclinical-information/80a1d387-00c7-42b3-90ef-982941cdff8b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/psychedelic-drugs-considerations-for-clinical-investigations/c22c8005-efa9-4373-893d-cf27911562b6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-290-vich-gl61-pharmaceutical-development/e8fd92df-cd71-4f54-be38-a00b312eecbb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pediatric-drug-development-under-the-pediatric-research-equity-act-and-the-best-pharmaceuticals-for-children-act-scientific-considerations/ec636095-c1f7-4772-8dae-ff1ea7ee80fc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-555250-draft-major-food-allergen-labeling-and-cross-contact/bc24c2eb-ce93-4a04-8be6-67ce45584639 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-biosimilar-and-interchangeable-biosimilar-products/54a5f712-03f5-4993-b0d7-6a1c2f261eff 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bladder-cancer-developing-drugs-and-biologics-for-adjuvant-treatment-guidance-for-industry/b3fd959c-72c5-4e86-a4a9-5fa31d0ce7b7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/renal-cell-carcinoma-developing-drugs-and-biologics-for-adjuvant-treatment-guidance-for-industry/db30c852-ed7b-4054-8906-3aadd3851179 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-use-of-physiologically-based-pharmacokinetic-analyses-biopharmaceutics-applications-for-oral-drug-product-development-manufacturing-changes-and-controls-draft-guidance-for-industry/1478d7de-3011-4521-8336-5e9803457e9e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cover-letter-attachments-for-controlled-correspondences-and-anda-submissions-guidance-for-industry/2b16776c-c5b5-4985-bb58-5746b2e77188 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/questions-and-answers-m7r2-assessment-and-control-of-dna-reactive-mutagenic-impurities-in-pharmaceuticals-to-limit-potential-carcinogenic-risk-guidance-for-industry/c4192f88-a166-40a9-900f-0f22f5a5373a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compliance-with-21-cfr-part-1271150c1-manufacturing-arrangements-guidance-for-industry/21f3b771-082c-4fa4-bcb3-11816cc92176 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/identification-of-manufacturing-establishments-in-applications-submitted-to-cber-and-cder-questions-and-answers/4f5d2866-e1a8-4a27-8196-db286649fbfb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-returning-refrigerated-transport-vehicles-and-refrigerated-storage-units-to-food-uses-after-using-them-to-preserve-human-remains/0c371b06-7997-46ad-a88f-61d0b836fa01 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/technical-considerations-for-non-clinical-assessment-of-medical-devices-containing-nitinol-guidance-for-industry-and-food-and-drug-administration-staff/efbd5db2-6144-455e-b295-348f496e7554 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/release-of-ora-laboratory-analytical-results-to-the-responsible-party-guidance-for-food-and-drug-administration-staff/dc7018a4-6503-4f69-90c7-e7c2c13f3ba2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/electronic-submission-of-ind-safety-reports-technical-conformance-guide-guidance-for-industry/9ed4ff9c-5d3c-41d5-aacc-06ba022dab28 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/classification-categories-for-certain-supplements-under-bsufa-iii/f09c6e0e-9036-4b71-a1b0-4304825ad58b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/contents-of-a-complete-submission-for-threshold-analyses-and-human-factors-submissions-to-drug-and-biologic-applications/59c7d8e1-bb70-4df0-8d2e-5035b24198f7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-enforcement-policy-for-entities-growing-harvesting-packing-or-holding-hops-wine-grapes-pulse-crops-and-almonds/506304ed-decd-41cf-96f1-5779fdfe84dc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/competitive-generic-therapies/402bfb2a-4126-427d-9a19-4507e22c6b0e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/master-protocols-efficient-clinical-trial-design-strategies-to-expedite-development-of-oncology-drugs-and-biologics-guidance-for-industry-guidance-for-industry/102e00b9-5d33-4bc1-ac6f-2d1c86b63720 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/data-integrity-and-compliance-with-drug-cgmp-questions-and-answers-guidance-for-industry/6c715dd0-9083-429b-971c-4542b115bfed 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/questions-and-answers-on-biosimilar-development-and-the-bpci-act-guidance-for-industry-guidance-for-industry/37eb8581-8678-45a9-bb8d-7e8754cae01a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/current-good-manufacturing-practiceguidance-for-human-drug-compounding-outsourcing-facilities-under-section-503b-of-the-fdc-act-guidance-for-industry-draft-guidance-for-industry/bd9edb09-3aaf-4e80-b088-c65aa8949a54 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-labeling-of-plant-based-milk-alternatives-and-voluntary-nutrient-statements/1fb39fed-4014-498a-b8a5-ba030c7bcd4c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/post-complete-response-letter-clarification-teleconferences-between-fda-and-anda-applicants-under-gdufa-guidance-for-industry/04568e14-0429-4c8d-ac7e-f865e2dc2669 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/chronic-hepatitis-b-virus-infection-developing-drugs-for-treatment/1ca15a4e-3e51-4f12-8e00-cbe8778e2304 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/anda-submissions-refuse-to-receive-standards-rev2/78b570c1-44d2-45b3-b780-47480621496b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/meta-analyses-of-randomized-controlled-clinical-trials-to-evaluate-the-safety-of-human-drugs-or-biological-products/0ed49ff3-89c9-4436-8c06-0324d3e2aff2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-serving-sizes-of-foods-that-can-reasonably-be-consumed-at-one-eating-occasion-reference-amounts-customarily-consumed-serving-size-related-issues-dual-column-labeling-and-miscellaneous-topics/6a997600-aaf6-4ec2-9e43-cf24dbdbf654 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/rare-diseases-early-drug-development-and-the-role-of-pre-ind-meetings-draft-guidance-for-industry/3c7d812a-8f9d-42ac-b54e-ad63ed389dab 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bacterial-risk-control-strategies-for-blood-collection-establishments-and-transfusion-services-to-enhance-the-safety-and-availability-of-platelets-for-transfusion-guidance-for-industry/333bd28f-2882-4660-b183-54b97fa26003 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/gluten-in-drug-products-and-associated-labeling-recommendations-draft-guidance-for-industry/7c089d7c-0cae-4796-899d-09c5a25a376f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-trial-endpoints-for-the-approval-of-non-small-cell-lung-cancer-drugs-and-biologics/8e9a6bba-beb8-4d9a-8054-5bfd214b7427 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/oversight-of-clinical-investigations-a-risk-based-approach-to-monitoring-guidance-for-industry/ad5abb22-0ad2-4152-a7b3-c9de659f6843 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/drug-induced-liver-injury-premarketing-clinical-evaluation/de53c59a-0e5e-4eeb-9106-8a5a0947edbc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/incorporation-of-physical-chemical-identifiers-into-solid-oral-dosage-form-drug-products-for-anticounterfeiting-guidance-for-industry/aaf3882a-6876-4866-8763-fc1971c39742 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/safety-labeling-changes-implementation-of-section-505o4-of-the-federal-food-drug-and-cosmetic-act/2ee1cd52-3926-4b4e-8acb-2ae6e7eea9c8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/premarket-notification-requirements-concerning-gowns-intended-for-use-in-health-care-settings-guidance-for-industry-and-food-and-drug-administration-staff/c5e87407-606e-4a6d-bbff-36b19acebe1c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/design-considerations-for-pivotal-clinical-investigations-for-medical-devices-guidance-for-industry-clinical-investigators-institutional-review-boards-and-fda-staff/70ecd475-412f-4924-ace8-87075c777f34 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/size-shape-and-other-physical-attributes-of-generic-tablets-and-capsules/4e3a8c2e-7d8d-4203-b803-002205d0e2a6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/naming-of-drug-products-containing-salt-drug-substances/6349086a-e347-40fe-9ee8-4077817ab32c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-premarket-notification-510k-submissions-for-nucleic-acid-based-human-leukocyte-antigen-hla-test-kits-used-for-matching-of-donors-and-recipients-in-transfusion-and-transplantation-guidance-for-industry/c3991a09-4456-4aa7-9caf-359965bbb120 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/endotoxin-testing-recommendations-for-single-use-intraocular-ophthalmic-devices/634c9890-4791-491a-a0dc-5692d9e03615 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/immunogenicity-related-considerations-for-low-molecular-weight-heparin-guidance-for-industry/3f5ab3c9-bcf6-4c53-bf06-2133ec436dd8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pulmonary-tuberculosis-developing-drugs-for-treatment/8b46de55-ddca-4887-a2ad-5d46be5633aa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550050-canned-ackee-frozen-ackee-and-other-ackee-products-hypoglycin-a-toxin/04b0c1b0-d25f-4a31-83d5-7d12d83f285e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/color-additive-petitions-medical-devices/41497bbc-b2da-416b-a51f-e4cc3241b510 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/humanitarian-device-exemption-hde-program-guidance-for-industry-and-food-and-drug-administration-staff/885b4c01-4faf-4488-9f83-7ef6dd2aab6c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dental-curing-lights-premarket-notification-510k-guidance-for-industry-and-fda-staff/7a5ab36a-cccd-4e15-99b7-0ec7d6908b1d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guide-for-establishing-and-maintaining-a-calibration-constancy-intercomparison-system-for-microwave-oven-compliance-survey-instruments-fda-88-8264-pdf-only/ced58a71-980c-4533-be6f-8da09b2e56ee 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compliance-guide-for-laser-products-fda-86-8260/e214ffb7-e070-4f10-b54b-abfccb5a1f31 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/manufacturersassemblers-of-diagnostic-x-ray-systems-enforcement-policy-for-positive-beam-limitation-pbl-requirements-in-21-cfr-102031g/07b3fcb1-4458-4026-aaea-7510e4870953 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/hernia-mesh-package-labeling-recommendations-draft-guidance-for-industry-and-food-and-drug-administration-staff/f3f2df12-07bc-40dd-9050-853b9e9e58a8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-developmental-toxicity-studies-for-preventive-and-therapeutic-vaccines-for-infectious-disease-indications-guidance-for-industry/84223118-f6e6-4029-b7dc-665bd6fd62dd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/policy-on-lamp-compatibility-sunlamps/afc66aa5-be89-4993-95d4-d4facb244895 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-device-reporting-for-user-facilities/b0da1f94-9b65-49d9-a1ac-e1c781b3107d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/review-criteria-for-premarket-approval-of-in-vitro-diagnostic-devices-for-detection-of-antibodies-to-parvovirus-b19/1967b9f1-6a42-4fbb-89f3-c4d392b2563d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/phs-guideline-on-infectious-disease-issues-in-xenotransplantation-phs-guideline/6ad666e5-0c89-4e24-91f4-b518b4c0a452 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-data-needed-to-support-the-licensure-of-seasonal-inactivated-influenza-vaccines-guidance-for-industry/8abbbed1-8777-499a-91fd-772a160cac67 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-plasmid-dna-vaccines-for-infectious-disease-indications-guidance-for-industry/da019869-962b-482b-9b49-7c21f332239b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-data-needed-to-support-the-licensure-of-pandemic-influenza-vaccines-guidance-for-industry/5df1a2f0-7963-4753-b8ac-2165b3fa2eef 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assay-migration-studies-for-in-vitro-diagnostic-devices-guidance-for-industry-and-fda-staff/7800aabf-40dc-4ade-890e-83c1ec312a77 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/exemption-from-reporting-and-record-keeping-requirements-for-certain-sunlamp-product-manufacturers/f5fba460-cb99-408a-aabd-ede42407f98d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postmarketing-safety-reporting-for-human-drug-and-biological-products-including-vaccines-draft-guidance-for-industry/c479f7a0-a940-4f91-b4b6-db286a5af68b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-review-of-vaccine-labeling-requirements-for-warnings-use-instructions-and-precautionary-information-guidance-for-industry/99ec601e-f337-4c0d-8e45-f7e53d6623c3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/premarket-assessment-of-pediatric-medical-devices-guidance-for-industry-and-fda-staff/dbfa187c-5a67-45ee-b3ca-a04850a54c6a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-and-industry-actions-on-premarket-notification-510k-submissions-effect-on-fda-review-clock-and-goals-guidance-for-industry-and-food-and-drug-administration-staff/1b817555-8c71-4c1f-904b-ebdafdbb724d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-and-industry-actions-on-premarket-approval-applications-pmas-effect-on-fda-review-clock-and-goals-guidance-for-industry-and-food-and-drug-administration-staff/cf05b035-842e-40f1-9394-508e4e1f6dbd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bundling-multiple-devices-or-multiple-indications-in-a-single-submission-guidance-for-industry-and-fda-staff/3a89ce6d-78fd-4b7d-9a46-1f67c0746805 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/annual-reports-for-approved-premarket-approval-applications-pma-guidance-for-industry-and-food-and-drug-administration-staff/571b5649-d42a-4ea5-96f0-88bc553832be 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/influenza-developing-drugs-for-treatment-andor-prophylaxis/a4d179ce-df0b-4756-bae7-0992c4445d2a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/validation-of-procedures-for-processing-of-human-tissues-intended-for-transplantation-guidance-for-industry/098dfce7-8124-4658-98c8-d92a922f6766 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/latex-condoms-for-men-information-for-510k-premarket-notifications-use-of-consensus-standards-for-abbreviated-submissions-guidance-for-industry/42ca3233-9c11-45de-97c2-203d747638ca 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-least-burdensome-provisions-concept-and-principles-guidance-for-industry-and-fda-staff/fc4a73a9-2564-4ee2-80e6-e9c3faeb16b1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-annex-7-r2-dissolution-test-general-chapter/37852cc1-fb0a-49e8-8bce-436b1222fcea 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-obtaining-a-labeling-claim-for-communicable-disease-donor-screening-tests-using-cadaveric-blood-specimens-from-donors-of-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-guidance-for-industry/2565c7c9-cea3-4b8f-b6bd-75572e27c93d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/30-day-notices-135-day-premarket-approval-pma-supplements-and-75-day-humanitarian-device-exemption-hde-supplements-for-manufacturing-method-or-process-changes-guidance-for-industry-and-fda-staff/c8324ced-47fd-4902-b674-48b71b10e44d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-otc-human-drug-products-updating-labeling-in-rlds-and-andas/f3147bb2-3c37-41e5-8e86-75e7c535af06 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recognition-and-use-of-a-standard-for-uniform-blood-and-blood-component-container-labels-guidance-for-industry/0e9cea00-e3f4-4dd6-baa1-7649940358c5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submitting-debarment-certification-statements/02f51441-128a-4fc9-a874-1feac482d4d7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-on-premarket-notification-510k-for-sterilizers-intended-for-use-in-health-care-facilities/2af1cad4-e00e-4637-a61b-4259a1c50bd4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submitting-and-reviewing-complete-responses-to-clinical-holds-revised/add0f63f-a485-451a-9637-97795d98c43f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/master-files-part-iii-guidance-on-scientific-and-technical-information/1e989f04-b6c4-429a-9562-1a8757f4668b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/reports-on-the-status-of-postmarketing-study-commitments-implementation-of-section-130-of-the-food-and-drug-administration-modernization-act-of-1997/ec0f0699-da15-4639-8504-483baf9b5ea9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/implementation-of-section-120-of-the-food-and-drug-administration-modernization-act-of-1997-advisory-committees/45b9b815-ce9c-4261-b77c-20e27647c07e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pet-drug-applications-content-and-format-for-ndas-and-andas-attachment-i-sample-formats-for-chemistry-manufacturing-and-controls-cmc-sections_2011/a4320966-98dd-464c-8b5e-d455c45c3f0e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/single-dose-acute-toxicity-testing-for-pharmaceuticals/daee90ca-d341-46e0-9470-bbd8b5c640c8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/content-and-format-of-inds-for-phase-1-studies-of-drugs-including-well-characterized-therapeutic-biotechnology-derived-products-questions-and-answers-guidance-for-industry-qa/0b58e6c1-3ce5-461a-be2e-38697dc3a308 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/efficacy-studies-to-support-marketing-of-fibrin-sealant-products-manufactured-for-commercial-use-guidance-for-industry/7113f8a1-f4d9-40a6-b922-ff153ca851f0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-nucleic-acid-tests-on-pooled-and-individual-samples-from-donors-of-whole-blood-and-blood-components-including-source-plasma-and-source-leukocytes-to-adequately-and-appropriately-reduce-the-risk-of-transmission-of-of-hiv-1-and-hcv-guidance-for-industry/0f8804f2-4963-49e6-81ca-6607c2f954aa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/concept-paper/animal-models-essential-elements-to-address-efficacy-under-the-animal-rule_09/c8507f1f-fd35-4321-b4b7-cd1d06847ba3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/electronic-submission-template-for-medical-device-q-submissions-draft-guidance-for-industry-and-food-and-drug-administration-staff/b43cb4df-8bcd-4688-ae4c-c71e675cca46 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/checklist-for-mechanical-lithotripters-and-stone-dislodgers-used-in-gastroenterology-and-urology/e653d817-195f-4e96-927e-bd1e1f53141a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommended-clinical-study-design-for-ventricular-tachycardia-ablation/0337e091-097b-4de8-a712-bd3e1f5368a4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/letter-manufacturers-distributors-and-importers-of-condom-products-included-in-condom-packet-398-letter-manufacturers-distributors-and-importers-of-condom-products/4691242f-f73b-463c-ae81-9a1f76104905 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-acceptance-of-foreign-clinical-studies-not-conducted-under-an-ind-frequently-asked-questions-guidance-for-industry-and-fda-staff/5708effd-f435-4af2-bdba-f8d7590073d4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-578450-wheat-flour-adulteration-with-insect-fragments-and-rodent-hairs/04d36354-34fe-4bb9-9f08-79a4c2dd25d0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s3b-pharmacokinetics-guidance-for-repeated-dose-tissue-distribution-studies/05507ee5-4516-40d8-9c89-68fe4835e9fd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s3a-toxicokinetics-the-assessment-of-systemic-exposure-in-toxicity-studies/e53cdb09-0178-4fb9-ad0d-f3288ea32cdd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-555850-water-damaged-food-products-in-screw-top-crimped-cap-and-similar-containers/647e7c0d-16bb-4841-8576-e074812ea6a7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s2r1-genotoxicity-testing-and-data-interpretation-for-pharmaceuticals-intended-for-human-use/bdcb4e58-2f39-40e7-90c5-9f222d9203c1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525825-vinegar-definitions-adulteration-with-vinegar-eels/9040cab0-bfc6-4ae9-9297-777abe83eab7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s1b-testing-for-carcinogenicity-of-pharmaceuticals/8cc92fb9-6b17-465b-8cf3-ba1e865720dd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-590400-natural-bristle-brushes-ie-hair-brushes-shaving-brushes-nit-contamination/7c67ad63-19ae-4e53-b7de-cb50d2879960 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525700-sesame-seeds-adulteration-with-insect-filth-decomposition-mammalian-excreta-foreign-matter/6bd83521-785b-4f52-b95c-3bafe9d99d48 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550800-standardized-canned-fruit-misbranding-involving-improper-declaration-of-packing-medium/fbac98a3-d124-4fd4-8678-1958e4562c3c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s1a-the-need-for-long-term-rodent-carcinogenicity-studies-of-pharmaceuticals/47727f71-5bb8-4ab4-b93a-c974612755da 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-590300-direct-reference-authority-for-pseudomonas-contamination-of-cosmetics-used-in-the-eye-area/daa2186b-a2fa-46d3-b7f0-1ae5ee0dc244 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525625-whole-and-ground-pepper-adulteration-with-insect-rodent-filth-mold-mammalian-excreta-foreign-matter/c97051b0-c4f6-41be-9778-e871feb0a29f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525300-condimental-seeds-other-than-fennel-seeds-and-sesame-seeds-adulteration-by-mammalian-excreta/05b75d9c-8607-46e6-98fd-2d0e546a2dcd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550690-plums-canned-adulteration-with-rot/2b5a7300-fffe-4861-9449-8b20e1123f29 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525550-mace-adulteration-with-insect-filth-mold-foreign-matter-mammalian-excreta/798a9015-be45-43aa-9be1-9be169fda6f9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525500-leafy-spices-other-than-bay-leaves-whole-oregano-leaves-whole-marjoram-whole-sage-leaves-and-whole-thyme-leaves-adulteration-with-insect-filth-mold-mammalian-excreta/332c5794-2d35-4360-83cb-488787e509ce 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550685-pineapple-canned-imported-and-domestic-misbranding-involving-food-standards/d004be92-bd08-41cc-996e-83b7b0791c02 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525200-capsicum-pods-ground-capsicums-excluding-paprika-ground-paprika-adulteration-with-insect-and-rodent-filth-mold-mammalian-excreta/84eebdfd-5a93-43fb-8402-52f0e5f6a100 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585890-tomato-products-adulteration-with-drosophila-fly-eggs-and-maggots/d7b1adcb-d843-4266-a9cb-2088703f98ba 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550680-pineapple-canned-pineapple-juice-adulteration-with-mold/023c0de4-7758-470e-a89b-b25487416480 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585875-tomatoes-canned-misbranding-involving-food-standards-peel/292b4793-5d66-4a05-9402-292958ca9071 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/premarketing-risk-assessment-guidance-for-industry/232a7962-0cba-49be-a6b4-356c35b5f91f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postmarketing-adverse-experience-reporting-for-human-drug-and-licensed-biological-products-clarification-of-what-to-report/89a5f407-ec41-4ec0-bf36-c5a19b96b776 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/ind-exemptions-for-studies-of-lawfully-marketed-drug-or-biological-products-for-the-treatment-of-cancer-guidance-for-industry/fa85146f-e37f-41a7-a38d-60e7f38b337d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/variations-in-drug-products-that-may-be-included-in-a-single-anda/ce22de7a-f17d-437d-bcd0-2ab5803add37 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/orally-inhaled-and-intranasal-corticosteroids-evaluation-of-the-effects-on-growth-in-children/c4c75ea8-e4ee-4ab0-8ebb-c0191cd85f05 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/hospital-bed-system-dimensional-and-assessment-guidance-to-reduce-entrapment-guidance-for-industry-and-fda-staff/9d1bd7d5-b407-47f5-ac27-0bfe4bfc53e2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submitting-nonclinical-datasets-for-evaluation-of-rodent-carcinogenicity-studies-of-pharmaceuticals/5558f50a-6637-45c7-9848-23f5e55738d6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/keratome-and-replacement-keratome-blades-premarket-notification-510k-submissions-guidance-for-industry-and-fda-staff/b7b82704-1434-479f-8695-869b8cd23319 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q8r2-pharmaceutical-development/952b87d6-d764-4049-94ad-25d668f24c35 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/special-controls-document/class-ii-special-controls-guidance-document-serological-assays-for-the-detection-of-beta-glucan-pdf-version/4fa93abb-1a1e-4d2b-ac9e-eed807e3dfbf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q7-good-manufacturing-practice-guidance-for-active-pharmaceutical-ingredients-guidance-for-industry/4c33ca12-225d-4a88-aaa5-3f0f8357fdd9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e14-clinical-evaluation-of-qtqtc-interval-prolongation-and-proarrhythmic-potential-for-non-antiarrhythmic-drugs-questions-and-answers-r3-guidance-for-industry/6bec247e-a472-41b1-83c1-27ce44ad427a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e8r1-general-considerations-for-clinical-studies/c5e52286-b058-4b0f-b1f2-e589be1aaf84 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q6b-specifications-test-procedures-and-acceptance-criteria-for-biotechnologicalbiological-products/740f7ae1-889d-4f37-a427-0155ae5957c6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q5e-comparability-of-biotechnologicalbiological-products-subject-to-changes-in-their-manufacturing-process/9a44cd22-b665-4ffa-bb74-136ea2893c92 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submission-of-documentation-in-applications-for-parametric-release-of-human-and-veterinary-drug-products-terminally-sterilized-by-moist-heat-processes-guidance-for-industry/5ca3ae22-e166-456b-bc1f-be17ce9ca044 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q5c-quality-of-biotechnological-products-stability-testing-of-biotechnologicalbiological-products/371b51f2-ae87-4ef8-aa87-6a82dbe5a1eb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submission-documentation-for-sterilization-process-validation-in-applications-for-human-and-veterinary-drug-products-guidance-for-industry/de753251-391e-49ff-a5ac-26a5cad0728a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/review-criteria-for-assessment-of-c-reactive-protein-crp-high-sensitivity-c-reactive-protein-hscrp-and-cardiac-c-reactive-assays-guidance-for-industry-and-fda-staff/04502e16-fef0-4033-a292-0ec180d25217 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dental-handpieces-premarket-notification-510k-submissions-guidance-for-industry-and-fda-staff/7aa25e62-346c-4cb8-9791-431db46c770d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/hemodialysis-blood-tubing-sets-premarket-notification-510k-submissions-guidance-for-industry-and-fda-staff/a50fef58-09c4-45a9-95b7-61eff98924c0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pre-clinical-and-clinical-studies-for-neurothrombectomy-devices-guidance-for-industry-and-fda-staff/a97c1beb-0738-4dfb-ac96-2a4d3b75cfab 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e15-pharmacogenomics-definitions-and-sample-coding/cb4bd50b-7b32-43b6-914f-75cddddc7b2b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/special-controls-document/class-ii-special-controls-guidance-document-immunomagnetic-circulating-cancer-cell-selection-and-enumeration-system-pdf-version/f84853b4-bc39-44bc-93a2-d0af4a5d8f2d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/andaspharmaceutical-solid-polymorphism-chemistry-manufacturing-and-controls-information-guidance-for-industry/ea6f758d-a4f3-4afe-b529-2949f9e35169 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/evaluating-the-risks-of-drug-exposure-in-human-pregnancies/4ca9c67c-ee5f-4610-bcaf-163848c7aa3a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/180-day-exclusivity-when-multiple-andas-are-submitted-on-the-same-day/26a43ba4-c062-4358-b394-9623fa7f9f78 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-annex-2-test-for-extractable-volume-of-parenteral-preparations-general-chapter/292269d7-ccc6-4b40-b054-d180b547c287 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/systemic-lupus-erythematosus-developing-medical-products-for-treatment/067dc730-0e77-42b9-a240-78f5dae2130b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/technical-specifications-for-submitting-clinical-trial-data-sets-for-treatment-of-noncirrhotic-nonalcoholic-steatohepatitis-nash-guidance-for-industry-technical-specifications-document/1ca754ae-28e0-43c4-a47f-4d90a8697a4f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-527225-cheese-misbranding-due-to-moisture-and-fat/212521fa-38d7-42a4-9588-f4b15f603870 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/chronic-obstructive-pulmonary-disease-use-of-the-st-georges-respiratory-questionnaire-as-a-pro-assessment-tool-guidance-for-industry/4027ee92-8cfb-4ad2-8e77-14364c6dafdb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compliance-with-section-301-of-the-medical-device-user-fee-and-modernization-act-of-2002-as-amended-prominent-and-conspicuous-mark-of-manufacturers-on-single-use-devices-guidance-for-industry-and-fda-staff/90696dfc-0825-4c69-a6cb-c8ad0d418e1c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e1a-the-extent-of-population-exposure-to-assess-clinical-safety-for-drugs-intended-for-long-term-treatment-of-non-life-threatening-conditions/71a56556-e3ab-4bf3-8fd7-bbf16d42b30a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/marketing-clearance-of-diagnostic-ultrasound-systems-and-transducers-guidance-for-industry-and-food-and-drug-administration-staff/e10cbe3b-d9fb-44f2-b3d9-6d6b7cb7b8ef 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/acne-vulgaris-establishing-effectiveness-of-drugs-intended-for-treatment/513aaac8-5cc8-4e47-8797-621cd7679a08 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-587300-color-additives/b0889769-9006-4a8e-879f-dfdb4af8ace6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/acute-bacterial-exacerbations-of-chronic-bronchitis-in-patients-with-chronic-obstructive-pulmonary-disease-developing-antimicrobial-drugs-for-treatment/fd5d0be9-06b4-40f7-b7ca-d8edca103a27 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-in-electronic-format-drug-establishment-registration-and-drug-listing/9e44a90c-3c3f-4864-b69c-5a13ac1fafb9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/coronary-and-carotid-embolic-protection-devices-premarket-notification-510k-submissions-guidance-for-industry-and-fda-staff/a5ecf116-4c3e-4916-bee4-c75880dabd02 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/supac-ss-nonsterile-semisolid-dosage-forms-scale-up-and-post-approval-changes-chemistry-manufacturing-and-controls-in-vitro-release-testing-and-in-vivo-bioequivalence-documentation-guidance-for-industry/d127b90c-a5cb-4a59-8be5-7d05eabe3377 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/quality-system-information-for-certain-premarket-application-reviews-guidance-for-industry-and-fda-staff/9d8b50e3-4d72-4415-834b-a6bbad02368f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/in-vitro-diagnostic-ivd-device-studies-frequently-asked-questions-guidance-for-industry-and-fda-staff/d1b047e5-dc30-4134-b852-9ab7c8e9397b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/preparation-and-review-of-investigational-device-exemption-applications-ides-for-total-artificial-discs-guidance-for-industry-and-fda-staff/c0f2683e-9f2f-4a30-9074-61d1242a7e6f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/sterile-drug-products-produced-by-aseptic-processing-current-good-manufacturing-practice-guidance-for-industry/0404765b-fedd-4d75-91f6-24f8781614ad 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-annex-6-uniformity-of-dosage-units-general-chapter/54b2ddf1-def6-4b73-beb7-0e1a5364992d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/process-validation-general-principles-and-practices-guidance-for-industry/38024bdb-dc3f-40dd-b115-6125cb5be8bb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/impact-resistant-lenses-questions-and-answers-guidance-for-industry-and-fda-staff/e6576693-9131-43d8-bfe9-276d3f990c02 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/surveillance-and-detention-without-physical-examination-of-condoms-guidance-for-industry-and-fda-staff/cacd06be-e29a-4d0d-aec8-8dfc3735869c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/possible-dioxinpcb-contamination-of-drug-and-biological-products/0b7513ce-1394-47e9-950d-c555f4b6845a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/ndas-impurities-in-drug-substances/9a9aed41-ecdb-4d76-ae37-eed05ef236c6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pat-a-framework-for-innovative-pharmaceutical-development-manufacturing-and-quality-assurance-guidance-for-industry/d65c2527-8510-4985-816b-b044ea882c66 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-hospitals-nursing-homes-and-other-health-care-facilities-fda-public-health-advisory-guidance-for-hospitals-nursing-homes-and-other-health-care-facilities/ddf505c5-8f88-4e0e-b386-f815dcbd495c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pediatric-inflammatory-bowel-disease-developing-drugs-for-treatment/f199b979-79a2-47a4-99e4-b55e181a268d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/premarket-notification-submissions-for-transfer-sets-excluding-sterile-connecting-devices-guidance-for-fda-reviewers/36256b3e-fb0f-4e7f-8d49-94b462d9827f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/current-good-manufacturing-practice-for-medical-gases-draft-guidance-for-industry/e034a13a-d795-47fa-b9ff-d7f1dd835ffa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/statistical-approaches-to-establishing-bioequivalence/3391de1a-8097-49d5-83f8-195b2013a5e2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/supac-mr-modified-release-solid-oral-dosage-forms-scale-up-and-postapproval-changes-chemistry-manufacturing-and-controls-in-vitro-dissolution-testing-and-in-vivo-bioequivalence-documentation-guidance-for-industry/905b2817-1f3e-48cc-8872-e817148c0415 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s2a-specific-aspects-of-regulatory-genotoxicity-tests-for-pharmaceuticals/ca49b04b-b2c6-46ef-b611-f5fbdfa7f55f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/exposure-response-relationships-study-design-data-analysis-and-regulatory-applications/e3b78410-ce8b-46f8-9ae8-b9df1485d11e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/food-effect-bioavailability-and-fed-bioequivalence-studies-guidance-for-industry/87398e1d-12f5-46f8-8375-39a26544ab11 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/extended-release-oral-dosage-forms-development-evaluation-and-application-of-in-vitroin-vivo-correlations/c2ea6b85-0c9d-4fc1-80f0-2b5b1c5dea0e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/residual-solvents-in-drug-products-marketed-in-the-united-states-guidance-for-industry/2d91b105-6b2c-4231-bcff-63a0d7fdc832 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pac-atls-postapproval-changes-analytical-testing-laboratory-sites-guidance-for-industry/655cb6dd-896b-4f24-b17a-5f1c796c873e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-sterile-connecting-devices-in-blood-bank-practices-guidance-for-industry/c7b2f019-4de3-4d87-8be2-246024487c08 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/statistical-information-from-the-june-1999-draft-guidance-and-statistical-information-for-in-vitro-bioequivalence-data-posted-on-august-18-1999/e0d3007b-c1cb-4b4c-b214-7aac511f0a59 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/orally-disintegrating-tablets-guidance-for-industry/e9db30b4-68fc-445e-9286-7e4573fd1c00 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-recommendations-for-submission-of-chemical-and-technological-data-for-food-additive-petitions-and-gras-notices-for-enzyme-preparations/840a74d9-64f1-401b-aab7-89b92313905e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-light-mild-low-or-similar-descriptors-in-the-label-labeling-or-advertising-of-tobacco-products-guidance-for-industry-and-fda-staff/cc070593-590a-41d3-b27a-f5f79b02930e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/tobacco-retailer-training-programs-guidance-for-industry/e9bebca3-645d-4e3f-bb5e-b0dda3e0f673 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-food-labeling-guide/801450a7-39af-40ab-a55d-c1f32f4b3ec0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compliance-guide-for-cabinet-x-ray-systems/c9dabd8f-89b5-4913-afe0-ef3be2124be2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-fdas-policy-on-declaring-small-amounts-of-nutrients-and-dietary-ingredients-on-nutrition-labels/dce3b53a-74b3-470c-aa81-72a6c41f4437 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/industry-letter/guidance-for-industry-dear-manufacturer-letter-regarding-changes-to-fdas-administration-of-process-filings-forms-fda-2541a-and-fda-2541c-for-acidified-foods-and-low-acid-canned-foods/4fb2c16a-fd1a-41e6-bee6-9587c0ab24a8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-meaning-of-spouse-and-family-in-fdas-regulations-after-the-supreme-courts-ruling-in-united-states-v-windsor-questions-and-answers-guidance-for-industry-consumers-and-fda-staff/2216c8ee-57d9-4561-83dc-c2a78bcab634 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/collection-of-race-and-ethnicity-data-in-clinical-trials-and-clinical-studies-for-fda-regulated-medical-products/bb445da4-30af-4d88-b3c5-a289c2f74d92 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/computer-crossmatch-computerized-analysis-of-the-compatibility-between-the-donors-cell-type-and-the-recipients-serum-or-plasma-type-guidance-for-industry/1a1fe388-f721-4c5e-ab85-ef8178139070 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-335700-surgeons-gloves-and-patient-examination-gloves-defects-criteria-for-direct-reference-seizure/dc5fbf7d-82f7-4d88-b5d9-26a19906eb3e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e21-inclusion-of-pregnant-and-breastfeeding-women-in-clinical-trials-draft-guidance-for-industry/d8ff86c3-7344-41eb-b6eb-88c5a122c46f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compliance-policy-for-combination-product-postmarketing-safety-reporting-immediately-in-effect-guidance-for-industry-and-food-and-drug-administration-staff/58ccec37-8610-4672-a40f-c7d571feb0f9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-132-administrative-applications-and-the-phased-review-process/defb3d37-1f77-45b4-8456-eb80fbb74dc8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-foreign-supplier-verification-programs-for-importers-of-food-for-humans-and-animals/60c96280-73d7-48f8-964a-516655ec2c03 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-use-of-the-terms-brown-king-crab-and-golden-king-crab-in-the-labeling-of-human-food-products/7efcca50-bc7e-4b89-95f1-432d68f09b65 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-application-of-the-solely-engaged-exemptions-in-parts-117-and-507/ea4d881d-4255-448d-8e38-064d57fcb145 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-nutrition-and-supplement-facts-labels-questions-and-answers-related-to-the-compliance-date-added-sugars-and-declaration-of-quantitative-amounts-of-vitamins-and-minerals/da624222-6a2b-498c-b922-6a9c0219c1d7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/anthrax-developing-drugs-for-prophylaxis-of-inhalational-anthrax-guidance-for-industry/42e7890d-c6f4-4da5-839f-438c6dc2dcf4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compliance-policy-for-required-warning-statements-on-small-packaged-cigars-guidance-for-industry/564682fc-f54c-4ae5-ad1e-129f61ea0165 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-use-of-the-term-healthy-in-the-labeling-of-human-food-products/6f5e5f97-a6aa-47d2-aa60-a8552fa9fbc0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/requirements-for-the-submission-of-data-needed-to-calculate-user-fees-for-domestic-manufacturers-and-importers-of-tobacco-products-guidance-for-industry/f09fd136-15c2-4e86-b6b4-afcb3b92b665 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-determination-of-status-as-a-qualified-facility/005d11df-efa8-4c44-a010-4c644a119d30 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/national-environmental-policy-act-environmental-assessments-for-tobacco-products-categorical-exclusions-small-entity-compliance-guide-guidance-for-industry/41086da4-d79b-4250-b45a-1387fc2ea941 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/small-entity-compliance-guide-nutrition-labeling-of-standard-menu-items-in-restaurants-and-similar-retail-food-establishments/42946b6a-1b06-4d45-a2a7-ffda4caf43a1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cpg-sec-398350-regulatory-actions-against-assemblers-of-x-ray-equipment-that-fail-to-file-reports-of-assembly/8b397019-7e55-4ba3-860c-955b0f35d1fb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525600-whole-and-ground-nutmeg-adulteration-with-insect-filth-mold-rodent-filth/5ee31b18-4a5b-4c69-b87c-312f8c43e53e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-demonstration-of-the-quality-factor-requirements-under-21-cfr-10696i-for-eligible-infant-formulas/45f2b8d6-a7c5-4308-b8d5-7dc6be573f86 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-what-you-need-to-know-about-establishment-and-maintenance-of-records/9dca4137-05a3-491d-a09e-9ac8c7556605 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-what-you-need-to-know-about-administrative-detention-of-foods/be74d52c-692a-4526-b24c-72ca8e8983e0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/further-amendments-to-general-regulations-of-the-food-and-drug-administration-to-incorporate-tobacco-products-small-entity-compliance-guide-guidance-for-industry/55784818-25cd-4dca-9bea-91258a995ad1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/civil-money-penalties-and-no-tobacco-sale-orders-for-tobacco-retailers-responses-to-frequently-asked-questions-revised-guidance-for-industry/28dfc0d9-e7eb-4f8f-a4fb-d0fe54d51e7f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-questions-and-answers-regarding-the-reportable-food-registry-as-established-by-the-food-and-drug-administration-amendments-act-of-2007-edition-2/eeb33cd9-67a8-45e3-9b28-1d8750ca7753 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enforcement-policy-concerning-certain-regulations-restricting-the-sale-and-distribution-of-cigarettes-and-smokeless-tobacco-guidance-for-industry-and-fda-staff/8692689a-77f9-4dfd-bede-4a68de2009b2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s9-nonclinical-evaluation-for-anticancer-pharmaceuticals/0d1f71ec-dd43-4c57-befe-2d7eb7e145f2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/procedures-for-class-ii-device-exemptions-from-premarket-notification-guidance-for-industry-and-cdrh-staff/b63609b3-e69f-44e1-9551-7f9686852c3f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-the-content-of-premarket-notifications-for-esophageal-and-tracheal-prostheses-guidance-for-industry/46fe7cde-e307-4c9f-975d-1ab97be1c601 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/otc-denture-cushions-pads-reliners-repair-kits-and-partially-fabricated-denture-kits-guidance-for-industry-and-fda-staff/e2bc6f82-5a7f-47bc-b671-3c2a5246cfcc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-the-preparation-of-a-premarket-notification-for-extended-laparoscopy-devices-eld/b7ca9407-2ab6-4c23-b07b-1ae2b3be525f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/establishing-the-performance-characteristics-of-in-vitro-diagnostic-devices-for-the-detection-or-detection-and-differentiation-of-influenza-viruses-guidance-for-industry-and-fda-staff/0d36538a-a98b-45b1-a9f0-96a4a8149a60 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-testing-blood-donations-for-hepatitis-b-surface-antigen-draft-guidance-for-industry/4e07aa0d-d856-4299-8e74-28096bb16d92 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/approaches-to-assessment-of-overall-survival-in-oncology-clinical-trials-draft-guidance-for-industry/58214f23-534c-4277-9edd-e5f553d63680 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/oncology-therapeutic-radiopharmaceuticals-dosage-optimization-during-clinical-development-draft-guidance-for-industry/401e294a-8da1-4a1d-9457-e02da07a92af 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/development-of-cancer-drugs-for-use-in-novel-combination-determining-the-contribution-of-the-individual-drugs-effects-draft-guidance-for-industry/bd360fda-a944-4c60-9940-379a8b849635 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/unique-device-identifier-requirements-for-combination-products-draft-guidance-for-industry/0554749c-ec49-4c7a-a941-ccddf805374a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cybersecurity-in-medical-devices-quality-system-considerations-and-content-of-premarket-submissions-guidance-for-industry-and-food-and-drug-administration-staff/f60f693d-5633-45fe-bd51-0326ab2a951d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q1-stability-testing-of-drug-substances-and-drug-products-draft-guidance-for-industry/f97d5bb6-a78c-45d5-be86-41bb6e6c13b2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/transfer-of-a-premarket-notification-510k-clearance-questions-and-answers-draft-guidance-for-industry-and-food-and-drug-administration-staff/76eacc48-6d53-40f0-80fb-98adbfc5c390 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m13b-bioequivalence-for-immediate-release-solid-oral-dosage-forms-additional-strengths-biowaiver-draft-guidance-for-industry/ac185a33-db56-4b82-aaa5-ce74c415127c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/replacing-color-additives-in-approved-or-marketed-drug-products-draft-guidance-for-industry/6023f7ca-47a7-493c-a448-f1f458f12fbc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e2br3-electronic-transmission-of-individual-case-safety-reports-implementation-guide-data-elements-and-message-specification-and-appendix-to-the-implementation-guide-backwards-and-forwards-compatibility/748f45a2-e93b-49ba-bbac-b2386763f14e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/tissue-agnostic-drug-development-in-oncology-draft-guidance-for-industry/3835823e-c995-46e5-98c7-9422ad94971f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/warnings-and-precautions-contraindications-and-boxed-warning-sections-of-labeling-for-human-prescription-drug-and-biological-products-content-and-format/568083e9-c4f3-4df6-8658-e5f4d5f903c0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/demonstrating-substantial-evidence-of-effectiveness-for-human-drug-and-biological-products-draft-guidance-for-industry/e87aec53-a6ee-4592-abd8-fcaee3f9dd84 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-approval-of-new-cancer-treatment-uses-for-marketed-drug-and-biological-products/7f4f1e6d-23ce-420e-8af4-f2708be1f47c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/environmental-assessment-of-human-drug-and-biologics-applications-guidance-for-industry/bb52d98f-02d3-44f5-afc9-c2bd3d5b737a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e4-dose-response-information-to-support-drug-registration/95e56cfc-d7a4-41e9-ac07-8ba69fda8f4c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/vaginal-microbicidesdevelopment-for-the-prevention-of-hiv-infection-pdf/bcbc01f3-c6a4-4cc0-80b2-946c72091696 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/women-and-minorities-guidance-requirements/f1f8bc4c-c9fc-42d8-8991-9752cf52ac29 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e7-studies-in-support-of-special-populations-geriatrics-questions-and-answers/763c730c-788a-48d7-a8b1-a2867830bfc9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/gingivitis-development-and-evaluation-of-drugs-for-treatment-or-prevention/bec1ab26-9d0e-468e-ac35-7797add101ae 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/real-world-data-assessing-registries-to-support-regulatory-decision-making-for-drug-and-biological-products/c6608901-2ab6-4ea9-874e-5a6c2a65f9a4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/real-world-data-assessing-electronic-health-records-and-medical-claims-data-to-support-regulatory-decision-making-for-drug-and-biological-products-guidance-for-industry/acb241e2-27a2-4f0c-9d67-8a9472ad939a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/exception-from-informed-consent-requirements-for-emergency-research-guidance-for-institutional-review-boards-clinical-investigators-and-sponsors/c1c4c389-82e0-4459-b587-78c877667c9b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postmarketing-adverse-event-reporting-for-nonprescription-human-drug-products-marketed-without-an-approved-application/95170478-4748-49e7-88f5-b582dc43e2ee 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/immunogenicity-information-in-human-prescription-therapeutic-protein-and-select-drug-product-labeling-content-and-format-draft-guidance-for-industry/7ecfa0a7-217f-451f-a5d5-0ffe4d7afd5d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e2a-clinical-safety-data-management-definitions-and-standards-for-expedited-reporting/373306e7-8aec-4c71-aa10-b4aa9d7f4c04 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-decision-support-software-guidance-for-industry-and-food-and-drug-administration-staff/0eddc26f-67fc-413b-9f3e-ba8798353fe6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/volume-limits-for-automated-collection-of-source-plasma/c00375ca-2408-4bc5-9774-51befd13a7d0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/how-to-complete-the-vaccine-adverse-event-reporting-system-form-vaers-1-guidance-for-industry/5a5b0da1-acd0-4c11-b7cc-12cd5b4b526e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/contents-of-a-complete-submission-for-the-evaluation-of-proprietary-names/8bbe789c-b7fd-4a76-9e78-6ea3344719df 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/content-and-review-of-chemistry-manufacturing-and-control-cmc-information-for-human-somatic-cell-therapy-investigational-new-drug-applications-inds-guidance-for-fda-reviewers-and-sponsors/b31bbe0c-42aa-4671-a86f-7bc15821926b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/toxicity-grading-scale-for-healthy-adult-and-adolescent-volunteers-enrolled-in-preventive-vaccine-clinical-trials-guidance-for-industry/7c3a47a1-1818-4890-90c4-c6ea36b43c83 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigating-and-reporting-adverse-reactions-related-to-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-regulated-solely-under-section-361-of-the-public-health-service-act-and-21-cfr-part-1271-guidance-for-industry/4d5c1dc2-b92f-4125-883d-f9883e7a1a2d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/survey-methodologies-to-assess-rems-goals-that-relate-to-knowledge/bcb5a228-55b4-4b37-bc3d-412094b65302 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/data-standards-for-drug-and-biological-product-submissions-containing-real-world-data-guidance-for-industry/7cd29686-06b7-467b-bad3-2023b48076b2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/prevention-and-treatment-of-chemotherapy-induced-peripheral-neuropathy-developing-drug-and-biological-products-in-oncology/21c15304-ad79-4fb0-8609-1712f3c9952b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/developing-drugs-for-optical-imaging/231d0a9f-1739-4bcd-8393-28d3bcb52cfa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-including-tissue-biopsies-in-clinical-trials/857b6b17-0402-45c3-8095-dcd482a60269 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-collecting-red-blood-cells-by-automated-apheresis-methods-technical-correction-february-2001-guidance-for-industry/20d599e6-09ca-479d-b448-629dede1b354 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/accelerated-approval-and-considerations-for-determining-whether-a-confirmatory-trial-is-underway/ae83d008-58ac-4e99-bb05-ca1492236392 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/validation-of-certain-in-vitro-diagnostic-devices-for-emerging-pathogens-during-a-section-564-declared-emergency-draft-guidance-for-industry-and-food-and-drug-administration-staff/3594dad0-5e3f-41d0-8d24-8085dde76c83 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-determining-eligibility-of-donors-of-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-draft-guidance-for-industry/34d3fa14-1a2f-4058-96a0-b008d076762a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-to-reduce-the-risk-of-transmission-of-mycobacterium-tuberculosis-mtb-by-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-draft-guidance-for-industry/c8709494-c6de-4e86-bfbd-0427cfa21259 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-to-reduce-the-risk-of-transmission-of-disease-agents-associated-with-sepsis-by-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-draft-guidance-for-industry/eaa9076d-b6ed-4e0a-a30f-6eaf0e512040 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-to-reduce-the-risk-of-transmission-of-hepatitis-b-virus-hbv-by-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-draft-guidance-for-industry/a4f2585e-bbe8-4b64-b297-07e60634bf05 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pulse-oximeters-for-medical-purposes-non-clinical-and-clinical-performance-testing-labeling-and-premarket-submission-recommendations-draft-guidance-for-industry-and-food-and-drug-administration-staff/0501096b-4fc1-492b-9162-43d891128680 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-251-heritable-intentional-genomic-alterations-in-animals-of-food-producing-species-for-use-as-models-of-disease/0b9dcdac-5bfa-4a1c-91c3-6b177a5cd480 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-260-type-vii-veterinary-master-file-for-research-and-development-and-risk-reviews/36a6aca6-ef3d-4bb2-9da5-618c44e89a39 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/protocol-deviations-for-clinical-investigations-of-drugs-biological-products-and-devices/12be365f-ede2-4671-b6b7-8da74c7c3635 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/accelerated-approval-expedited-program-for-serious-conditions/7bda38cb-af37-463c-93d1-9a573a6f6fc9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-notifying-fda-of-a-permanent-discontinuance-in-the-manufacture-or-an-interruption-of-the-manufacture-of-an-infant-formula/b570c536-156a-44dc-b97e-92907c8f922f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessment-of-ovarian-toxicity-in-premenopausal-adults-during-drug-development-for-oncologic-products/c3b8f633-4560-4ecf-a713-34ac782330d1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/transitional-enforcement-policy-for-ethylene-oxide-sterilization-facility-changes-for-class-iii-devices-guidance-for-industry-and-food-and-drug-administration-staff/a70d34d5-e3fe-401b-b098-92f3fd9abcc6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/frequently-asked-questions-developing-potential-cellular-and-gene-therapy-products/18812f43-d054-46e4-b040-2e02c42fb4a3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-safety-assessment-of-oligonucleotide-based-therapeutics/98302410-dce1-4d17-92eb-6b05f834b01c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/drug-interaction-information-in-human-prescription-drug-and-biological-product-labeling/8bdf2914-581b-4e86-8a13-dacb0ef306c0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-the-development-of-blood-collection-processing-and-storage-systems-for-the-manufacture-of-blood-components-using-the-buffy-coat-method/f2f59f9e-1837-4a72-b25b-95ceaa3cdf48 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/temporary-policies-for-compounding-certain-parenteral-drug-products-guidance-for-industry/46ee42bb-92f0-47bf-a6e8-2980ea59392a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/endosseous-dental-implants-and-endosseous-dental-implant-abutments-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/2f5c81fa-1a82-4bb7-befb-d06f75f0128b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m15-general-principles-for-model-informed-drug-development/0c262249-637c-4377-ac7f-9fc2fa0ab688 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dental-ceramics-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/d02b4aac-aee7-46d5-bd9a-b44a3d3a4ffd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dental-cements-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/aa018202-9e68-4e19-9519-a472d9708143 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/biocompatibility-testing-of-medical-devices-standards-specific-information-for-the-accreditation-scheme-for-conformity-assessment-asca-program-draft-guidance-for-industry-accreditation-bodies-testing-laboratories-and-food-and-drug-administration-staff/40f624d6-a86b-40bd-ac2b-7e4189655ece 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/demonstrating-substantial-evidence-of-effectiveness-with-one-adequate-and-well-controlled-clinical-investigation-and-confirmatory-evidence/b9da6d6b-ce16-4b00-8230-317aa96fa4e7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-accreditation-scheme-for-conformity-assessment-asca-program-draft-guidance-for-industry-accreditation-bodies-testing-laboratories-and-food-and-drug-administration-staff/a58de170-810e-44d6-91f6-f08acf3dcaf9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/chemical-analysis-for-biocompatibility-assessment-of-medical-devices-draft-guidance-for-industry-and-food-and-drug-administration-staff/f3f65c3f-b5be-4870-b4c0-2c48bc374b2e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/integrating-randomized-controlled-trials-for-drug-and-biological-products-into-routine-clinical-practice-draft-guidance-for-industry/63a40530-083e-4a42-9e35-e536fe18d3da 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-generating-clinical-evidence-from-oncology-multiregional-clinical-development-programs/78fa8deb-dab7-4321-a08d-f5971e107619 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/incorporating-voluntary-patient-preference-information-over-the-total-product-life-cycle-draft-guidance-for-industry-food-and-drug-administration-staff-and-other-interested-parties/0145afc8-90d6-4a3f-88f5-7c5ebae40042 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/mammography-quality-standards-act-and-regulation-amendments-small-entity-compliance-guide-guidance-for-industry-and-food-and-drug-administration-staff/69dcd66a-bdb6-4549-a51d-92327da07d63 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/predetermined-change-control-plans-for-medical-devices-draft-guidance-for-industry-and-fda-staff/693b4b6d-283e-481a-bbdf-352498ee619e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-voluntary-sodium-reduction-goals-edition-2/0cac2fc0-6241-4788-9cc6-2b805688efbf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postapproval-manufacturing-changes-to-biosimilar-and-interchangeable-biosimilar-products-questions-and-answers/f791f37f-3382-48a9-8fcb-f27046ac94a4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-investigational-and-licensed-covid-19-convalescent-plasma-guidance-for-industry/b5fc3ade-12ac-4c44-9169-ec203fa8a321 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dental-composite-resin-devices-premarket-notification-510k-submissions-draft-guidance-for-industry-and-food-and-drug-administration-staff/5acc0690-622c-4e84-8cb9-fbd1309550d2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/purpose-and-content-of-use-related-risk-analyses-for-drugs-biological-products-and-combination-products/53619b8d-27a9-4506-b006-144d1a9be3d4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m14-general-principles-on-plan-design-and-analysis-of-pharmacoepidemiological-studies-that-utilize-real-world-data-for-safety-assessment-of-medicines/90dcd460-563e-47bc-a95b-fd98dc534067 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/laboratory-developed-tests-small-entity-compliance-guide-guidance-for-laboratory-manufacturers-and-food-and-drug-administration-staff/96c89968-a780-4018-8eca-3d679d71ed9e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/myelodysplastic-syndromes-developing-drug-and-biological-products-for-treatment-draft-guidance-for-industry/4c1a6b62-5c53-485e-9004-1b388e3f1bf3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-292-chemistry-manufacturing-and-controls-considerations-for-type-a-medicated-articles/bce81678-991e-43a6-aa52-621cacf9a9be 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-in-demonstrating-interchangeability-with-a-reference-product-update/f154845a-a15e-4508-a634-dd22f907a286 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/processes-and-practices-applicable-to-bioresearch-monitoring-inspections-draft-guidance-for-industry/de2847ff-8b71-474f-8e61-87ff7e13dde9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-complying-with-over-the-counter-monograph-procedure-for-minor-changes-c001-minor-changes-to-solid-oral-dosage-forms-for-certain-over-the-counter-monograph-drugs-draft-guidance-for-industry/2359800d-6604-4abc-9239-c326823db9f3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/platform-technology-designation-program-for-drug-development/c0869fde-efe2-459a-bb5d-9ae107865376 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/rems-logic-model-a-framework-to-link-program-design-with-assessment/5debec5b-45a1-4ad3-93b4-80e8ec45c756 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-187b-heritable-intentional-genomic-alterations-in-animals-the-approval-process/89f3d209-82e9-47da-b016-2f170c66a337 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/consideration-of-enforcement-policies-for-tests-during-a-section-564-declared-emergency-draft-guidance-for-industry-and-food-and-drug-administration-staff/5b96a603-b214-494d-8fa0-a5b8afbd1c7c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enforcement-policy-for-certain-in-vitro-diagnostic-devices-for-immediate-public-health-response-in-the-absence-of-a-declaration-under-section-564-draft-guidance-for-laboratory-manufacturers-and-food-and-drug-administration-staff/966637d7-cac0-46c1-9ebb-bf25c55c8774 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-287-raw-data-for-safety-and-effectiveness-studies/548d8798-548b-4bd9-89e2-d6bccb951d82 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/content-and-format-of-composition-statement-and-corresponding-statement-of-ingredients-in-labeling-in-ndas-and-andas/a430f093-c9f8-4001-aef8-771d98ffdbf0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cancer-clinical-trial-eligibility-criteria-performance-status-draft-guidance-for-industry-irbs-and-clinical-investigators/cf636800-9d9c-44a9-a346-a5cd9d380d56 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cancer-clinical-trial-eligibility-criteria-washout-periods-and-concomitant-medications-draft-guidance-for-industry-irbs-and-clinical-investigators/ab8bf32b-a854-471f-87a8-ba2ee2a5a8b0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/data-integrity-for-in-vivo-bioavailability-and-bioequivalence-studies/04d979b3-3f1d-4515-b9c1-f1a8fb7fb19b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/animal-studies-for-dental-bone-grafting-material-devices-premarket-notification-510k-submissions-guidance-for-industry-and-food-and-drug-administration-staff/a9477738-f51d-4e59-a4f6-e8ba0ed0e5b4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/real-world-evidence-considerations-regarding-non-interventional-studies-for-drug-and-biological-products/48325e39-b445-4a53-8cc0-7483dcf3e352 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/evaluation-of-thermal-effects-of-medical-devices-that-produce-tissue-heating-andor-cooling-draft-guidance-for-industry-and-food-and-drug-administration-staff/5c57aa76-026d-4be7-9189-e40f2025f95d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/annual-reportable-labeling-changes-for-new-drug-applications-and-abbreviated-new-drug-applications-for-nonprescription-drug-products/d9b364f3-3dda-4016-b1bb-5c4149f0f32b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/key-information-and-facilitating-understanding-in-informed-consent-guidance-for-sponsors-investigators-and-institutional-review-boards/015fb9da-fe66-4838-a5f4-d2dd19dde786 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m10-bioanalytical-method-validation-and-study-sample-analysis/ae7fec2e-4331-4dbe-a88a-8bb7bbd7e464 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-foods-derived-from-plants-produced-using-genome-editing/d0c77b32-d596-4feb-85aa-904a9cef2e6c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-device-user-fee-small-business-qualification-and-determination-guidance-for-industry-food-and-drug-administration-staff-and-foreign-governments/ff6a07ba-e7c4-4910-87dc-38b1dfcbdfb7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-data-monitoring-committees-in-clinical-trials/9d0ee35d-4fcc-4c44-88ac-f56c6a60187b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-use-of-artificial-intelligence-to-support-regulatory-decision-making-for-drug-and-biological-products-draft-guidance-for-industry-and-other-interested-parties/f50a55ce-ff4f-49ce-8c87-908cd129fb0e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-666100-alternate-feeding-of-different-medicated-feeds/a2f4cfb5-4e51-424b-93c7-676f3a71882a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-use-of-real-world-evidence-to-support-regulatory-decision-making-for-medical-devices-draft-guidance-for-industry-and-food-and-drug-administration-staff/ad93f8d3-b443-4dfe-abe1-ec343e380179 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-283-priority-zoonotic-animal-drug-designation-and-review-process/36e3200e-ea05-4655-8115-3704a2a82b22 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-to-reduce-the-risk-of-transmission-of-human-immunodeficiency-virus-hiv-by-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-draft-guidance-for-industry/bcf419dc-e52e-405e-9b8d-0581acca6b14 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/interim-policy-on-compounding-using-bulk-drug-substances-under-section-503a-of-the-federal-food-drug-and-cosmetic-act/37088f71-b697-408b-9b76-44a304f6d475 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-284-using-relative-supersaturation-to-support-urinary-tract-health-claims-for-adult-maintenance-cat-food/79b322d0-b440-4cd6-bc4c-db72582032a2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/translation-of-good-laboratory-practice-study-reports-questions-and-answers/d24a7556-16d8-47e2-86bf-ca971a9ef59d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-compliance-policy-for-cosmetic-product-facility-registration-and-cosmetic-product-listing/dfd835f1-d5fd-4041-b1ed-19db3ea2bcc5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-establishing-sanitation-programs-for-low-moisture-ready-to-eat-human-foods-and-taking-corrective-actions-following-a-pathogen-contamination-event/98028bdf-bf09-4fb1-833b-c1e1fa2f4045 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submitting-patient-reported-outcome-data-in-cancer-clinical-trials/cdd19350-5c19-44b6-9812-51398fa0fc71 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/remote-interactive-evaluations-of-drug-manufacturing-and-bioresearch-monitoring-facilities/b3f969a3-6d17-4b51-aee6-e6cb19f8e4ba 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/communications-from-firms-to-health-care-providers-regarding-scientific-information-on-unapproved-uses-of-approvedcleared-medical-products-questions-and-answers/c004be3e-7718-4cf0-a0c5-d32077669fce 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-complying-with-21-cfr-211110/3d80c8ad-a552-4ac0-9f33-3581f781f0c3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/diabetic-foot-infections-developing-drugs-for-treatment/262afa6a-d4f3-470f-a3ad-247a8c349b67 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-milk-and-cream-products-and-yogurt-products-final-rule-to-revoke-the-standards-for-lowfat-yogurt-and-nonfat-yogurt-and-to-amend-the-standard-for-yogurt/8dbc6992-933d-40ea-b0c6-0c6675a96f36 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/quality-considerations-for-topical-ophthalmic-drug-products/19494a43-f26e-42c9-b1ad-99a1126b3d42 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/stimulant-use-disorders-developing-drugs-for-treatment/396da81b-e089-444c-9781-b40a43a1cff2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/antimicrobial-susceptibility-test-ast-system-devices-updating-breakpoints-in-device-labeling-guidance-for-industry-and-food-and-drug-administration-staff/75f8c8db-da73-47f6-af44-69ed63ea0312 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-standards-for-the-growing-harvesting-packing-and-holding-of-sprouts-for-human-consumption/d503597a-0ad7-4142-80f8-24d3eeaed01d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-273-defining-durations-of-use-for-approved-medically-important-antimicrobial-drugs-fed-to-food-producing-animals/d71e00cb-1004-4420-880f-04599e25d8bf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/alternative-tools-assessing-drug-manufacturing-facilities-identified-in-pending-applications/23929cb0-dbb8-4c69-beab-70862d709f97 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-conduct-of-clinical-trials-of-medical-products-during-major-disruptions-due-to-disasters-and-public-health-emergencies/c8517058-2a59-4ca3-be07-e0046663793f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-devices-with-indications-associated-with-weight-loss-non-clinical-recommendations-draft-guidance-for-industry-and-food-and-drug-administration-staff/41990366-0088-4e4b-923f-c43dc6077244 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-devices-with-indications-associated-with-weight-loss-clinical-study-and-benefit-risk-considerations-draft-guidance-for-industry-and-food-and-drug-administration-staff/1bd2627c-f33e-4f60-abd9-edb7104aa188 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-282-informed-consent-forms-for-studies-that-enroll-client-owned-companion-animals/6ef63af9-60e9-435e-a58a-83aa736fd44f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/air-powered-dental-handpieces-and-air-motors-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/bb3fc4db-8239-4800-9f63-ead25b3f9652 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/best-practices-for-selecting-a-predicate-device-to-support-a-premarket-notification-510k-submission-draft-guidance-for-industry-and-food-and-drug-administration-staff/2dec4ff6-6af1-41a5-87fb-193c6bb8a13f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-the-use-of-clinical-data-in-premarket-notification-510k-submissions-draft-guidance-for-industry-and-food-and-drug-administration-staff/b928b357-83ae-4836-9aad-28ebb7169cc6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/evidentiary-expectations-for-510k-implant-devices-draft-guidance-for-industry-and-food-and-drug-administration-staff/023e407a-7df9-45f5-ba8c-31b660b7ab79 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/wholesale-distributor-verification-requirement-for-saleable-returned-drug-product-and-dispenser-verification-requirements-when-investigating-a-suspect-or-illegitimate-productcompliance-policies/8051ece5-c3bd-4820-b9de-32f418360572 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enhanced-drug-distribution-security-requirements-under-section-582g1-of-the-federal-food-drug-and-cosmetic-act-compliance-policies/81e414c7-4ee9-4a96-aba3-257bbafce4bd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postmarketing-approaches-to-obtain-data-on-populations-underrepresented-in-clinical-trials-for-drugs-and-biological-products/46edf900-58f2-4f79-bf45-4baa56d25006 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/qtc-information-in-human-prescription-drug-and-biological-product-labeling-draft-guidance-for-industry/31125149-7d83-4062-9793-55cba93d1ee0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-revocation-of-uses-of-partially-hydrogenated-oils-in-foods/32ba4df2-4759-4d5a-8ea5-5c5e60887d3c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pdufa-waivers-reductions-and-refunds-for-fixed-combinations-and-single-entity-versions-of-previously-approved-antiretrovirals-under-pepfar/6d0b93d6-4d11-41b1-815d-d6970112dcdd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommended-acceptable-intake-limits-for-nitrosamine-drug-substance-related-impurities/6238372e-b9bf-421b-9c22-eda707398371 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-considerations-for-studies-of-devices-intended-to-treat-opioid-use-disorder-guidance-for-industry-and-food-and-drug-administration-staff/490f436a-da64-4aba-a89e-e33e1daf6197 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-293-fda-enforcement-policy-for-aafco-defined-animal-feed-ingredients/0898fe4b-517b-455f-998f-9e6e6e4567c6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/prohibition-on-wholesaling-under-section-503b-of-the-federal-food-drug-and-cosmetic-act/dd86fdd5-6650-410b-8062-44da26860675 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/patient-matched-guides-to-orthopedic-implants-draft-guidance-for-industry-and-food-and-drug-administration-staff/96a75e9a-9df0-41d4-ba84-45d0cb82f905 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/presenting-quantitative-efficacy-and-risk-information-in-direct-to-consumer-dtc-promotional-labeling-and-advertisements/bb6d5d7c-0aa7-47cd-9c04-8a080c2201b7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-540750-use-of-the-seafood-list-to-determine-acceptable-seafood-names/154546ab-d87b-4523-89f3-599e5d89788d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/oncology-drug-products-used-with-certain-in-vitro-diagnostic-tests-pilot-program-guidance-for-industry-clinical-laboratories-and-food-and-drug-administration-staff/b901f295-6476-4a9d-8803-b6fedae71771 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-insanitary-conditions-in-the-preparation-packing-and-holding-of-tattoo-inks-and-the-risk-of-microbial-contamination/91259077-78cc-468b-8b7c-d97195a26c7a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-279-demonstrating-bioequivalence-for-type-a-medicated-articles-containing-active-pharmaceutical-ingredients-considered-to-be-poorly-soluble-in-aqueous-media-that-exhibit-little-to-no-systemic-bioavailability-and-are-locally-acting/6563f603-dbc6-4d95-942f-0438c0f7d455 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-288-chemistry-manufacturing-and-controls-in-support-of-recombinant-protein-products-for-veterinary-medicinal-use/e1abc597-6139-4802-b4fe-8fc042cf7114 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-guide-to-minimize-microbial-food-safety-hazards-for-fresh-fruits-and-vegetables/d433a577-65ee-474e-b53e-1604179d4cf6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessing-user-fees-under-the-prescription-drug-user-fee-amendments-of-2022/a1bfde05-8672-4537-9ef7-bdf6377a9f3b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/acute-radiation-syndrome-developing-drugs-for-prevention-and-treatment/a8417155-eb91-45ad-9133-c5685df4fb6d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/safety-testing-of-human-allogeneic-cells-expanded-for-use-in-cell-based-medical-products/6a8e9f02-c6de-403a-9762-daffba371531 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-transition-from-temporary-policy-during-the-covid-19-public-health-emergency-regarding-the-qualified-exemption-from-the-standards-for-the-growing-harvesting-packing-and-holding-of-produce-for-human-consumption/be49c9c2-1924-4f61-b9b7-2f19a83ff44c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-requirements-for-additional-traceability-records-for-certain-foods-what-you-need-to-know-about-the-fda-regulation/308221f2-4412-448c-b930-0eab02b433d3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/notifying-fda-of-a-discontinuance-or-interruption-in-manufacturing-of-finished-products-or-active-pharmaceutical-ingredients-under-section-506c-of-the-fdc-act/4bb3edae-dd26-480a-a41b-2f2b6bd19311 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-278-human-user-safety-in-new-and-abbreviated-new-animal-drug-applications/0a0c64dc-c687-44fe-b47c-72ab2723a713 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-new-dietary-ingredient-notification-master-files-for-dietary-supplements/c905e295-a7c5-4690-9b01-f633fc3032da 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/identification-of-medicinal-products-implementation-and-use/389d6672-9c7a-4d0b-8c2f-dfd968df1f09 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/research-involving-children-as-subjects-and-not-otherwise-approvable-by-an-institutional-review-board-process-for-referrals-to-food-and-drug-administration-and-office-for-human-research-protections-draft-guidance-for-institutional-review-boards-investigators-and-sponsors/26eaec4e-0434-4c59-a182-47818d614186 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-281-infectious-otitis-externa-drugs-for-topical-use-in-dogs/3f14b826-7ba7-4dd4-8e19-0506e82a1e99 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e2dr1-post-approval-safety-data-definitions-and-standards-for-management-and-reporting-of-individual-case-safety-reports/d300a747-e4a5-431a-aeb4-03dd8f84a959 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/orthopedic-non-spinal-bone-plates-screws-and-washers-premarket-notification-510k-submissions-guidance-for-industry-and-food-and-drug-administration-staff/1aa20bdc-4e32-4f2b-b2fc-32b165a1cd00 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-questions-and-answers-about-dietary-guidance-statements-in-food-labeling/e90ccb77-5a40-4a8e-8f53-5a16a608ee04 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-trial-considerations-to-support-accelerated-approval-of-oncology-therapeutics/adf9cb72-5955-4d5f-8f26-4e226281ace9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/development-of-local-anesthetic-drug-products-with-prolonged-duration-of-effect/e615d63e-8ed8-401e-a11d-6c93855b2dbd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/potency-assay-considerations-for-monoclonal-antibodies-and-other-therapeutic-proteins-targeting-viral-pathogens/1953041c-b51e-461d-b446-46cb6faf0d86 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/neovascular-age-related-macular-degeneration-developing-drugs-for-treatment/3b32c08c-4e69-42f4-ba19-cda20a8af050 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/product-specific-guidance-meetings-between-fda-and-anda-applicants-under-gdufa-guidance-for-industry/46fd1a27-e84d-47dd-b1fe-94fef41f16db 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-protein-efficiency-ratio-per-rat-bioassay-studies-to-demonstrate-that-a-new-infant-formula-supports-the-quality-factor-of-sufficient-biological-quality-of-protein/3a21122b-1117-487d-b1d7-9d38dd778f86 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m13a-bioequivalence-for-immediate-release-solid-oral-dosage-forms/3432d6e2-cab4-4cd5-8507-43579051debb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/early-lyme-disease-as-manifested-by-erythema-migrans-developing-drugs-for-treatment/59e6ea32-f774-48d5-8d7a-10fc9065ebd0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-evaluating-donor-eligibility-using-individual-risk-based-questions-to-reduce-the-risk-of-human-immunodeficiency-virus-transmission-by-blood-and-blood-products-guidance-for-industry/2aa5412b-2ce3-4c75-b71e-e133b6e6afe5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/manufacturing-changes-and-comparability-for-human-cellular-and-gene-therapy-products/b4919edd-67a6-490a-ab51-aa1a3c93944e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/optimizing-the-dosage-of-human-prescription-drugs-and-biological-products-for-the-treatment-of-oncologic-diseases-guidance-for-industry-availability/65250af0-1be1-43c2-bace-d1002014248b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/photobiomodulation-pbm-devices-premarket-notification-510k-submissions-draft-guidance-for-industry-and-food-and-drug-administration-staff/5fa43dca-92ac-4952-8dc4-dd21344f325b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/controlled-correspondence-related-to-generic-drug-development/55babf6e-6cea-4e6c-80f6-3892feff9aab 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/voluntary-malfunction-summary-reporting-vmsr-program-for-manufacturers-guidance-for-industry-and-food-and-drug-administration-staff/71c8b89e-0aaa-48f7-812d-411407531825 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/content-of-human-factors-information-in-medical-device-marketing-submissions-draft-guidance-for-industry-and-food-and-drug-administration-staff/6b81845f-385d-4062-90f7-c9f35edefab7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e19-a-selective-approach-to-safety-data-collection-in-specific-late-stage-pre-approval-or-post-approval-clinical-trials/1c6ec306-023c-4065-80cd-a01e6993d76b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-276-effectiveness-of-anthelmintics-specific-recommendations-for-products-proposed-for-the-prevention-of-heartworm-disease-in-dogs/6428bf8e-1efb-4173-8319-d9cf1d953630 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/small-volume-parenteral-drug-products-and-pharmacy-bulk-packages-for-parenteral-nutrition-aluminum-content-and-labeling-recommendations/084de7dc-b9f6-49bc-9ad9-fb1d8f394044 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compounding-certain-beta-lactam-products-in-shortage-under-section-503a-of-the-federal-food-drug-and-cosmetic-act/f00471a1-ecd8-4043-adad-09109215c898 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/sameness-evaluations-in-an-anda-active-ingredients/56e63be0-f1f7-48cf-90e1-c9eb340486ef 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/expanded-access-to-investigational-drugs-for-treatment-use-questions-and-answers/c8db4f04-043a-440b-838b-50bc0e9b17c9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/measuring-growth-and-evaluating-pubertal-development-in-pediatric-clinical-trials-draft-guidance-for-industry-availability/b3766e09-0a47-4099-a69c-f48ac2979eb8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550260-cranberry-sauce-adulteration-with-mold/2c0da24f-fc79-4943-8cd3-bac244bde870 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clostridioides-difficile-infection-developing-drugs-for-treatment-reduction-of-recurrence-and-prevention/b0e5f4fd-4c99-48d2-ad08-77dfb3fc2cc2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigational-new-drug-application-submissions-for-individualized-antisense-oligonucleotide-drug-products-for-severely-debilitating-or-life-threatening-diseases-chemistry-manufacturing-and-controls-recommendations-guidance-for-sponsor-investigators-draft-guidance-for-industry/c5f4b007-c758-4255-aaa0-4221bb556cd0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/graft-versus-host-diseases-developing-drugs-biological-products-and-certain-devices-for-prevention-or-treatment/30eba576-b6ea-4536-918e-e634aefadcc4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/topical-dermatologic-corticosteroids-in-vivo-bioequivalence/7cf691b8-82e3-41a4-a550-b4285ce9a9bf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/in-vitro-release-test-studies-for-topical-drug-products-submitted-in-andas/c7ff8356-0869-42f7-a5dc-76e32fe0380b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/breakthrough-devices-program-guidance-for-industry-and-food-and-drug-administration-staff/615429e8-d815-4bf4-bfc5-68955cba75bb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-laboratory-accreditation-for-analyses-of-foods-what-you-need-to-know/fc84047e-fdef-4a05-9384-bac4080054d8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/acute-myeloid-leukemia-developing-drugs-and-biological-products-for-treatment-guidance-for-industry-availability/7511194b-76aa-4116-a433-198583956923 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/regulatory-considerations-for-prescription-drug-use-related-software/91768cc9-a953-4b59-9da8-4726750c15e7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/characterizing-collecting-and-reporting-immune-mediated-adverse-reactions-in-cancer-immunotherapeutic-clinical-trials-draft-guidance-for-industry-availability/f687702e-a09a-4529-b573-6d8a028c8779 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/facility-readiness-goal-date-decisions-under-gdufa/f1987d5b-a4ff-4694-8ecd-47fc70768a33 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/ethical-considerations-for-clinical-investigations-of-medical-products-involving-children-draft-guidance-for-industry-sponsors-and-irbs/e95b55bc-b376-4b9d-a28e-612d442be498 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/exemption-and-exclusion-from-certain-requirements-of-the-drug-supply-chain-security-act-for-the-distribution-of-fda-approved-naloxone-products-during-the-opioid-public-health-emergency-guidance-for-industry/d210019a-9b7e-4dde-8567-15304071541d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/endogenous-cushings-syndrome-developing-drugs-for-treatment/c89a914f-8df3-4543-87dc-697dcbc10611 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/computer-software-assurance-for-production-and-quality-system-software-draft-guidance-for-industry-and-food-and-drug-administration-staff/e9e68dc8-73d8-465c-9c55-da8ca7b9eb69 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q14-analytical-procedure-development/7f445a67-e90c-4c67-a0c6-958d21e1d405 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/policy-for-monkeypox-tests-to-address-the-public-health-emergency-guidance-for-laboratories-commercial-manufacturers-and-food-and-drug-administration-staff/2668bb56-8427-4f20-97ac-6db37d1f5d0b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m12-drug-interaction-studies/2ca5aef5-80cc-464b-ba2c-bd69d35dfc2d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/hydrogen-peroxide-based-contact-lens-care-products-consumer-labeling-recommendations-premarket-notification-510k-submissions-guidance-for-industry-and-food-and-drug-administration-staff/bad59cb4-dd60-41ee-ba97-c787dd647457 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/changes-to-disposable-manufacturing-materials-questions-and-answers-guidance-for-industry/2f19a674-0482-4a39-94dc-e1041edbd884 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/laser-assisted-in-situ-keratomileusis-lasik-lasers-patient-labeling-recommendations-draft-guidance-for-industry-and-food-and-drug-administration-staff/138b3ed6-d13f-4c56-a77c-a039bf5e4f14 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postmarketing-studies-and-clinical-trials-determining-good-cause-for-noncompliance-with-section-505o3eii-of-the-federal-food-drug-and-cosmetic-act-draft-guidance-for-industry/e8ac2a5e-a08e-4bc6-b2bd-5feb7968f8ae 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/statement-of-identity-and-strength-content-and-format-of-labeling-for-human-nonprescription-drug-products/eedd66d7-1c8a-4071-8ce6-a53c3f8790a3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/real-time-oncology-review-rtor-guidance-for-industry/5d600007-ac00-4be9-8047-0a2e0cfaeca2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/conducting-remote-regulatory-assessments-questions-and-answers-guidance-for-industry/76800750-6d33-4c38-94de-91b3bda8716d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/alternative-procedures-for-the-manufacture-of-cold-stored-platelets-intended-for-the-treatment-of-active-bleeding-when-conventional-platelets-are-not-available-or-their-use-is-not-practical-guidance-for-industry/8cc4070d-c47d-4c02-9bda-48157ed8f034 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/human-prescription-drug-and-biological-products-labeling-for-dosing-based-on-weight-or-body-surface-area-for-ready-to-use-containers-dose-banding/449ec718-c571-47c0-a6d1-05154128ae01 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/patient-focused-drug-development-selecting-developing-or-modifying-fit-for-purpose-clinical-outcome-assessments/2b824356-e323-42ee-9188-d57fbb4ec54d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-rescinding-breakthrough-therapy-designation/adc0ae37-722c-4b21-90ea-5a2087f771f0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/non-clinical-performance-assessment-of-tissue-containment-systems-used-during-power-morcellation-procedures-guidance-for-industry-and-food-and-drug-administration-staff/d18da2a6-8f21-4167-8eb5-6bbcf8c14103 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/voluntary-consensus-standards-recognition-program-for-regenerative-medicine-therapies-guidance-for-industry/532afdaa-2167-4373-8507-eb06f5184eff 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/contact-lens-care-products-labeling-guidance-for-industry-and-food-and-drug-administration-staff/588c8797-f3bd-48d5-8d39-4287d620fd21 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/testing-of-glycerin-propylene-glycol-maltitol-solution-hydrogenated-starch-hydrolysate-sorbitol-solution-and-other-high-risk-drug-components-for-diethylene-glycol-and-ethylene-glycol/c8a74c49-b384-48bc-ae23-67d70dd41b1d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q9r1-quality-risk-management/3a048fa1-d9e8-42c1-a9f5-9f508b708dad 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/importation-of-prescription-drugs-final-rule-questions-and-answers-small-entity-compliance-guide/4db6f7d6-7fd6-4a57-9087-4891a248c653 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/antibacterial-therapies-for-patients-with-an-unmet-medical-need-for-the-treatment-of-serious-bacterial-diseases-questions-and-answers-guidance-for-industry/55dfd7fd-6c4c-47d9-996f-7fb8c588de59 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m11-clinical-electronic-structured-harmonised-protocol/08512de5-c7ff-456b-b915-b60eff6e9560 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-policy-regarding-certain-new-dietary-ingredients-and-dietary-supplements-subject-to-the-requirement-for-pre-market-notification/24e20985-c1b0-4fcc-b7ab-6709dab2fe64 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/over-the-counter-monograph-order-requests-format-and-content/eb4d3058-6081-407e-aa26-b551185c8260 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-voluntary-labeling-indicating-whether-foods-have-or-have-not-been-derived-from-genetically-engineered-plants/f8084cb0-997b-42ef-aabd-cdc690028312 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/risk-management-plans-to-mitigate-the-potential-for-drug-shortages/bd27fc63-0c90-4718-abd5-2b5af99e540e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-infant-formula-enforcement-discretion-policy/c51cf37a-6ba4-4d84-8884-7dbeb8d3c31a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fostering-medical-device-improvement-fda-activities-and-engagement-with-the-voluntary-improvement-program-guidance-for-industry-and-food-and-drug-administration-staff/0127b17c-93f7-4cf9-918b-5026bb90aa49 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/marketing-submission-recommendations-for-a-predetermined-change-control-plan-for-artificial-intelligence-enabled-device-software-functions-guidance-for-industry-and-food-and-drug-administration-staff/29b4b7c8-45f6-478c-bb72-f39ffd88cc9a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-human-radiolabeled-mass-balance-studies/3a1b0e14-f87e-4c72-b198-baa24f196e9a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-circulating-tumor-deoxyribonucleic-acid-for-early-stage-solid-tumor-drug-development-guidance-for-industry-availability/58138a0c-a510-4218-8ac6-5a85d090e8b0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-questions-and-answers-on-the-accredited-third-party-certification-program/8a1002b1-241d-4103-b094-19acc4fd6e5a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-action-levels-for-lead-in-juice/e773e4cf-6b03-4d77-b304-bec0db68d24e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/electronic-systems-electronic-records-and-electronic-signatures-in-clinical-investigations-questions-and-answers/e5689679-aaef-4ab4-9a7e-d50eaf459dce 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-policy-regarding-n-acetyl-l-cysteine/30f4c8fe-fd79-4e6c-af2c-bf8726fb158a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/celiac-disease-developing-drugs-for-adjunctive-treatment-to-a-gluten-free-diet/4fbd41e3-3158-4644-a1f3-69e97587f939 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-waiver-requests-for-ph-adjusters-in-generic-drug-products-intended-for-parenteral-ophthalmic-or-otic-use-draft-guidance-for-industry/72d47f74-c8a1-4b7b-8d10-222b23fcd90c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/surgical-sutures-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/f5170fd6-264d-4344-b8f1-34fb3b794d19 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-long-term-clinical-neurodevelopmental-safety-studies-in-neonatal-product-development-guidance-for-industry/22231631-637d-4cb6-b141-338bfd78deaf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/orthopedic-fracture-fixation-plates-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/54819ef6-b6ab-4a52-bc24-e7674d6008f7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m7r2-addendum-application-of-the-principles-of-the-ich-m7-guideline-to-calculation-of-compound-specific-acceptable-intakes-guidance-for-industry/868061ca-5806-48f0-9ad8-f904ab7868fc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/certain-ophthalmic-products-policy-regarding-compliance-with-21-cfr-part-4-guidance-for-industry-guidance-for-industry/8a04c815-2f7f-4f7e-908b-6a62504eb3e4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-current-good-manufacturing-practice-and-preventive-controls-foreign-supplier-verification-programs-intentional-adulteration-and-produce-safety-regulations-enforcement-policy-regarding-certain-provisions/167881c1-d580-4f12-a734-2fbc94248388 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-action-levels-for-lead-in-processed-food-intended-for-babies-and-young-children/a680a2a7-32a1-4ee5-9bc3-226a1cefb6e5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-258-use-of-tracers-in-animal-food-type-a-medicated-articles-and-medicated-feeds/4e1e1ca1-798f-46c2-b006-2761ba9ae5f2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/development-of-non-opioid-analgesics-for-acute-pain-draft-guidance-for-industry-draft-guidance-for-industry/713b2eb7-8a4f-499d-a0e2-6ff44a5ecff9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-antibody-drug-conjugates-guidance-for-industry-guidance-for-industry/ee3ed09c-6580-489f-bb06-0e93f612d604 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/mpox-development-of-drugs-and-biological-products-guidance-for-industry/ef1c9a82-c229-49ef-a357-d9947fb4dcdb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m11-technical-specification-clinical-electronic-structured-harmonised-protocol/a64c3fb5-ec8d-43b0-af0e-5170b4319e37 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/revising-anda-labeling-following-revision-of-the-rld-labeling-guidance-for-industry-guidance-for-industry/806edfce-5e20-40ff-b54f-bbaca98cdfba 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/collecting-and-providing-702b-portions-of-fda-official-samples-draft-guidance-for-industry/784eb4d1-7052-4789-b216-73f085854015 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/transition-plan-for-medical-devices-issued-emergency-use-authorizations-euas-related-to-coronavirus-disease-2019-covid-19-guidance-for-industry-other-stakeholders-and-food-and-drug-administration-staff/21dfc21f-0bb6-4a2e-a099-d8ffd9f8ad7f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/transition-plan-for-medical-devices-that-fall-within-enforcement-policies-issued-during-the-coronavirus-disease-2019-covid-19-public-health-emergency-guidance-for-industry-other-stakeholders-and-food-and-drug-administration-staff/3185a397-5ea4-4f60-b8ce-4008d0b638e4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessing-the-credibility-of-computational-modeling-and-simulation-in-medical-device-submissions-guidance-for-industry-and-food-and-drug-administration-staff/deda9f0c-89aa-46ae-8793-ff31b91a4909 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/technical-considerations-for-medical-devices-with-physiologic-closed-loop-control-technology-guidance-for-industry-and-food-and-drug-administration-staff/5b98dd0f-3b60-4ea7-b3c6-d7e17e5b540c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/validation-and-verification-of-analytical-testing-methods-used-for-tobacco-products/f4c08afe-1e39-4192-a224-2c1e088649fe 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/inspection-of-injectable-products-for-visible-particulates-draft-guidance-for-industry/3db61da7-cb07-4d7e-b933-ef2ea35c7c1c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessing-user-fees-under-the-over-the-counter-monograph-drug-user-fee-program/cd0a751e-3682-43b3-b40d-fb7c5e1da162 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/referencing-the-definition-of-device-in-the-federal-food-drug-and-cosmetic-act-in-guidance-regulatory-documents-communications-and-other-public-documents-guidance-for-industry-and-food-and-drug-administration-staff/d129e237-573b-4154-b731-0db0644370be 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bowel-cleansing-for-colonoscopy-efficacy-and-safety-considerations-for-developing-new-products-draft-guidance-for-industry/e6750ecc-4eb0-43ff-a9fe-8c7f51833049 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-use-of-real-world-data-and-real-world-evidence-to-support-regulatory-decision-making-for-drug-and-biological-products-guidance-for-industry/41d12e6b-4639-4430-9ace-220364a487a1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e10-choice-of-control-group-and-related-issues-in-clinical-trials/c5fec9b1-2f5e-4a87-9fda-d276bbfb5cbb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/in-vitro-permeation-test-studies-for-topical-drug-products-submitted-in-andas/8770bfc5-6951-467a-905c-ebd361ba4aac 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/ind-submissions-for-individualized-antisense-oligonucleotide-drug-products-for-severely-debilitating-or-life-threatening-diseases-clinical-recommendations-draft-guidance-for-industry/2fbda0fb-0b43-42de-8bce-881ee5336b6e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/content-of-premarket-submissions-for-device-software-functions-guidance-for-industry-and-food-and-drug-administration-staff/0cee2fd2-94a6-466f-b1b8-836fd3c8d30f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/reporting-amount-of-listed-drugs-and-biological-products-technical-conformance-guide-guidance-for-industry/4222c78a-5db6-449e-826e-6bfd5b426574 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-infant-formula-transition-plan-for-exercise-of-enforcement-discretion/bddba3d2-eaff-4fcc-a0d7-21d60f1efbef 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q13-continuous-manufacturing-of-drug-substances-and-drug-products-guidance-for-industry/2724500a-92c1-4369-92e2-13983181dbcf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s1br1-addendum-to-s1b-testing-for-carcinogenicity-of-pharmaceuticals-guidance-for-industry/1d41223b-0838-4b9d-ad50-e8e6371d700e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/benefit-risk-assessment-for-new-drug-and-biological-products/90bf84f4-05cf-4617-b13d-bbb345349aed 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/microbiological-quality-considerations-in-non-sterile-drug-manufacturing-draft-guidance-for-industry/37a0a205-577b-4738-a343-eec1075de07d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/electronic-submission-template-for-medical-device-510k-submissions-guidance-for-industry-and-food-and-drug-administration-staff/e2d20776-7b21-4f34-8478-557a8c57b649 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/quantitative-labeling-of-sodium-potassium-and-phosphorus-for-human-over-the-counter-and-prescription-drug-products/e89b7637-7879-45da-9ba2-25c8cdf31cf8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nontuberculous-mycobacterial-pulmonary-disease-caused-by-mycobacterium-avium-complex-developing-drugs-for-treatment-guidance-for-industry/dda15f98-e807-4823-898a-ad26150481d1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-254-donor-eligibility-for-animal-cells-tissues-and-cell-and-tissue-based-products/d5eb6da2-94b5-41a2-a968-ac68b7a3a918 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/questions-and-answers-on-quality-related-controlled-correspondence-guidance-for-industry-guidance-for-industry/36e0e984-b134-47b6-bee8-6f25aa0282c1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e11a-pediatric-extrapolation/01ffe475-9ecf-45c9-ad29-f4b2a89bcb52 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/facet-screw-systems-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/a855811f-87d3-467e-bc0b-401b05179553 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/denture-base-resins-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/3b752acd-c3d4-4586-bcd1-10ec52ee90f0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pharmacokinetic-based-criteria-for-supporting-alternative-dosing-regimens-of-programmed-cell-death-receptor-1-pd-1-or-programmed-cell-death-ligand-1-pd-l1-blocking-antibodies-for-treatment-of-patients-with-cancer-guidance-for-industry/39b5200a-95fe-45d2-ac1a-170502282ac4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-oversight-of-food-covered-by-systems-recognition-arrangements/fde79197-1a46-4de7-95c6-46f1ed26c567 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessment-of-adhesion-for-topical-and-transdermal-systems-submitted-in-new-drug-applications-draft-guidance-for-industry/2c6ec6df-cd19-4af8-ac74-0ccd1281b8ef 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/sponsor-responsibilities-safety-reporting-requirements-and-safety-assessment-for-ind-and-bioavailabilitybioequivalence-studies-draft-guidance-for-industry/3ddf69d5-0ade-4f23-bd0b-b3c057455a7c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cancer-clinical-trial-eligibility-criteria-available-therapy-in-non-curative-settings-guidance-for-industry/d21a3c21-c758-4f3f-b215-edfe13aa09a3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/remanufacturing-of-medical-devices-guidance-for-industry-entities-that-perform-servicing-or-remanufacturing-and-food-and-drug-administration-staff/64f116aa-ebd5-47c9-9941-2a120cd08231 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/non-penicillin-beta-lactam-drugs-a-cgmp-framework-for-preventing-cross-contamination-draft-guidance-for-industry/0995d9e6-6e6d-4bdf-880c-7d5338ab692d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enhanced-drug-distribution-security-at-the-package-level-under-the-drug-supply-chain-security-act-guidance-for-industry/b59d912a-eda7-45e5-9447-14d418b8e529 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/oral-drug-products-administered-via-enteral-feeding-tube-in-vitro-testing-and-labeling-recommendations-draft-guidance-for-industry/fb28d96f-0326-4f8f-99c6-1fbcc75b445e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/tobacco-product-user-fees-responses-to-frequently-asked-questions/45be5e37-e658-4740-a843-04fd276300bf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/feasibility-and-early-feasibility-clinical-studies-for-certain-medical-devices-intended-to-therapeutically-improve-glycemic-control-in-patients-with-type-2-diabetes-mellitus-guidance-for-industry-and-food-and-drug-administration-staff/beb50e65-0eb4-41d4-adac-bdf7103fa447 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/blood-pressure-and-pulse-donor-eligibility-requirements-compliance-policy-guidance-for-industry/615d0678-665d-430f-b65f-b6436cb2069f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s12-nonclinical-biodistribution-considerations-for-gene-therapy-products-guidance-for-industry/f0e813d3-46bd-49f2-846f-f5f95f9d4892 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/information-sheet-guidance-for-sponsors-clinical-investigators-and-irbs-frequently-asked-questions-statement-of-investigator-form-fda-1572-revision-1-draft-information-sheet-guidance-for-sponsors-clinical-investigators-and-irbs-frequently-asked-questions-statement-of-investigator-form-fda-1572-revision-1/24f9b588-7ada-4ab8-9dd7-e90f06330564 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/covid-19-master-protocols-evaluating-drugs-and-biological-products-for-treatment-or-prevention-guidance-for-industry/44e328fb-a98c-4db7-af9a-8b94f4ea28ea 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postmarketing-studies-and-clinical-trialsimplementation-of-section-505o3-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry-draft-guidance-for-industry/956f83ff-a6ef-4206-a544-56a3e8a65ee9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/benefit-risk-considerations-for-product-quality-assessments/dd4547d7-4ac9-437a-8d9b-b88b234da4bc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/container-closure-system-and-component-changes-glass-vials-and-stoppers/2ef26548-0e06-40e5-ae20-e2d4e37dc791 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/covid-19-developing-drugs-and-biological-products-for-treatment-or-prevention-guidance-for-industry/a6c3249b-9395-4d0b-96dd-986a992b4139 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-labeling-of-plant-based-alternatives-to-animal-derived-foods/ff384ab3-8f2f-410c-85d5-46809b694078 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/development-of-monoclonal-antibody-products-targeting-sars-cov-2-for-emergency-use-authorization/0146d188-0350-4f83-b103-4193b8be1e41 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-fda-staff-and-interested-parties-evaluating-the-public-health-importance-of-food-allergens-other-than-the-major-food-allergens-listed-in-the-federal-food-drug-and-cosmetic-act/2635395b-eb6e-488d-9573-6ec65c0f0ab3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/protection-of-human-subjects-categories-of-research-that-may-be-reviewed-by-the-institutional-review-board-irb-through-an-expedited-review-procedure-guidance-for-institutional-review-boards-and-clinical-investigators/3f36bd8c-c7f3-43b6-8b85-5e6e92984169 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/policy-for-testing-of-alcohol-ethanol-and-isopropyl-alcohol-for-methanol-guidance-for-industry/a25ea3c0-e08b-4e4a-a585-a8d8648fe2a6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/human-gene-therapy-for-neurodegenerative-diseases-guidance-for-industry/f637c287-4075-481d-aeea-05a41cbacefa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-whole-slide-imaging-in-nonclinical-toxicology-studies-questions-and-answers-guidance-for-industry/fc84d5fe-2f95-4d3c-9001-406c9aa4ef09 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/consumer-antiseptic-rub-final-rule-questions-and-answers-guidance-for-industry-guidance-for-industry/8c26ae69-8d0f-400c-82bd-a4ea1fbb7b1b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dry-eye-developing-drugs-for-treatment-guidance-for-industry/c72442af-b5f2-4a62-88b5-4261f9399657 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-enforcement-policy-for-providing-an-acceptable-unique-facility-identifier-ufi-for-the-2020-food-facility-registration-biennial-renewal-period/1d03a5f9-8f5f-4755-9fff-1f70c43b0f83 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/evaluation-of-gastric-ph-dependent-drug-interactions-with-acid-reducing-agents-study-design-data-analysis-and-clinical-implications-guidance-for-industry-guidance-for-industry/37fa6a5f-3563-4e1a-93c3-41b2507b80dc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-development-of-chimeric-antigen-receptor-car-t-cell-products/cdb5020e-7bcf-4cca-a732-0231b04e3869 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-drug-interaction-studies-with-combined-oral-contraceptives-guidance-for-industry-guidance-for-industry/66dca3d2-f3c0-447f-8085-fd2e7ebd60c6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cross-labeling-oncology-drugs-in-combination-regimens/d50f604f-4d0f-4aaa-a83a-b8a75b4a71ee 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/biosimilarity-and-interchangeability-additional-draft-qas-on-biosimilar-development-and-the-bpci-act-revision-1-draft-guidance-for-industry/b8ab7745-3ad5-4de1-8e9c-9262c73cdacd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/notifying-fda-of-a-permanent-discontinuance-or-interruption-in-manufacturing-of-a-device-under-section-506j-of-the-fdc-act-guidance-for-industry-and-food-and-drug-administration-staff/5d3b0ec7-bd9b-4b37-afcb-2bbba12501ad 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/tobacco-products-principles-for-designing-and-conducting-tobacco-product-perception-and-intention-studies/f58eb206-c387-47a4-a174-636d08fc88db 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/wholesale-distributor-verification-requirement-for-saleable-returned-drug-productcompliance-policy-guidance-for-industry-guidance-for-industry/9c37f21d-8925-4eca-96b6-c5ce923c6966 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/annual-status-report-information-and-other-submissions-for-postmarketing-requirements-and-commitments-using-forms-fda-3988-and-fda-3989-guidance-for-industry-guidance-for-industry/837f8e23-bcb2-4e1d-8522-93e875ad78c3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-over-the-counter-monograph-submissions-in-electronic-format/772bd042-0dda-4d43-a221-6577f1e823b9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/manufacture-of-blood-components-using-a-pathogen-reduction-device-in-blood-establishments-questions-and-answers-guidance-for-industry/4bb1276b-ec33-409e-82ac-d359a4c4d5af 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/early-alzheimers-disease-developing-drugs-for-treatment/ef0ff9a7-7208-4951-acbb-acb9937f83e7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/control-of-nitrosamine-impurities-in-human-drugs-guidance-for-industry/540c1e3e-a057-4a4f-9ede-0b1290a5cf04 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/principles-for-selecting-developing-modifying-and-adapting-patient-reported-outcome-instruments-for-use-in-medical-device-evaluation-guidance-for-industry-and-food-and-drug-administration-staff-and-other-stakeholders/e5b1e628-90bc-4808-9dcf-5491e6d5c43d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/evaluating-cancer-drugs-in-patients-with-central-nervous-system-metastases-guidance-for-industry/cd630104-b6ee-4993-a2ff-85effca3e866 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/studying-multiple-versions-of-a-cellular-or-gene-therapy-product-in-an-early-phase-clinical-trial-guidance-for-industry/8b768a82-5ebf-4899-ad60-25692f1674d9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/acute-myeloid-leukemia-developing-drugs-and-biological-products-for-treatment-draft-guidance-for-industry/8143a606-18fc-488c-b3ab-4c23bdcd999a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cannabis-and-cannabis-derived-compounds-quality-considerations-for-clinical-research-guidance-for-industry-guidance-for-industry/529cc738-130c-4b4d-afb4-d2ea5f0fe894 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/appeal-options-available-to-mammography-facilities-concerning-adverse-accreditation-decisions-suspensionrevocation-of-certificates-or-patient-and-referring-provider-notification-orders-guidance-for-mammography-facilities-and-food-and-drug-administration-staff/3597db48-284e-4ca0-a3b5-0be064f98911 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q2r1-validation-of-analytical-procedures-text-and-methodology-guidance-for-industry-guidance-for-industry/8d826e71-f7db-43f1-b28a-787f4e374c57 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-268-adaptive-and-other-innovative-designs-for-effectiveness-studies-of-new-animal-drugs/aec0e84d-2ef0-4428-b0c0-3cb5a94073b5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-267-biomarkers-and-surrogate-endpoints-in-clinical-studies-to-support-effectiveness-of-new-animal-drugs/017aa044-c960-4f4a-b6e9-4aed194af7c4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/development-and-licensure-of-vaccines-to-prevent-covid-19-guidance-for-industry/c33dc669-49bf-43f1-a92c-97b2eb6d44a5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/development-of-anti-infective-drug-products-for-the-pediatric-population-guidance-for-industry/93fc101d-c235-4c5e-8254-82649ec6d7fb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/rabies-developing-monoclonal-antibody-cocktails-for-the-passive-immunization-component-of-post-exposure-prophylaxis-guidance-for-industry-draft-guidance-for-industry/6ffd0752-9587-416f-8c63-5f1ab53186bd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/accidental-radioactive-contamination-of-human-food-and-animal-feeds-recommendations-for-state-and-local-agencies/8a1009a0-ab6e-40a9-8b28-5c96b831e63e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/orange-book-questions-and-answers-guidance-for-industry-guidance-for-industry/8492a175-773f-4d3e-a92c-aec1f10c8bda 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q3cr8-impurities-guidance-for-residual-solvents-guidance-for-industry-guidance-for-industry/5d102000-693a-43cc-8f78-dc661ff31752 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/consumer-directed-broadcast-advertisements-guidance-for-industry/91a74b38-7614-49df-9da1-d64c111be3db 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/plasma-derived-from-therapeutic-plasma-exchange/83d64ec6-ba80-482f-a450-aac3b802f645 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/recommendations-for-the-management-of-donor-and-units-that-are-initially-reactive-for-hepatitis-b-surface-antigen-hbsag/0783c417-4bec-4063-bda4-98590b89d010 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/revised-recommendations-for-testing-whole-blood-blood-components-source-plasma-and-source-leukocytes-for-antibody-to-hepatitis-c-virus-encoded-antigen-anti-hcv/42a2606c-55c7-41fb-bfc7-fc548bbc8704 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/recommendations-regarding-license-amendments-and-procedures-for-gamma-irradiation-of-blood-products/8ced993c-d318-47e1-8ed9-f59777b4c99c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/revised-recommendations-for-testing-whole-blood-blood-components-source-plasma-and-source-leukocytes-for-antibody-to-hepatitis-c-virus-encoded-antigen-anti-hcv/fec579ab-4311-4caf-a1d4-a68957466e0e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/revised-recommendations-for-red-blood-cell-immunization-programs-for-source-plasma-donors-memorandum-to-licensed-establishments/c8e92a9b-5906-4c80-86fb-cae7eb41c447 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/ich-q12-implementation-considerations-for-fda-regulated-products-draft-guidance-for-industry/2c7d4c33-4495-4c29-abb1-22058de23404 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/conducting-clinical-trials-with-decentralized-elements/dc054f22-ff9d-4ea3-8083-fe59c7622408 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/donor-deferral-due-to-red-blood-cell-loss-during-collection-of-source-plasma-by-automated-plasmapheresis/5e298c66-6f31-48eb-ac26-66adf2b26fe6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/additional-recommendations-for-donor-screening-with-a-licensed-test-for-hiv-1-antigen-memorandum-to-registered-blood-and-plasma-establishments/2ef3cada-6ec9-4b93-8983-833ab72b7346 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/additional-recommendations-for-testing-whole-blood-blood-components-source-plasma-and-source-leukocytes-for-antibody-to-hepatitis-c-virus-encoded-antigen-anti-hcv-memorandum-to-registered-blood-and-plasma-establishments/a2f23724-9762-4715-8ff8-7fab8fd14fe5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-testing-of-individualized-antisense-oligonucleotide-drug-products-for-severely-debilitating-or-life-threatening-diseases-guidance-for-sponsor-investigators-draft-guidance-for-sponsor-investigators/0a1b71f0-6d88-41f2-84d4-290080233486 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/patient-focused-drug-development-incorporating-clinical-outcome-assessments-into-endpoints-for-regulatory-decision-making/602cd947-34b1-41f2-adaf-e98010054159 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/classification-of-posterior-cervical-screw-systems-small-entity-compliance-guide-guidance-for-industry-and-food-and-drug-administration-staff/b2125432-cdef-4b27-b814-93f95d941c9c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s6r1-addendum-preclinical-safety-evaluation-of-biotechnology-guidance-for-industry/23ee2aae-70be-4e30-bfcb-a4cf7a016b71 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/technical-considerations-for-demonstrating-reliability-of-emergency-use-injectors-submitted-under-a-bla-nda-or-anda-draft-guidance-for-industry-and-food-and-drug-administration-staff/abee485e-e6e0-4d16-957f-8b6073ad267a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/manufacturing-considerations-for-licensed-and-investigational-cellular-and-gene-therapy-products-during-covid-19-public-health-emergency-guidance-for-industry/20ac34c3-75bd-45e5-8338-ca633985c05c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/standards-for-the-prompt-review-of-efficacy-supplements-including-priority-efficacy-supplements-guidance-for-industry/b8c315e8-9952-4fdf-8200-d0e668dfb47d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enforcement-policy-for-face-masks-and-barrier-face-coverings-during-the-coronavirus-disease-covid-19-public-health-emergency-guidance-for-industry-and-food-and-drug-administration-staff/d5e9f013-a025-42cb-85f6-421dba8c2dc5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/temporary-policy-regarding-preventive-controls-and-fsvp-food-supplier-verification-onsite-audit-requirements-due-to-covid-19-guidance-for-industry/e32dd1be-8865-4ce1-a1db-76ab9ceebe91 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/required-warnings-for-cigarette-packages-and-advertisements-small-entity-compliance-guide-revised-guidance-for-industry/ead54df9-ea37-464d-a859-b2b553d8b923 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/best-practices-in-developing-proprietary-names-for-human-nonprescription-drug-products-draft-guidance-for-industry-draft-guidance-for-industry/5574de95-cac8-42dc-9e8f-20bb345394e6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-in-alternate-electronic-format-guidance-for-industry-guidance-for-industry/c95b38e3-1b57-413c-b3fc-da380f4218da 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/contact-dermatitis-from-topical-drug-products-for-cutaneous-application-human-safety-assessment-guidance-for-industry/56b78fa3-b2a8-4192-8217-17aadeb25cb7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/inclusion-of-older-adults-in-cancer-clinical-trials-guidance-for-industry/58e758a2-a626-41ba-8346-44066b8cd50f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/soft-hydrophilic-daily-wear-contact-lenses-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/2438a588-d8bf-45ab-aacb-820d8e89ed8f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/convenience-kits-interim-regulatory-guidance/a682044d-031c-455c-89fe-76613056126a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/policy-for-coronavirus-disease-2019-tests-revised-guidance-for-developers-and-food-and-drug-administration-staff/e078beb2-f4b7-4f16-afb1-98c6aad53b11 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-exports-under-the-fda-export-reform-and-enhancement-act-of-1996-guidance-for-industry/b0ac77c4-249b-4646-9720-a7bd621441fc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/rems-fdas-application-of-statutory-factors-in-determining-when-a-rems-is-necessary-guidance-for-industry/decb6a17-0d69-46dd-aca8-c4de8c5d15cd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e2br3-the-electronic-transmission-of-individual-case-safety-reports-implementation-guide-appendix-to-the-implementation-guide-backwards-and-forwards-compatibility/4492f052-a664-4c4f-808e-f1683d329b6d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-us-agent-voluntary-identification-system-vis-for-food-facility-registration/8a983a8b-6c69-4d6c-a645-7354e06b4fb7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/quality-considerations-in-demonstrating-biosimilarity-of-a-therapeutic-protein-product-to-a-reference-product-guidance-for-industry/f1b25c36-0d87-42be-b734-ad29acc267ea 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-electronic-transmission-of-individual-case-safety-reports-implementation-guide-data-elements-and-message-specification/08685a30-e4ed-42f5-ba23-02c097f8a598 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-264-standardized-medicated-feed-assay-limits/2cc97c03-a52f-438a-816f-e73486d935d4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s10-photosafety-evaluation-of-pharmaceuticals/a680cedd-1608-4be5-88b0-5c2e50a39111 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e14-and-s7b-clinical-and-nonclinical-evaluation-of-qtqtc-interval-prolongation-and-proarrhythmic-potential-questions-and-answers-guidance-for-industry/c6214e5a-c9e4-4ba4-9685-598dee7a9985 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/study-data-technical-conformance-guide-technical-specifications-document/d939977f-6a47-4225-a2cd-3ffaa7be4502 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/points-to-consider-in-the-manufacture-and-testing-of-monoclonal-antibody-products-for-human-use/a46ecfe6-3346-4604-96dc-b32e5e663fff 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/supplemental-draft-guidance-for-industry-mitigation-strategies-to-protect-food-against-intentional-adulteration/c1458147-3e32-467f-9859-42bd83805a9b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/geriatric-information-in-human-prescription-drug-and-biological-product-labeling-guidance-for-industry-draft-guidance-for-industry/bc558261-75a7-4f5d-a91c-5d632df2642a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-262-pre-submission-consultation-process-for-animal-food-additive-petitions-or-generally-recognized-as-safe-gras-notices/dd6618e4-716d-44c5-8a1a-9013d69e6318 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/product-recalls-including-removals-and-corrections-guidance-for-industry/93577bcf-9c66-4e9c-b630-6f19d1473d18 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enforcement-policy-for-required-warnings-for-cigarette-packages-and-advertisements/90fc303d-d0a7-49b1-ae68-a54d32b4e865 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/promotional-labeling-and-advertising-considerations-for-prescription-biological-reference-and-biosimilar-products-questions-and-answers-guidance-for-industry/5c8b9c05-0acc-4e14-a3bd-6fdff92000ae 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/setting-endotoxin-limits-during-development-of-investigational-oncology-drugs-and-biological-products-guidance-for-industry-draft-guidance-for-industry/ef751a3a-e9d6-4489-b86d-73f2411682c1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-revision-of-the-nutrition-and-supplement-facts-labels/bd641e24-e295-498d-95e0-e0f5d7b83a9d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-on-labeling-of-foods-that-need-refrigeration-by-consumers/b0163e5c-00fa-4ef3-a459-4872c8aee001 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/arthroscopy-pump-tubing-sets-intended-for-multiple-patient-use-premarket-notification-510k-submissions-guidance-for-industry-and-food-and-drug-administration-staff/2722ba93-946d-4ed7-87d5-ed773e263221 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-266-use-of-real-world-data-and-real-world-evidence-to-support-effectiveness-of-new-animal-drugs/525f6470-8ff5-452d-90dd-0083fd6675cc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postmarketing-studies-and-clinical-trialsimplementation-of-section-505o3-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry/5ddef98b-24ad-4f80-a57b-2bd98fbf3a27 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/requesting-fda-feedback-on-combination-products-guidance-for-industry-and-fda-staff/75e50be8-56cc-4974-b1c1-f604869c590c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/importation-of-certain-fda-approved-human-prescription-drugs-including-biological-products-and-combination-products-under-section-801d1b-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry/77ae82d8-d3eb-4e4a-84cd-e016e647d286 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/institutional-review-board-irb-review-of-individual-patient-expanded-access-submissions-for-investigational-drugs-and-biological-products-guidance-for-irbs-and-clinical-investigators/d18c103b-b568-496d-a0f1-6c8fa7abdd67 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fdara-implementation-guidance-for-pediatric-studies-of-molecularly-targeted-oncology-drugs-amendments-to-sec-505b-of-the-fdc-act-guidance-for-industry/7a11011d-8bb1-46e2-8382-c4460aea8ec8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/magnetic-resonance-mr-receive-only-coil-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/568ea33d-71dc-46fb-98d3-f2c72dbe1229 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/interstitial-cystitisbladder-pain-syndrome-establishing-drug-development-programs-for-treatment-draft-guidance-for-industry/4888997d-ae3c-4b28-948e-3ac98beec85e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-271-reporting-and-mitigating-animal-drug-shortages/b4f6fa83-203d-48af-8eb2-4ceebf9e2d16 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/memorandum/fda-recommendations-concerning-testing-for-antibody-to-hepatitis-b-core-antigen-anti-hbc/92f1e482-e9a5-40f1-b266-e3cc4bb7a292 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-immunogenicity-considerations-for-biosimilar-and-interchangeable-insulin-products/a298f68f-edb6-4662-b8d8-18120d2ae9f0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/transdermal-and-topical-delivery-systems-product-development-and-quality-considerations/c271fdae-0acd-4bb8-a2b4-464dde75fe25 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-in-electronic-format-ind-safety-reports-guidance-for-industry/d8a7e884-2739-4461-b12b-7feef9321c17 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/type-v-dmfs-for-cder-led-combination-products-using-device-constituent-parts-with-electronics-or-software-guidance-for-industry/36095128-42c2-40d0-9a42-baf546d680db 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/breast-implants-certain-labeling-recommendations-to-improve-patient-communication-guidance-for-industry-and-food-and-drug-administration-staff/573d65df-4023-4b9b-8725-cf0b00b005b9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-171-demonstrating-bioequivalence-for-soluble-powder-oral-dosage-form-products-and-type-a-medicated-articles-containing-active-pharmaceutical-ingredients-considered-to-be-soluble-in-aqueous-media/2e8121bb-916c-4f32-9b35-27b6a2c08a4a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-261-eligibility-criteria-for-expanded-conditional-approval-of-new-animal-drugs/f14b98b9-4e54-4fbf-8ced-f5788ccefc39 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/wholesale-distributor-verification-requirement-for-saleable-returned-drug-product-and-dispenser-verification-requirements-when-investigating-a-suspect-or-illegitimate-productcompliance-policies/603f621c-1702-4d43-a708-2222017b9566 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/product-name-placement-size-and-prominence-in-advertising-and-promotional-labeling-final/fa68136f-ad70-49ea-a8cd-cc47e646f4a1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/patient-engagement-in-the-design-and-conduct-of-medical-device-clinical-studies-guidance-for-industry-food-and-drug-administration-staff-and-other-stakeholders/4fd69950-e1df-4bef-96df-98876c880143 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-accreditation-scheme-for-conformity-assessment-asca-pilot-program-guidance-for-industry-accreditation-bodies-testing-laboratories-and-food-and-drug-administration-staff/92e0773c-84a0-4cf7-a1a0-23e3e974cddc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/conventional-foley-catheters-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/63423f29-b8a3-411a-aa99-86e514212a00 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/restricted-delivery-systems-flow-restrictors-for-oral-liquid-drug-products-guidance-for-industry/15d40148-65c3-459a-bdeb-40d8eb6e77da 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/spinal-plating-systems-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/9b6099f2-dd3d-40cb-b1b5-5db32066311a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/orthopedic-non-spinal-metallic-bone-screws-and-washers-performance-criteria-for-safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration-staff/fe38bf10-d15c-4184-b150-42a82b65df56 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/safer-technologies-program-for-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/550343a5-c0c9-44e5-9b3e-333f80238188 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-reconditioning-of-fish-and-fishery-products-by-segregation/94a8ac36-97f0-4852-843d-b23204a710f3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/male-breast-cancer-developing-drugs-for-treatment-guidance-for-industry/76829c69-4547-4b3d-bde5-9bf7ef4e1490 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-policy-related-to-cranberry-products-with-added-flavorings/f12dec9a-6cf3-4558-b46f-e20fead807cd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-converting-units-of-measure-for-folate-niacin-and-vitamins-a-d-and-e-on-the-nutrition-and-supplement-facts-labels/ad05facb-6c74-4ecd-a0e8-2f8a0936df89 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-regional-implementation-guide-for-e2br3-electronic-transmission-of-individual-case-safety-reports-for-drug-and-biological-products/80bd5bd7-a638-473b-b68a-dd6de78189c5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/child-resistant-packaging-statements-in-drug-product-labeling-guidance-for-industry/6c75fc9c-8e65-49a0-ad1d-eb6162ad92b8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/general-clinical-pharmacology-considerations-for-neonatal-studies-for-drugs-and-biological-products-guidance-for-industry/0c57731e-55bc-4962-a619-54444aa22335 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/delayed-graft-function-in-kidney-transplantation-developing-drugs-for-prevention-guidance-for-industry/f8ba6733-8126-457f-a655-8004f97ba158 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-the-submission-of-loinc-codes-in-regulatory-applications-to-the-us-food-and-drug-administration-guidance-for-industry/ce6835ad-0bdd-4e08-b063-0e7dc3ae34d1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submitting-next-generation-sequencing-data-to-the-division-of-antiviral-products-guidance-for-industry-technical-specifications-document/4edd1e8a-43c4-4293-b6b8-ac9472e1a619 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/advanced-prostate-cancer-developing-gonadotropin-releasing-hormone-analogues-guidance-for-industry-clinicalmedical/3000f20b-5abd-4861-8188-ffcc1d35913d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/using-the-inactive-ingredient-database-guidance-for-industry/0bf5000a-4dfb-4c0c-b619-fdb0e028ed1d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/harmonizing-compendial-standards-with-drug-application-approval-using-the-usp-pending-monograph-process-guidance-for-industry/2bca3b51-14c5-4542-ac74-37c261ce6f8d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/mucopolysaccharidosis-type-iii-sanfilippo-syndrome-developing-drugs-for-treatment-guidance-for-industry-draft-guidance-for-industy/942f35fd-9db0-4292-9bf9-3ebc347373df 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/risk-evaluation-and-mitigation-strategies-modifications-and-revisions-guidance-for-industry/97c2bcd1-cfbd-4928-92c1-d3ac287909b5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/instructions-for-use-patient-labeling-for-human-prescription-drug-and-biological-products-content-and-format/6292a71a-45d3-4698-bff7-3fab3969aacb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/drug-abuse-and-dependence-section-of-labeling-for-human-prescription-drug-and-biological-products-content-and-format-guidance-for-industry/e65bdb77-e74c-42d7-aab4-482af24834d1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/peripheral-percutaneous-transluminal-angioplasty-pta-and-specialty-catheters-premarket-notification-510k-submissions-guidance-for-industry-and-food-and-drug-administration-staff/32b5da37-c588-499e-b185-8836c149827f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m10-bioanalytical-method-validation/0bcad818-8b44-4227-b811-ea24e68f81cd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e19-optimisation-of-safety-data-collection/e2f8a0da-582a-4c4a-946d-b9039d8729bb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-investigations-for-prostate-tissue-ablation-devices-guidance-for-industry-and-food-and-drug-administration-staff/6adcb58a-5c5d-4fde-bb6c-ff2c7666bced 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/opioid-analgesic-drugs-considerations-for-benefit-risk-assessment-framework-guidance-for-industry/c20377b8-3086-48cf-be2b-b9cd12520573 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bridging-for-drug-device-and-biologic-device-combination-products-draft-guidance-for-industry/b906c8bd-9549-44b2-903e-95838dcc4ec3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/testing-for-biotin-interference-in-in-vitro-diagnostic-devices-guidance-for-industry/1a6a74f2-3b19-490b-9847-11a56bd093bf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/mouse-embryo-assay-for-assisted-reproduction-technology-devices/a9abbbb9-85c6-4354-bc6a-3f37a329e826 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonalcoholic-steatohepatitis-with-compensated-cirrhosis-developing-drugs-for-treatment-guidance-for-industry/71c114f5-4930-4cda-87ef-12936678931f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-the-use-of-an-alternate-name-for-potassium-chloride-in-food-labeling/29e8b3f0-dc67-4949-8566-c4ba3e5298c4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/rare-diseases-considerations-for-the-development-of-drugs-and-biological-products/de40ca53-dec2-46b7-8321-a251e09d47bb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/compliance-policy-for-limited-modifications-to-certain-marketed-tobacco-products-guidance-for-industry/14c37843-75fb-415a-8d5b-078f839cf1e8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-lactation-studies-considerations-for-study-design/7e2a7cd7-32ed-4962-a11a-5ece5acd2cb4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-256-compounding-animal-drugs-from-bulk-drug-substances/d22e3403-a3c1-4e66-b794-86f1c53bc8fe 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-review-staff-and-industry-good-review-management-principles-and-practices-for-pdufa-products/2063ec1b-8811-4dd6-88f7-f0849ff947a9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessing-user-fees-under-the-generic-drug-user-fee-amendments-of-2022/f97fbaf6-3c85-4cbc-ac92-15d0649f8092 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submitting-documents-using-real-world-data-and-real-world-evidence-to-fda-for-drug-and-biological-products/42c343c9-e823-43a4-a2f7-a2fe152b02aa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/manufacturing-site-change-supplements-content-and-submission-guidance-for-industry-and-food-and-drug-administration-staff/dd373521-4774-4b83-8a99-f2906d67f004 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/coordinated-development-of-antimicrobial-drugs-and-antimicrobial-susceptibility-test-devices-guidance-for-industry-and-food-and-drug-administration-staff/696c3f6c-c04a-4c7d-87cd-d64b7c3de498 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cancer-clinical-trial-eligibility-criteria-patients-with-organ-dysfunction-or-prior-or-concurrent-malignancies/05aa2403-3ce3-4030-81d9-e59b704fd60c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/reporting-harmful-and-potentially-harmful-constituents-in-tobacco-products-and-tobacco-smoke-under-section-904a3-of-the-federal-food-drug-and-cosmetic-act-draft-guidance-for-industry/5c927cd9-04a6-4a65-a37e-c8bae7b609fa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/initiation-of-voluntary-recalls-under-21-cfr-part-7-subpart-c-guidance-for-industry-and-fda-staff/b9272870-cad6-4e91-9fc0-e325feb24e43 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/hematologic-malignancies-regulatory-considerations-for-use-of-minimal-residual-disease-in-development-of-drug-and-biological-products-for-treatment-guidance-for-industry/5e0485fc-a570-4965-bae5-05741639f886 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-the-declaration-of-allulose-and-calories-from-allulose-on-nutrition-and-supplement-facts-labels/f322bd19-ea51-4a85-a308-d340e2a1a8a7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-263-recommendations-for-sponsors-of-medically-important-antimicrobial-drugs-approved-for-use-in-animals-to-voluntarily-bring-under-veterinary-oversight-all-products-that-continue-to-be-available-over-the-counter/407951dd-51f8-47fc-ab03-daf135a661a4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bispecific-antibody-development-programs-guidance-for-industry/16d40dbb-63de-4441-b656-7949b4a1018d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recognition-and-withdrawal-of-voluntary-consensus-standards-guidance-for-industry-and-food-and-drug-administration-staff/326d6f39-f285-4c68-9869-d969e12ed7dc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/policy-on-maximum-timer-interval-and-exposure-schedule-for-sunlamp-products/f08a2f99-dcb5-4788-8a5f-67a5ea02c1cd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/evaluation-of-internal-standard-responses-during-chromatographic-bioanalysis-questions-and-answers/b6406530-3d19-422f-9e77-6a76e2a1cbcb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/unique-device-identification-system-form-and-content-of-the-unique-device-identifier-udi-guidance-for-industry-and-food-and-drug-administration-staff/fcaa9093-e1fb-43d3-aa8d-da6dfbfc4a01 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-in-electronic-format-submissions-under-section-745aa-of-the-federal-food-drug-and-cosmetic-act/e05964dd-2751-4636-8630-94e3ed036135 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/rare-diseases-natural-history-studies-for-drug-development-draft-guidance-for-industry/a0f2f4af-4b97-4e7b-8e82-b4911a5d32e4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/standards-development-and-the-use-of-standards-in-regulatory-submissions-reviewed-in-the-center-for-biologics-evaluation-and-research-guidance-for-industry/51d68e06-fcf7-4a0e-b596-a949b93aad30 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fabry-disease-developing-drugs-for-treatment-guidance-for-industry/37d2e0fe-939f-490c-8fec-d2753a0f2f8c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/prussian-blue-drug-products-submitting-a-new-drug-application/50eeb151-80bd-4aa2-8526-e3d53b652af5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enforcement-priorities-for-electronic-nicotine-delivery-system-ends-and-other-deemed-products-on-the-market-without-premarket-authorization-guidance-for-industry/47ad7a8e-1654-4ef8-a09b-bc3b97998388 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enrichment-strategies-for-clinical-trials-to-support-approval-of-human-drugs-and-biological-products-guidance-for-industry/7a080f34-cb3a-4789-b96a-a16fd0b0e9ef 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cancer-clinical-trial-eligibility-criteria-brain-metastases/18dfb9e1-7a58-4743-8321-ecddace907a4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/establishing-effectiveness-and-safety-for-hormonal-drug-products-intended-to-prevent-pregnancy-guidance-for-industry/ae256303-8c59-45e0-969b-4eeacc21736c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cancer-clinical-trial-eligibility-criteria-minimum-age-considerations-for-inclusion-of-pediatric-patients/3666fbd1-9a8e-4d1e-bc77-6f3feec9ce81 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonproprietary-naming-of-biological-products-update-guidance-for-industry/8adaef5a-6903-4e65-ac57-121d51429730 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/evaluation-of-bulk-drug-substances-nominated-for-use-in-compounding-under-section-503b-of-the-federal-food-drug-and-cosmetic-act/32f6b565-3151-4e63-8311-63f0e604bece 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessing-the-effects-of-food-on-drugs-in-inds-and-ndas-clinical-pharmacology-considerations/8e6ecd60-8eb4-40cc-a985-2dfdb04c74be 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pharmacogenomic-data-submissions/9a29ff18-0847-4eaa-b84e-2e4b7bd5d29e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/rems-assessment-planning-and-reporting/c1fedc97-921d-4bcf-8c8f-2ea35b441b95 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/immunogenicity-testing-of-therapeutic-protein-products-developing-and-validating-assays-for-anti-drug-antibody-detection/ea78d6b5-b969-4817-b06b-f7e0cfa9b536 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s11-nonclinical-safety-testing-in-support-of-development-of-pediatric-pharmaceuticals-international-council-for-harmonisation-draft-guidance-for-industry/fced35c3-d5e6-4841-8ff6-57b97393063c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/anda-submissions-amendments-and-requests-for-final-approval-to-tentatively-approved-andas-guidance-for-industry/eac298b4-7442-4924-b433-f71c0be0a2f6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-reducing-microbial-food-safety-hazards-in-the-production-of-seed-for-sprouting/93763041-e65e-4039-af6a-2b83654a2bb4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-evaluating-alternate-curricula-for-the-standards-for-the-growing-harvesting-packing-and-holding-of-produce-for-human-consumption/580a528b-7d3f-4da4-8a42-0a76bcaed5fc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/implanted-brain-computer-interface-bci-devices-for-patients-with-paralysis-or-amputation-non-clinical-testing-and-clinical-considerations-guidance-for-industry-and-food-and-drug-administration-staff/012c0761-c8dd-44b6-a0ad-6e11698baf50 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/developing-and-labeling-in-vitro-companion-diagnostic-devices-for-a-specific-group-of-oncology-therapeutic-products-guidance-for-industry/82ea240f-dc2b-46d0-ae91-99195d7be074 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cders-program-for-the-recognition-of-voluntary-consensus-standards-related-to-pharmaceutical-quality/8610d370-6b09-40a5-9d6b-24ac4df3f732 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonbinding-feedback-after-certain-fda-inspections-of-device-establishments-guidance-for-industry-and-food-and-drug-administration-staff/c9f1509b-5d61-41db-a6be-476732325608 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/attention-deficit-hyperactivity-disorder-developing-stimulant-drugs-for-treatment-guidance-for-industry/0fcd99c6-644f-41df-81ff-6f0bd09628b2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-safety-evaluation-of-drug-or-biologic-combinations/a7c3b200-9178-4944-81a0-27721e31a958 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/industry-supported-scientific-and-educational-activites/7f993aa8-82f6-41d2-9705-09bbd3c87f05 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/non-inferiority-clinical-trials/c4be9c7c-051a-4a72-8e2e-d996945a9cd9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-safety-evaluation-of-pediatric-drug-products/a5729b5c-7a6e-40c1-861d-e8acf3cd178a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/blood-glucose-monitoring-test-systems-for-prescription-point-of-care-use-guidance-for-industry-and-food-and-drug-administration-staff/4ea2f26d-acc7-4d7c-8b2e-18e0d211f522 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/surgical-staplers-and-staples-for-internal-use-labeling-recommendations-guidance-for-industry-and-food-and-drug-administration-staff/25aa7e12-49f9-417f-b926-d5311be85e4a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/planning-for-the-effects-of-high-absenteeism-to-ensure-availability-of-medically-necessary-drug-products/08a2bd54-10f9-493d-9a2b-e5dd0c222f5b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-259-vich-gl58-stability-testing-of-new-veterinary-drug-substances-and-medicinal-products-in-climatic-zones-iii-and-iv/beee0208-1df9-4294-a967-d9dd2a544b7c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/addressing-misinformation-about-medical-devices-and-prescription-drugs-questions-and-answers/d6c8e69d-781e-4fe8-b28c-d3e357829a89 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/impact-of-certain-provisions-of-the-revised-common-rule-on-fda-regulated-clinical-investigations-guidance-for-sponsors-investigators-and-institutional-review-boards/1422bcc4-3c75-42a9-8d4e-3fae4c517eaf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/principles-of-premarket-pathways-for-combination-products-guidance-for-industry-and-fda-staff/fef66533-8c76-453a-898c-236775eb59fe 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/hypertension-developing-fixed-dose-combination-drugs-for-treatment/1a5d992e-fb16-402a-8d7a-11d62e5e766f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/verification-systems-under-the-drug-supply-chain-security-act-for-certain-prescription-drugs-guidance-for-industry/78f63573-4158-4893-a86a-0ef80badd99f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/citizen-petitions-and-petitions-for-stay-of-action-subject-to-section-505q-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry/f2b5ad51-4873-4c0b-b0c5-cfb4081aad18 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/marketing-status-notifications-under-section-506i-of-the-federal-food-drug-and-cosmetic-act/3ac0774c-4c44-47b4-a602-7f011b30b3b0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cancer-clinical-trial-eligibility-criteria-patients-with-hiv-hepatitis-b-virus-or-hepatitis-c-virus-infections/4ebc5ded-b823-4045-9dc1-5e281b7b39f2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-lead-in-cosmetic-lip-products-and-externally-applied-cosmetics-recommended-maximum-level/0b6d9592-bbba-4cac-87a1-d36d9bd29aa8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-safety-of-nanomaterials-in-cosmetic-products/2eb8f28e-7bf4-4e05-b8aa-6392db9c1046 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessing-the-irritation-and-sensitization-potential-of-transdermal-and-topical-delivery-systems-for-andas-draft-guidance-for-industry/1472ed4f-fea1-4017-b0d7-d7fcd5e86e6d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-guide-to-minimize-food-safety-hazards-of-fresh-cut-produce/15db614d-c5e7-49cf-9ad3-3b0bcad7b141 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bioavailability-studies-submitted-in-ndas-or-inds-general-considerations/8946e94a-0bb7-41ed-a95c-e1fed34bf86b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/design-control-guidance-for-medical-device-manufacturers-guidance-for-industry/a58d3f96-e74a-4ff7-a00a-ba7e9c9306a3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-special-510k-program-guidance-for-industry-and-food-and-drug-administration-staff/4f4aa315-7b28-464a-abc4-9844f976f26a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/biomarker-qualification-evidentiary-framework-draft-guidance-for-industry-and-fda-staff/c198796d-4230-4499-a6ee-2f84eed424c9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/product-identifiers-under-the-drug-supply-chain-security-act-questions-and-answers-guidance-for-industry/d3880c89-0e09-41de-baae-d56590db8510 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/eosinophilic-esophagitis-developing-drugs-for-treatment-guidance-for-industry/e454ac25-939f-4e9c-a8f1-b2613feff0b3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/consideration-of-uncertainty-in-making-benefit-risk-determinations-in-medical-device-premarket-approvals-de-novo-classifications-and-humanitarian-device-exemptions-guidance-for-industry-and-food-and-drug-administration-staff/fa2f7c02-f5db-49ed-a379-d25573c9b9f9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/slowly-progressive-low-prevalence-rare-diseases-with-substrate-deposition-that-results-from-single-enzyme-defects-providing-evidence-of-effectiveness-for-replacement-or-corrective-therapies-guidance-for-industry-guidance-for-industry/edfb93d1-715f-42f9-b789-3cd598a3290d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fulfilling-regulatory-requirements-for-postmarketing-submissions-of-interactive-promotional-media-for-prescription-human-and-animal-drugs-and-biologics/5f7419f6-fd7b-431f-8024-58dc07fee6c6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/expansion-cohorts-use-in-first-in-human-clinical-trials-to-expedite-development-of-oncology-drugs-and-biologics-guidance-for-industry-guidance-for-industry/c3a82e7e-71fa-4de1-a294-c42a2c2954cd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-testing-of-orally-inhaled-nicotine-containing-drug-products-guidance-for-industry/0ffdae5e-74df-4de2-b513-31064caf444d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/new-and-revised-draft-qas-on-biosimilar-development-and-the-bpci-act-revision-3-draft-new-and-revised-draft-qas-on-biosimilar-development-and-the-bpci-act-revision-3/fa17132a-ca0a-4f0c-8b68-5b45a40f4059 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/interpretation-of-the-deemed-to-be-a-license-provision-of-the-biologics-price-competition-and-innovation-act-of-2009-guidance-for-industry/154bca51-03bf-47a8-8b5d-81c56ff9454a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-liquids-andor-soft-foods-as-vehicles-for-drug-administration-general-considerations-for-selection-and-in-vitro-methods-for-product-quality-assessments/2a815448-edd9-4cd0-8d53-104da4a8ee0c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/peripheral-vascular-atherectomy-devices-premarket-notification-510k-submissions-guidance-for-industry-and-food-and-drug-administration-staff/2b1144d8-b7d4-40e7-b482-d9d591a966fd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/inborn-errors-of-metabolism-that-use-dietary-management-considerations-for-optimizing-and-standardizing-diet-in-clinical-trials-for-drug-product-development-draft-guidance-for-industry/325cca3e-8b3a-4f04-9dda-5271c7389dd4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/hypertension-conducting-studies-of-drugs-to-treat-patients-on-a-background-of-multiple-antihypertensive-drugs-guidance-for-industry/4e191c93-73a7-441d-880d-19605847d3b1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/field-alert-report-submission-questions-and-answers-guidance-for-industry-guidance-for-industry/b554a2c6-8278-4f9a-a91c-72bcdd411715 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/innovative-approaches-for-nonprescription-drug-products/212b0dcc-7c8f-44f5-8fd2-1af604a50f9a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/cvm-gfi-252-small-entity-compliance-guide-antimicrobial-animal-drug-sales-and-distribution-reporting/46d189ad-b66c-43d3-8de3-d9a051b8cfa3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/prescription-drug-user-fee-act-waivers-for-fixed-combination-antiretroviral-drugs-for-the-presidents-emergency-plan-for-aids-relief-draft-guidance-for-industry/9c15c557-6fcc-4a2d-a6ed-54dc154f114a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/requests-for-feedback-and-meetings-for-medical-device-submissions-the-q-submission-program-final-guidance-for-industry-and-food-and-drug-administration-staff/56b237df-6d34-4ac7-b71b-a29b57e8cc71 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/epidermolysis-bullosa-developing-drugs-for-treatment-of-cutaneous-manifestations-guidance-for-industry/3a5ca8cb-694b-49c7-9a78-110c0ad383ca 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/logical-observation-identifiers-names-and-codes-for-in-vitro-diagnostic-tests-guidance-for-industry-and-food-and-drug-administration-staff/23b8934c-1d96-4b2e-a85a-adc58f82a2ba 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/coronary-peripheral-and-neurovascular-guidewires-performance-tests-and-recommended-labeling-guidance-for-industry-and-food-and-drug-administration-staff/6a255bfe-d312-470c-8872-85b8a31ad806 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonmetastatic-castration-resistant-prostate-cancer-considerations-for-metastasis-free-survival-endpoint-in-clinical-trials/c32357fc-c9d0-4e62-95cb-8b3f815da638 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/intravascular-catheters-wires-and-delivery-systems-with-lubricious-coatings-labeling-considerations-guidance-for-industry-and-food-and-drug-administration-staff/b0a32614-b256-48a4-8e3b-9542000fbba4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/human-immunodeficiency-virus-1-infection-developing-systemic-drug-products-for-pre-exposure-prophylaxis/954b4104-b554-475b-90aa-d413f78e97c8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q12-technical-and-regulatory-considerations-for-pharmaceutical-product-lifecycle-management-annex/5379f689-7e71-423b-b00d-e8c8654bbd0b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/prescription-drug-user-fee-act-waivers-reductions-and-refunds-for-drug-and-biological-products-guidance-for-industry/1a0bec17-eee8-4dda-9b43-4ca488355d7f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/development-of-a-shared-system-rems-guidance-for-industry/b67470fa-28bc-4644-aeba-c9afd830c0cd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/human-gene-therapy-for-retinal-disorders-guidance-for-industry/3bca1550-9cef-41e0-b826-9a48c8984afa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/testing-of-retroviral-vector-based-human-gene-therapy-products-for-replication-competent-retrovirus-during-product-manufacture-and-patient-follow-up-guidance-for-industry/e81ad993-e1fd-4130-8c55-cd9ca8d5f6e2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/chemistry-manufacturing-and-control-cmc-information-for-human-gene-therapy-investigational-new-drug-applications-inds-guidance-for-industry/39f9f187-0a0c-44a1-8781-ebb975125baa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/acceptance-review-for-de-novo-classification-requests-guidance-for-industry-and-food-and-drug-administration-staff/af09eb3b-01c6-4971-993b-1068056591ae 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-inclusion-of-adolescent-patients-in-adult-oncology-clinical-trials/d9024369-3d11-4161-a606-70ab031e8871 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q12-technical-and-regulatory-considerations-for-pharmaceutical-product-lifecycle-management-guidance-for-industry-guidance-for-industry/3d2c4a48-664c-46f3-8af1-d21c9b7858a3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/waivers-exceptions-and-exemptions-from-the-requirements-of-section-582-of-the-federal-food-drug-and-cosmetic-act/12814847-c9c8-422a-b5c7-25abda117226 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommended-content-and-format-of-non-clinical-bench-performance-testing-information-in-premarket-submissions-guidance-for-industry-and-food-and-drug-administration-staff/51968bff-c42f-4ff9-a1c3-bb7cf9f3d4c3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/toll-free-number-labeling-and-related-requirements-for-over-the-counter-and-prescription-drugs-marketed-with-approved-applications/3dd055ae-75ac-4cc5-9844-15edd771787b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/maximal-usage-trials-for-topically-applied-active-ingredients-being-considered-for-inclusion-in-an-over-the-counter-monograph-study-elements-and-considerations/aba27acd-a192-453b-9d48-dde390d1e56f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/uncomplicated-urinary-tract-infections-developing-drugs-for-treatment-guidance-for-industry/c70a4ac7-4c57-4214-9174-25145ed55675 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/further-testing-of-donations-that-are-reactive-on-a-licensed-donor-screening-test-for-antibodies-to-hepatitis-c-virus-guidance-for-industry/0893a4f8-36e8-43c7-87c6-14868c8cfa7a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/severely-debilitating-or-life-threatening-hematologic-disorders-nonclinical-development-of-pharmaceuticals-guidance-for-industry/e5cdf45b-9688-49a6-8496-614c702750aa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/safety-and-performance-based-pathway-guidance-for-industry-and-food-and-drug-administration/65af9739-a83b-4df3-a745-9503362f447d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/multiple-function-device-products-policy-and-considerations-guidance-for-industry-and-food-and-drug-administration/033a3a57-676c-41db-b360-d0b0bda25434 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigational-in-vitro-diagnostics-in-oncology-trials-streamlined-submission-process-for-study-risk-determination-guidance-for-industry/ff9a397a-14c7-475f-9b86-e658211b0705 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-serological-tests-to-reduce-the-risk-of-transfusion-transmitted-human-t-lymphotropic-virus-types-i-and-ii-htlv-iii-guidance-for-industry/e8ad35aa-47eb-47df-bcd6-5f95ecae4ee9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pregnant-women-scientific-and-ethical-considerations-for-inclusion-in-clinical-trials/674ff9d8-e752-4113-b7fd-bc85b7646bd3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-255-elemental-impurities-in-animal-drug-products-questions-and-answers/d270daab-b0d8-413c-9870-899b1c8f31af 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-240-proprietary-names-for-new-animal-drugs/f55b2f01-4717-4a80-bb0b-58ef07fd3691 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/definitions-of-suspect-product-and-illegitimate-product-for-verification-obligations-under-the-drug-supply-chain-security-act-guidance-for-industry-guidance-for-industry/2690554e-db22-4dd6-998e-50b04043d5ec 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/final-in-vivo-bioavailability-bioequivalence-studies-analytical/79269a54-7602-4765-bb0d-fc1bb25d6c42 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-reducing-the-risk-of-transfusion-transmitted-babesiosis-guidance-for-industry/027542ba-a0a9-4d9e-a1d0-46e29312bcf5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/qualified-infectious-disease-product-designation-questions-and-answers-guidance-for-industy/fb3c8f5c-95db-4b2c-a63c-f9993883d2c4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/drugs-for-the-treatment-of-partial-onset-seizures-extrapolation-of-efficacy-from-adults-to-pediatric-patients-1-month-of-age-and-older/522e1ab7-d361-4026-b798-06e21bfaaa5e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/unique-device-identification-policy-regarding-compliance-dates-for-class-i-and-unclassified-devices-direct-marking-and-global-unique-device-identification-database-requirements-for-certain-devices-guidance-for-industry-and-food-and-drug-administration-staff/b467debb-ec61-46db-b572-e2edfd670361 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-245-hazard-analysis-and-risk-based-preventive-controls-for-food-for-animals/83b6e072-a253-43f6-910c-a2438d68866c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/indications-and-usage-section-of-labeling-for-human-prescription-drug-and-biological-products-content-and-format-guidance-for-industry/7d286113-df13-47f4-bc30-1a4d819e56c9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/product-title-and-initial-us-approval-in-the-highlights-of-prescribing-information-for-human-prescription-drug-and-biological-products-content-and-format-guidance-for-industry/e7792ae4-c049-4de1-bf07-f0bf1ff29121 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/material-threat-medical-countermeasure-priority-review-vouchers-draft-guidance-for-industry-draft-guidance-for-industry/ff3c70ba-5d5e-4df9-8ccb-352cf36c127e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/laser-products-conformance-with-iec-60825-1-ed-3-and-iec-60601-2-22-ed-31-laser-notice-no-56-guidance-for-industry-and-food-and-drug-administration-staff/10871f08-f034-4aef-9388-73a4781c3bd8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-combined-hormonal-contraceptives-guidance-for-industry/551e37b0-1741-4094-9133-77fbce2ceb68 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/replacement-reagent-and-instrument-family-policy-for-in-vitro-diagnostic-devices-guidance-for-industry-and-fda-staff/6acf5cea-4730-4835-bf2d-eb7474c6d3e6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/establishing-effectiveness-for-drugs-intended-to-treat-male-hypogonadotropic-hypogonadism-attributed-to-nonstructural-disorders-guidance-for-industry/45fa3246-6fd0-427b-9f31-dfee7ddb4a0a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/formal-meetings-between-the-fda-and-sponsors-or-applicants-of-pdufa-products/3344b1c7-a603-4d25-a0d9-fa9de797e2e7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/information-requests-and-discipline-review-letters-under-the-generic-drug-user-fee-amendments-guidance-for-industry/791723ae-658a-431c-8b44-6ba50a528579 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/changes-to-existing-medical-software-policies-resulting-from-section-3060-of-the-21st-century-cures-act-guidance-for-industry-and-food-and-drug-administration-staff/fa512248-f00a-497e-a47e-3d005bbcb252 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/chemistry-manufacturing-and-controls-changes-to-an-approved-application-certain-biological-products-guidance-for-industry/27111644-ec6f-4414-997c-1a3ca9f85b8a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/grandfathering-policy-for-packages-and-homogenous-cases-of-product-without-a-product-identifier/6ebf451c-99b2-45bb-bcb8-31ab0526d0ca 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-clinical-laboratory-improvement-amendments-of-1988-clia-waiver-applications-for-manufacturers-of-in-vitro-diagnostic-devices-guidance-for-industry-and-food-and-drug-administration-staff/599abc6a-4ceb-42a1-a45e-85d30e64cef0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/homeopathic-drug-products-guidance-for-fda-staff-and-industry/f8c7cdc9-599a-4ab0-9f93-eeb2b899427c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clarification-of-orphan-designation-of-drugs-and-biologics-for-pediatric-subpopulations-of-common-diseases-guidance-for-industry/254d968c-50ac-46d1-9627-0b4e065111ba 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pediatric-rare-diseases-a-collaborative-approach-for-drug-development-using-gaucher-disease-as-a-model-draft-guidance-for-industry-draft-guidance-for-industry/b1c7a136-55e0-4a98-90c5-8addb1b9544b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/patient-focused-drug-development-collecting-comprehensive-and-representative-input/abbf838a-9294-4c1b-a0d1-55c963831af5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/long-term-follow-up-after-administration-of-human-gene-therapy-products-guidance-for-industry/5f3e0db9-8c8a-45b5-864f-6250a3250b1b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/evaluation-of-devices-used-with-regenerative-medicine-advanced-therapies-guidance-for-industry/0bd9718e-c6aa-4925-902b-f84e80a50ef9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/regulatory-considerations-for-human-cells-tissues-and-cellular-and-tissue-based-products-minimal-manipulation-and-homologous-use-guidance-for-industry-and-food-and-drug-administration-staff/29251db7-6c74-4d63-affc-a906cc2d1efa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-a-drug-master-file-for-shared-system-rems-submissions-guidance-for-industry/bdcae9f2-6712-48b2-afb3-be17664f8562 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s5r3-detection-of-reproductive-and-developmental-toxicity-for-human-pharmaceuticals-guidance-for-industry/b68debd9-c581-404c-b7fd-963716474af6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e9r1-statistical-principles-for-clinical-trials-addendum-estimands-and-sensitivity-analysis-in-clinical-trials-guidance-for-industry/e136fe4a-71f3-4725-890a-e85d5d6c6414 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/respiratory-syncytial-virus-infection-developing-antiviral-drugs-for-prophylaxis-and-treatment-guidance-for-industry/59a11b52-4b6d-43c3-a5e2-4d57eedf16bc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submitting-study-datasets-for-vaccines-to-the-office-of-vaccines-research-and-review-guidance-for-industry-technical-specifications-document/9624501a-9be4-466b-9aef-167b34ebf0ca 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessing-user-fees-under-the-prescription-drug-user-fee-amendments-of-2017-guidance-for-industry-guidance-for-industry/0a6a0a53-093e-48c0-a832-4e3db4e95cd6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/oncology-pharmaceuticals-reproductive-toxicity-testing-and-labeling-recommendations-guidance-for-industry-guidance-for-industry/91713d82-572d-4f50-b440-cca500b50106 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/deviation-reporting-for-human-cells-tissues-and-cellular-and-tissue-based-products-regulated-solely-under-section-361-of-the-public-health-service-act-and-21-cfr-part-1271-guidance-for-industry/8e4fe25d-123f-4637-babd-6b10a4a39471 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/acceptance-of-clinical-data-to-support-medical-device-applications-and-submissions-frequently-asked-questions-guidance-for-industry-and-food-and-drug-administration-staff/c1dbb4a9-7603-48fc-ba28-eb1ec902118e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-colored-sea-salt/19edef28-544f-48eb-8591-27463b204117 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/utilizing-animal-studies-to-evaluate-organ-preservation-devices-guidance-for-industry-and-food-and-drug-administration-staff/e6f23ae2-2fa0-40d6-9abc-233e2ec8e4f6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/user-fees-and-refunds-for-de-novo-classification-requests-guidance-for-industry-and-food-and-drug-administration-staff/b07dfae6-7e29-424d-b010-bf0ac9928d5c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-and-industry-actions-on-de-novo-classification-requests-effect-on-fda-review-clock-and-goals-guidance-for-industry-and-food-and-drug-administration-staff/a4f96967-2fb4-48c8-954c-0608de9ddc7b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/formal-meetings-between-fda-and-anda-applicants-of-complex-products-under-gdufa-guidance-for-industry/86088692-efb1-40f5-89a1-4490b41c5955 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/good-anda-submission-practices-guidance-for-industry/c4f8f27a-3522-470b-8889-206366ebc0e7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/andas-for-certain-highly-purified-synthetic-peptide-drug-products-that-refer-to-listed-drugs-of-rdna-origin-guidance-for-industry-guidance-for-industry/937d62fa-bec4-42bb-8407-5ba2d45b9a68 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-in-electronic-format-content-of-the-risk-evaluation-and-mitigation-strategies-document-using-structured-product-labeling-guidance-for-industry/30645a17-5f24-407a-9837-05c1ed1d46be 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postoperative-nausea-and-vomiting-developing-drugs-for-prevention/d423e99c-8d8f-4f7a-bb91-694c270c2ba3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/amyotrophic-lateral-sclerosis-developing-drugs-for-treatment-guidance-for-industry-guidance-for-industry/933cd61f-72c5-470a-b6e9-21c7a3253529 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/identifying-trading-partners-under-the-drug-supply-chain-security-act-guidance-for-industry/c512f2f3-6e75-4820-87ed-3a9903da5fc3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/consumer-antiseptic-wash-final-rule-questions-and-answers-guidance-for-industry/cdd88ae1-5bae-456b-ada4-b35d7a37a3b3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-design-of-early-phase-clinical-trials-of-cellular-and-gene-therapy-products-guidance-for-industry/58006e15-498f-4ae9-a7c8-6112a8210c55 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/drug-products-including-biological-products-that-contain-nanomaterials-guidance-for-industry/0b0a870a-8d00-41ca-9657-6d9d2c754478 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/andas-pre-submission-of-facility-information-related-to-prioritized-generic-drug-applications-pre-submission-facility-correspondence-guidance-for-industry/b98ece19-e078-446b-9b61-835924e31cd9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q11-development-and-manufacture-of-drug-substances-questions-and-answers-chemical-entities-and-biotechnologicalbiological-entities/4bdf3485-1128-4a4c-bfdf-7ed5513ad725 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-180-day-exclusivity-questions-and-answers/ebd53cce-08cf-4a24-9e0b-1ec9ed1422d7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/multiple-endpoints-in-clinical-trials-guidance-for-industry/d08a7428-0534-4dad-83d9-37a60fc5fe62 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-to-reduce-the-possible-risk-of-transmission-of-creutzfeldt-jakob-disease-and-variant-creutzfeldt-jakob-disease-by-blood-and-blood-components-guidance-for-industry/5a1bc246-799a-4448-ad8b-9f02df441719 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/annual-reporting-by-prescription-drug-wholesale-distributors-and-third-party-logistics-providers-questions-and-answers-guidance-for-industry/96ea5b7a-1312-43e3-91d9-d9e770a90ee6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/2016-medical-gas-container-closure-rule-questions-and-answers-guidance-for-industry-guidance-for-industry/bb97ec2f-6197-4ea2-8c6c-a2ae8195f1bc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compounding-and-repackaging-of-radiopharmaceuticals-by-outsourcing-facilities-guidance-for-industry/4a6e41fb-5d18-47fc-98b0-1dbe619a89b6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-product-communications-that-are-consistent-with-the-fda-required-labeling-questions-and-answers-guidance-for-industry/f5790b05-bd18-4236-a580-c2ae7ca2a444 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/expedited-programs-for-regenerative-medicine-therapies-for-serious-conditions-guidance-for-industry/8797d365-c489-4514-ab4e-b382ecf2661c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-design-and-conduct-of-externally-controlled-trials-for-drug-and-biological-products/9dafe0c9-19d4-48c0-a1ca-6b2a04a813ed 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-243-vich-gl56-studies-to-evaluate-the-metabolism-and-residue-kinetics-of-veterinary-drugs-in-food-producing-species-study-design-recommendations-for-residue-studies-in-honey-for-establishing-maximum-residue-limits-and-withdrawal-periods/e7eaa2b6-0bb4-4c6b-96f8-56f26cc32321 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-242-in-use-stability-studies-and-associated-labeling-statements-for-multiple-dose-injectable-animal-drug-products/33ab4dc2-4b4f-44d3-a020-521b35e42bc9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/comparative-analyses-and-related-comparative-use-human-factors-studies-for-a-drug-device-combination-product-submitted-in-an-anda-draft-guidance-for-industry/c8e96dc7-4f82-494f-ae7f-c75cb0d5808d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pediatric-gastroesophageal-reflux-disease-developing-drugs-for-treatment-guidance-for-industry/eed3bedd-c895-4ca2-bd44-b1c92b786f14 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-of-red-blood-cell-units-with-historical-antigen-typing-results-guidance-for-industry/39eceff8-0db3-40ad-a2f9-d7dc1cf7df08 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-236-clarification-of-fda-and-epa-jurisdiction-over-mosquito-related-products/4d76a09b-6ebb-428a-a2a8-44bad84b528b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/source-animal-product-preclinical-and-clinical-issues-concerning-the-use-of-xenotransplantation-products-in-humans-guidance-for-industry/38608057-6efd-4c37-9075-3043bba2c602 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and-biological-products-for-treatment-draft-guidance-for-industry/3fae8291-7235-49ce-9d2d-1d17d90d4656 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/regulatory-considerations-for-microneedling-products-guidance-for-industry-and-food-and-drug-administration-staff/e4b948cf-1990-4081-8966-4fc200142253 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommended-statement-for-over-the-counter-aspirin-containing-drug-products-labeled-with-cardiovascular-related-imagery-guidance-for-industry/166bb50b-f162-4cfe-a252-d41e3ec062b5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/revised-recommendations-for-determining-eligibility-of-donors-of-human-cells-tissues-and-cellular-and-tissue-based-products-who-have-received-human-derived-clotting-factor-concentrates-guidance-for-industry/46133f75-38b3-4404-897e-4a18275401f5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e11r1-addendum-clinical-investigation-of-medicinal-products-in-the-pediatric-population/e3307e6f-23c2-45a6-9825-5ae810b26dda 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-serological-tests-to-reduce-the-risk-of-transmission-of-trypanosoma-cruzi-infection-in-blood-and-blood-components-guidance-for-industry/56941716-f51b-48de-a18b-b6d0a37a66e6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/low-sexual-interest-desire-andor-arousal-in-women-developing-drugs-for-treatment-guidance-for-industry/c2fadf0e-3e7e-4274-99c9-c81028d61542 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-101100-fda-considerations-for-recommending-charges-for-causing-the-introduction-of-violative-products-into-interstate-commerce/c2211323-9b00-49aa-ac0c-b59eb15c4576 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fdas-application-of-statutory-factors-in-determining-when-a-rems-is-necessary/5d692a06-6650-46b8-bfbd-88782ca49625 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cmc-postapproval-manufacturing-changes-for-specified-biological-products-to-be-documented-in-annual-reports/79b344db-7419-48ec-a38a-6715baf127b4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-150200-compliance-review-of-private-laboratory-analytical-packages-plaps/198fe637-886d-4f41-9c44-035beb58b52e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s3a-guidance-note-for-guidance-on-toxicokinetics-the-assessment-of-systemic-exposure-in-toxicity-studies-focus-on-microsampling/9ffd98db-d7b4-4ab7-a1b8-146abe8b400e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e17-general-principles-for-planning-and-design-of-multi-regional-clinical-trials/d2fa5bee-ac83-491d-99ad-7c4d046de439 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/factors-to-consider-when-making-benefit-risk-determinations-in-medical-device-premarket-approval-and-de-novo-classifications-guidance-for-industry-and-food-and-drug-administration-staff/d3767bb4-6796-480c-a116-c361a87c0f47 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/drug-and-device-manufacturer-communications-with-payors-formulary-committees-and-similar-entities-questions-and-answers-guidance-for-industry-and-review-staff/fef61098-3bf5-4dc1-8f77-41453aebdc3c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compounding-certain-ibuprofen-oral-suspension-products-under-section-503b-of-the-federal-food-drug-and-cosmetic-act/42ece20e-b981-40c7-8486-325a2b13d7dc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/insanitary-conditions-at-compounding-facilities-guidance-for-industry/6f8ff3c8-2f4a-49e4-a919-fc3c6b83579d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-nucleic-acid-tests-to-reduce-the-risk-of-transmission-of-hepatitis-b-virus-from-donors-of-human-cells-tissues-and-cellular-and-tissue-based-products-guidance-for-industry/ff060472-0a8c-471b-b947-33ce77342401 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-real-world-evidence-to-support-regulatory-decision-making-for-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/1de17575-088a-4770-a70b-99c29f9cf44d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compounding-and-repackaging-of-radiopharmaceuticals-by-state-licensed-nuclear-pharmacies-and-federal-facilities-guidance-for-industry/2b25a2e1-6aae-4b9c-a16b-579918ea3410 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s9-nonclinical-evaluation-for-anticancer-pharmaceuticals-questions-and-answers/5b838cf4-2c2e-4c10-8a24-439ce4ce61f1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/determining-donor-eligibility-for-autologous-donors-of-blood-and-blood-components-intended-solely-for-autologous-use-compliance-policy-guidance-for-industry/66ca6a85-aebe-4b20-a0ba-d0f7e4e393d3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/vulvovaginal-candidiasis-developing-drugs-for-treatment/3c14a50c-15d0-4ad3-94ec-76a32afa2bdb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bacterial-vaginosis-developing-drugs-for-treatment-guidance-for-industry/d280b63f-a1bf-46b4-aa9d-41f650dd1b70 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-design-development-and-analytical-validation-of-next-generation-sequencing-ngs-based-in-vitro-diagnostics-ivds-intended-to-aid-in-the-diagnosis-of-suspected-germline-diseases-guidance-for-stakeholders-and-food-and-drug-administration-staff/23d92ad8-5a27-4cf3-986b-82cc58005afd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/major-depressive-disorder-developing-drugs-for-treatment/8f70f512-6f81-4d11-86f6-e2abe0d6dcc0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/updating-anda-labeling-after-the-marketing-application-for-the-reference-listed-drug-has-been-withdrawn-guidance-for-industry/2304b7bc-985b-405c-a33a-6bb322af4fa6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/principles-for-codevelopment-of-an-in-vitro-companion-diagnostic-device-with-a-therapeutic-product-draft-guidance-for-industry-and-food-and-drug-administration-staff/4ce3b99f-f096-4bd8-987d-0240d96508d2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compounded-drug-products-that-are-essentially-copies-of-a-commercially-available-drug-product-under-section-503a-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry/57a1209c-86f8-4813-bb35-0bd3d8265bc2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/elemental-impurities-in-drug-products-guidance-for-industry/5931c496-e20b-426d-915b-0856db49e99e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/evaluation-and-reporting-of-age-race-and-ethnicity-specific-data-in-medical-device-clinical-studies-guidance-for-industry-and-food-and-drug-administration-staff/9fb9098f-5c24-4238-a9d8-64a10ae06702 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/factors-to-consider-regarding-benefit-risk-in-medical-device-product-availability-compliance-and-enforcement-decisions-guidance-for-industry-and-food-and-drug-administration-staff/3a9d88b3-4fe4-4b9a-a225-496754cfa069 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e18-genomic-sampling-and-management-of-genomic-data-guidance-for-industry/72ee1cb4-40ce-4946-a9c9-427e4bbb21d6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/software-as-a-medical-device-samd-clinical-evaluation-guidance-for-industry-and-food-and-drug-administration-staff/745234d9-1b52-4aa1-aff4-297a93f801f8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-categorization-of-investigational-device-exemption-ide-devices-to-assist-the-centers-for-medicare-and-medicaid-services-cms-with-coverage-decisions-guidance-for-sponsors-clinical-investigators-industry-institutional-review-boards-and-food-and-drug-administration-staff/a1c94b70-4f6c-4666-86e7-be6a464f5281 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/manufacturers-sharing-patient-specific-information-from-medical-devices-with-patients-upon-request-guidance-for-industry-and-food-and-drug-administration-staff/c6a2b9de-5d7c-4594-a9c0-c4fa7e9f15b9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessment-of-pressor-effects-of-drugs-guidance-for-industry-draft-guidance-for-industry/35abdc27-8b6a-4eb0-ba74-78a4a3840a3d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-electronic-health-record-data-in-clinical-investigations-guidance-for-industry/165621f1-dbb5-4b0f-a30a-c5d0ea2e7d02 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/deciding-when-to-submit-a-510k-for-a-change-to-an-existing-device-guidance-for-industry-and-food-and-drug-administration-staff/d023d66b-8356-4ef3-8e0a-ad5948dc5732 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/cvm-gfi-241-small-entity-compliance-guide-what-you-need-to-know-about-the-fda-regulation-current-good-manufacturing-practice-hazard-analysis-and-risk-based-preventive-controls-for-food-for-animals-21-cfr-part-507/7d1c02dc-f862-4ea9-bca8-2570d6119a54 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-235-current-good-manufacturing-practice-requirements-for-food-for-animals/e0a50cba-69ab-43b3-9801-26337718002f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-540275-crabmeat-fresh-and-frozen-adulteration-with-filth-involving-the-presence-of-escherichia-coli/57549de7-4960-40cb-b4c4-445ec8e2a582 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/quality-attribute-considerations-for-chewable-tablets-guidance-for-industry/04e1f98a-29f4-4cc9-a0ab-4017b9877ce9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/ulcerative-colitis-developing-drugs-for-treatment/9c536649-649f-4c1e-b31a-8ed733f15831 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/facility-definition-under-section-503b-of-the-federal-food-drug-and-cosmetic-act/0757072b-35f4-40f5-97ac-c401faa17cb3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/prescription-requirement-under-section-503a-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry/2deca755-c1a3-4959-81be-63a489f8e69c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/comparability-protocols-for-postapproval-changes-to-the-chemistry-manufacturing-and-controls-information-in-an-nda-anda-or-bla/99cef204-366c-4685-b26a-a6a1f744baa3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-biosimilar-products-guidance-for-industry/e13343b3-e9e8-436e-9bcc-ec73cae4d41c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-permanent-hysteroscopically-placed-tubal-implants-intended-for-sterilization-guidance-for-industry-and-food-and-drug-administration-staff/90c1f1b9-1a53-417f-8d58-7605e596a3a6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/evaluating-respiratory-symptoms-in-chronic-obstructive-pulmonary-disease-a-patient-reported-outcome-instrument-for-the-measurement-of-severity-of-respiratory-symptoms-in-stable-chronic-obstructive-pulmonary-disease-qualification-for-exploratory-use/a00af674-c3a1-4cdf-b25f-1b529c175262 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-considerations-for-investigational-device-exemptions-ides-for-neurological-devices-targeting-disease-progression-and-clinical-outcomes-guidance-for-industry-and-food-and-drug-administration-staff/020648af-72e8-497a-8075-cd70130a9dd3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/general-principles-for-evaluating-the-abuse-deterrence-of-generic-solid-oral-opioid-drug-products-guidance-for-industry/16f7c065-5c32-47ae-b140-ebaacee129ac 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compounded-drug-products-that-are-essentially-copies-of-approved-drug-products-under-section-503b-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry/01d6567b-d27c-4dc3-b329-01ed5a29bb89 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonallergic-rhinitis-developing-drug-products-for-treatment/5453a88f-6b6b-4771-8248-e324727993ad 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postmarket-management-of-cybersecurity-in-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/31ce85d3-4c54-4d7e-907a-0fcf0670a843 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/list-of-highest-priority-devices-for-human-factors-review-draft-guidance-for-industry-and-food-and-drug-administration-staff/0dc7b489-3bcc-4d2a-b052-209e46552610 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/display-devices-for-diagnostic-radiology-guidance-for-industry-and-food-and-drug-administration-staff/b1d79a2b-9d9a-4a18-b182-4f6f13e9b51b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-cosmetic-good-manufacturing-practices/d5931334-c860-40d6-9d0e-ca6a21ea0837 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/advancement-of-emerging-technology-applications-for-pharmaceutical-innovation-and-modernization-guidance-for-industry/255d3ea7-7c48-4de0-99d3-a3981ba4dde7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-238-modified-release-veterinary-parenteral-dosage-forms-development-evaluation-and-establishment-of-specifications/333ded48-5bc7-46f0-8879-30202adcb1a7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/osteoporosis-nonclinical-evaluation-of-drugs-intended-for-treatment-guidance-for-industry-guidance-for-industry/8305ef9e-7edf-412b-bb46-28ef3a7f9493 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/public-notification-of-emerging-postmarket-medical-device-signals-emerging-signals-guidance-for-industry-and-food-and-drug-administration-staff/3b4ae247-9771-40a1-b770-c934376f7835 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/good-review-practices/best-practices-for-communication-between-ind-sponsors-and-fda-during-drug-development/2c093434-6b20-4df3-af2a-d7af81ab3fd8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/electromagnetic-compatibility-emc-of-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/e2b6ede1-7bce-491a-b032-b5859d615a1f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-233-veterinary-feed-directive-common-format-questions-and-answers/c98a8f2b-2d14-4b01-865a-69e5eaedf8bd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m11-template-clinical-electronic-structured-harmonised-protocol-cesharp/624c83e7-f7b0-4bca-8fe5-3d1069d85331 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonprescription-sunscreen-drug-products-safety-and-effectiveness-data/fd78f6e6-4d72-4e25-a9b7-adc9e8ef611e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pharmacy-compounding-of-human-drug-products-under-section-503a-of-the-federal-food-drug-and-cosmetic-act-guidance/c027252e-0f07-4b88-baa1-313551e210ce 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonprescription-sunscreen-drug-products-format-and-content-of-data-submissions/4634e5dc-90b7-47fd-85c9-d7cbe6a199dc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-microbial-vectors-used-for-gene-therapy-guidance-for-industry/bdeabfdf-bbbe-4b57-a5be-ef92ff0cf1bd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-234-question-based-review-for-the-chemistry-manufacturing-and-controls-technical-section-of-animal-drug-applications/f9dfc463-3578-469b-946a-28813de7d5c9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-100101-crotalaria-spp-seeds-in-grains/42533fc7-6d09-4ca8-8475-75e4d18e5f4a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/general-considerations-for-animal-studies-intended-to-evaluate-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/20618a6e-ba4f-4f65-bbc8-b7b05e3afc90 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-submissions-in-electronic-format-postmarketing-safety-reports-for-vaccines-guidance-for-industry/3fe7ffbc-a5a4-42f8-8eb9-a684ef42f27d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/application-of-human-factors-engineering-principles-for-combination-products-questions-and-answers-guidance-for-industry-and-fda-staff/3176657b-ed7b-48d1-afa5-137dc87c9a42 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/heparin-containing-medical-devices-and-combination-products-recommendations-for-labeling-and-safety-testing-guidance-for-industry-and-food-and-drug-administration-staff/c17242d8-8b6d-4e81-bd26-f6de343cc103 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/select-updates-for-non-clinical-engineering-tests-and-recommended-labeling-for-intravascular-stents-and-associated-delivery-systems-guidance-for-industry-and-food-and-drug-administration-staff/1a0f0266-86e6-477b-8da6-0fb49b135f78 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/qualification-of-biomarker-total-kidney-volume-in-studies-for-treatment-of-autosomal-dominant-polycystic-kidney-disease-draft-guidance-for-industry/796ecc64-f708-40c5-b86c-611463dab75b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m4er2-the-ctd-efficacy/460793c4-42d9-4f9f-83c0-9ec5b1d6151d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/characterization-of-ultrahigh-molecular-weight-polyethylene-uhmwpe-used-in-orthopedic-devices-guidance-for-industry-and-food-and-drug-administration-staff/ce38a3ba-9732-4204-bb7b-6a1e3960209c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submission-of-quality-metrics-data-guidance-for-industry/7048879a-6021-4ea9-b070-11e6caa89646 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dissolution-testing-and-acceptance-criteria-for-immediate-release-solid-oral-dosage-form-drug-products-containing-high-solubility-drug-substances-guidance-for-industry/b9156407-8a16-47ed-a9dc-f5ba2ff61852 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submission-of-premarket-notifications-for-magnetic-resonance-diagnostic-devices-guidance-for-industry-and-food-and-drug-administration-staff/374fccc3-2ae3-4a94-b9f0-7042a3429a1d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-231-distributor-labeling-for-new-animal-drugs/f3f085c4-37b6-4386-8e93-136bc258ba82 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-assessment-of-blood-donor-eligibility-donor-deferral-and-blood-product-management-in-response-to-ebola-virus-guidance-for-industry/238a4406-3c0e-4cf7-afdd-0a11ad92aeb9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/adaptive-designs-for-medical-device-clinical-studies-guidance-for-industry-and-food-and-drug-administration-staff/70eec6c8-49d6-475b-8538-2f4e934cf72b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigational-new-drug-applications-prepared-and-submitted-by-sponsor-investigators/9c10b828-60b1-4f2f-acda-7011cf2ad95d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/patient-preference-information-voluntary-submission-review-in-premarket-approval-applications-humanitarian-device-exemption-applications-and-de-novo-requests-and-inclusion-in-decision-summaries-and-device-labeling-guidance-for-industry-food-and-drug-administration-staff-and-other-stakeholders/4183697f-cc20-45d7-8bac-c59db5807fae 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/interim-policy-on-compounding-using-bulk-drug-substances-under-section-503b-of-the-federal-food-drug-and-cosmetic-act/eabbf240-5386-496d-ad18-2d7246237567 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessment-of-radiofrequency-induced-heating-in-the-magnetic-resonance-mr-environment-for-multi-configuration-passive-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/f3d26520-4bf8-403a-bd4f-2924a62619cf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/factors-to-consider-when-making-benefit-risk-determinations-for-medical-device-investigational-device-exemptions-guidance-for-investigational-device-exemption-sponsors-sponsor-investigators-and-food-and-drug-administration-staff/2b27b206-5d0c-408c-a6c2-d8e855da1e12 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/duchenne-muscular-dystrophy-and-related-dystrophinopathies-developing-drugs-for-treatment-guidance-for-industry/a2b09b4f-527f-406f-a71d-c6e62d4737ad 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/acceptability-of-draft-labeling-to-support-abbreviated-new-drug-application-approval-guidance-for-industry/39b1bd86-7931-4b85-b913-e4374ce03b74 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/environmental-assessment-questions-and-answers-regarding-drugs-with-estrogenic-androgenic-or-thyroid-activity/4f1defd1-fc55-4b85-a9ba-279954bdd658 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-237-oncology-drugs-for-companion-animals/60191a5a-014c-4feb-8728-3adec4502ada 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/leveraging-existing-clinical-data-for-extrapolation-to-pediatric-uses-of-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/b3b2eb54-259d-4b88-a138-177641cbf944 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/procedures-for-meetings-of-the-medical-devices-advisory-committee-guidance-for-industry-and-food-and-drug-administration-staff/f9a402c7-0135-4aab-ac98-8b10ae0674e5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonproprietary-naming-of-biological-products-guidance-for-industry/2c820442-8476-4109-a13c-a42550929546 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/andas-pre-submission-facility-correspondence-related-to-prioritized-generic-drug-submissions/44de7e09-5433-4834-a1c2-11c6a384c15e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/determining-the-need-for-and-content-of-environmental-assessments-for-gene-therapies-vectored-vaccines-and-related-recombinant-viral-or-microbial-products-guidance-for-industry/7e121572-9573-4422-ac9b-6975e1e6dab6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-226-target-animal-safety-data-presentation-and-statistical-analysis/338704fb-d6b3-4880-a23f-4f22674825ed 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-229-evaluating-the-effectiveness-of-new-animal-drugs-for-the-reduction-of-pathogenic-shiga-toxin-producing-e-coli-in-cattle/cafa51a7-9df8-4840-9877-123cd25c033d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/qualification-of-biomarker-plasma-fibrinogen-in-studies-examining-exacerbations-andor-all-cause-mortality-in-patients-with-chronic-obstructive-pulmonary-disease-guidance-for-industry/01af26cc-b214-4770-8a30-fe46c0ed1bac 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-203-ensuring-safety-of-animal-feed-maintained-and-fed-on-farm/e796492e-6d0c-4f43-8ce0-798d0933afa9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/adverse-event-reporting-for-outsourcing-facilities-under-section-503b-of-the-federal-food-drug-and-cosmetic-act/4c23f98f-eaf3-4ed1-8f57-33ea6ba03529 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/mixing-diluting-or-repackaging-biological-products-outside-the-scope-of-an-approved-biologics-license-application-guidance-for-industry/10a78d19-deab-4319-a7fe-ebc2b6b0bb1e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-entities-considering-whether-to-register-as-outsourcing-facilities-under-section-503b-of-the-federal-food-drug-and-cosmetic-act/3fb7514b-990d-4598-b308-5504189da6fc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/pregnancy-lactation-and-reproductive-potential-labeling-for-human-prescription-drug-and-biological-products-content-and-format-guidance-for-industry-small-entity-compliance-guide/926e2fe0-f8f1-4c70-a766-2eefdef2ef51 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-devices-and-clinical-trial-design-for-the-treatment-or-improvement-in-the-appearance-of-fungally-infected-nails-guidance-for-industry-and-food-and-drug-administration-staff/85b69c73-53d8-4a3a-9f25-58dad5f243b9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/classification-and-requirements-for-laser-illuminated-projectors-lips-laser-notice-no-57-guidance-for-industry-and-food-and-drug-administration/2b744348-0ec2-49b2-8a01-1267e71cfe8a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/general-wellness-policy-for-low-risk-devices-guidance-for-industry-and-food-and-drug-administration-staff/557546f2-be1d-446b-b2c5-f259e243b803 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-glove-guidance-manual-guidance-for-industry-and-fda-staff/d2548566-4793-4a0b-91d0-d16f13c97188 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommended-warning-for-over-the-counter-acetaminophen-containing-drug-products-and-labeling-statements-regarding-serious-skin-reactions/18d91b25-4270-4f4e-86b9-a8430b4c2a0d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dscsa-standards-for-the-interoperable-exchange-of-information-for-tracing-of-certain-human-finished-prescription-drugs-guidance-for-industry/d738527c-0560-403a-b6a6-2a0d3055183f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dscsa-implementation-annual-reporting-by-prescription-drug-wholesale-distributors-and-third-party-logistics-providers/712ebdd8-de0d-4a6d-b6c3-0983093ca377 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-in-electronic-and-non-electronic-formatpromotional-labeling-and-advertising-materials-for-human-prescription-drugs/505d9bf5-96ba-4f03-a291-64f5c289be51 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/general-clinical-pharmacology-considerations-for-pediatric-studies-of-drugs-including-biological-products/764daa65-55f6-4702-b131-6e18ebf48434 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/evaluating-drug-effects-on-the-ability-to-operate-a-motor-vehicle/a8500c8d-7d16-45e2-8690-51cd991eae5e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-540275-draft-crabmeat-fresh-and-frozen-adulteration-with-filth-involving-the-presence-of-escherichia-coli/d3b7c2a8-ee4b-4c38-9cf0-b98110303b5f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/development-and-submission-of-near-infrared-analytical-procedures/7a79be2e-dca0-4d85-b129-219183db027f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/individual-patient-expanded-access-applications-form-fda-3926/6de5fa70-12b9-446e-a760-cc6dd4a4cb1d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-540700-labeling-of-processed-and-blended-seafood-products-made-primarily-with-fish-protein/64f321a2-a327-424c-814e-301049f474fc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/electronic-drug-product-reporting-for-human-drug-compounding-outsourcing-facilities-under-section-503b-of-the-federal-food-drug-and-cosmetic-act/663cef2e-7472-423d-8bba-249d7de0ea3d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/withdrawn-cder-product-specific-guidances/ad0e94d3-410a-4ef5-81ec-6efc05de2c6d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/product-labeling-for-laparoscopic-power-morcellators-guidance-for-industry-and-food-and-drug-administration-staff/590886e0-ab34-4eb9-8a71-7cd5457ddf8e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/premarket-studies-of-implantable-minimally-invasive-glaucoma-surgical-migs-devices-guidance-for-industry-and-food-and-drug-administration-staff/0dddd7a4-66f5-4a37-a281-f96722b7a67a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q5ar2-viral-safety-evaluation-of-biotechnology-products-derived-from-cell-lines-of-human-or-animal-origin/5176fb4c-a3d2-4aaf-85d0-dd246f7a9db1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/drug-product-tracing-the-effect-of-section-585-of-the-fdc-act/34847c6a-61d4-4e1e-838f-dad6e160e8c3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/same-surgical-procedure-exception-under-21-cfr-127115b-questions-and-answers-regarding-the-scope-of-the-exception/53846d3e-b806-4d4e-a3b3-6762c790bca5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/custom-device-exemption-guidance-for-industry-and-food-and-drug-administration-staff/5ea0b9ff-f6c9-4da3-99e8-adb1e121faca 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-224-vich-gl52-bioequivalence-blood-level-bioequivalence-study/7cc12568-964a-494b-8e09-40ddcb294891 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-device-accessories-describing-accessories-and-classification-pathways-guidance-for-industry-and-fda-staff/91a29ff0-0a6f-40e3-8738-e11e7f56ebdc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/migraine-developing-drugs-for-acute-treatment/39ba4b4b-6c93-4849-a087-866c6bf4edff 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/electronic-submission-of-lot-distribution-reports-guidance-for-industry/ebe62754-631b-404b-ad26-a30a313faa4a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/distinguishing-medical-device-recalls-from-medical-device-enhancements-guidance-for-industry-and-food-and-drug-administration-staff/3008fb0d-36fe-4243-9d66-88213ff44246 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-227-chemistry-manufacturing-and-controls-cmc-technical-section-filing-strategies/c17cd508-fad3-417c-ae11-e2e55091ec17 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/specification-of-the-unique-facility-identifier-ufi-system-for-drug-establishment/a5128e8e-b3f3-449e-bd8c-319ee46e9981 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dscsa-implementation-product-tracing-requirements-compliance-policy/9ad4eeb9-a4db-485a-8096-625f4de887c6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/qualification-of-biomarker-galactomannan-in-studies-of-treatments-of-invasive/609be9e9-d86e-4995-b7df-7b9095d54037 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/over-the-counter-pediatric-oral-liquid-drug-products-containing-acetaminophen/73b128be-d735-4bf2-9b74-2c85ea595082 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-225-vich-gl53-electronic-exchange-of-documents-file-format-recommendations/7b2cb628-1267-47ff-bacc-10718ab0432f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/unique-device-identifier-system-frequently-asked-questions-vol-1-guidance-for-industry-and-food-and-drug-administration-staff/56f22c9d-2dac-42cc-beeb-992a03bafd99 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/mitigating-the-risk-of-cross-contamination-from-valves-and-accessories-used-for-irrigation-through-flexible-gastrointestinal-endoscopes-guidance-for-industry-and-food-and-drug-administration-staff/2c42eaf2-562c-4f4b-a0c3-f26394873d77 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/anda-submissions-prior-approval-supplements-under-gdufa-guidance-for-industry/433ffd43-857c-4bec-84e3-acc6a271a04c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/anda-submissions-amendments-to-abbreviated-new-drug-applications-under-gdufa-guidance-for-industry/9fe16cd4-ef07-4dd1-8241-a762f71acbb7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/intent-to-exempt-certain-unclassified-medical-devices-from-premarket-notification-requirements-guidance-for-industry-and-food-and-drug-administration-staff/ccf098b7-6ec4-43b6-b471-921e6182d902 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/design-and-analysis-of-shedding-studies-for-virus-or-bacteria-based-gene-therapy-and-oncolytic-products-guidance-for-industry/d717cc69-a65f-4b33-94b8-cd9e6ff6f9c1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/policy-clarification-for-certain-fluoroscopic-equipment-requirements-guidance-for-industry-and-food-and-drug-administration-staff/96941091-1746-4c9e-9056-3c2d30da55b1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/benefit-risk-factors-to-consider-when-determining-substantial-equivalence-in-premarket-notifications-510k-with-different-technological-characteristics-guidance-for-industry-and-food-and-drug-administration-staff/9b4259f7-7bc8-42ed-aa66-3fd197961ad3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-218-cell-based-products-for-animal-use/75ff952d-26bc-416e-befa-98465a1b4db9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/uncomplicated-gonorrhea-developing-drugs-for-treatment/56891f77-fa9d-4c61-87e8-d129790d9d35 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/content-and-format-for-abbreviated-510ks-for-early-growth-response-1-egr1-gene-fluorescence-in-situ-hybridization-fish-test-system-for-specimen-characterization-devices-guidance-for-industry-and-food-and-drug-administration-staff/48e4f4e5-6d04-47ee-991d-451e7fafc090 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q3c-appendix-6/c3dc76f8-4481-4744-823c-911719e2728b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/drug-supply-chain-security-act-implementation-identification-of-suspect-product-and-notification-guidance-for-industry/b4c70c8e-e987-4e21-bc26-899f532ad5a1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/distributing-scientific-and-medical-publications-on-risk-information-for-approved-prescription-drugs-and-biological-productsrecommended-practices/69e4b507-d287-4a18-8387-90dfb7cd1805 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/product-development-under-the-animal-rule/e03ed1b9-cdb2-40a6-b4d6-28fc01609e6a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-data-to-support-a-demonstration-of-biosimilarity-to-a-reference-product/d14d1e42-3cce-41e9-863f-79be3022abbb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/best-practices-in-developing-proprietary-names-for-human-prescription-drug-products-guidance-for-industry-guidance-for-industry/884d34d7-a96d-446a-8c81-afb4c4e499ac 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/balancing-premarket-and-postmarket-data-collection-for-devices-subject-to-premarket-approval-guidance-for-industry-and-food-and-drug-administration-staff/0be21e15-5c88-436c-9ca5-5746e509f79c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fees-for-human-drug-compounding-outsourcing-facilities-under-sections-503b-and-744k-of-the-fdc-act/56f9622b-7869-4157-b784-d3446072e7da 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-human-prescription-drug-and-biological-products-approved-under-the-accelerated-approval-regulatory-pathway/53afccba-4a69-4547-878f-b1a1b9a1e7b9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/new-chemical-entity-exclusivity-determinations-for-certain-fixed-combination-drug-products/d74952b7-1888-42ca-8591-fe4e8262275d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/reference-product-exclusivity-for-biological-products-filed-under-section-351a-of-the-phs-act/7021cd9e-7798-464d-9e2b-7182acf180d8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/chronic-fatigue-syndromemyalgic-encephalomyelitis-developing-drug-products-for-treatment/1a25a9e8-1852-4b92-8380-feaa374b8e13 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/self-monitoring-blood-glucose-test-systems-for-over-the-counter-use-guidance-for-industry-and-food-and-drug-administration-staff/5762ec6f-0cf7-4f0a-848d-527568d77305 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/reporting-of-computational-modeling-studies-in-medical-device-submissions-guidance-for-industry-and-food-and-drug-administration-staff/422a1a1e-f32d-4df7-a042-f1af0d663768 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/attachement-qualification-process-for-drug-development-tools-qualification-of-exacerbations-of-chronic-pulmonary-disease-tool-for-measurement-of-symptoms-of-acute-bacterial-exacerbation-of-chronic-bronchitis-in-patients-with-chronic-obstructive-pulmonary-disease/88815054-17fc-4e46-a5c1-be7b0bad1ea9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/anda-submissions-content-and-format-of-abbreviated-new-drug-applications-guidance-for-industry/9e96159f-7071-4167-b6c2-79004f8ffc79 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency-guidance-for-submitting-hiv-1-resistance-data-attachment-to-the-guidance-draft-draft-guidance-this-draft-guidance-updates-the-final-guidance-posted-6206/5692d0bf-a0d8-4160-becb-4c084297e485 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-donor-screening-tests-to-test-donors-of-human-cells-tissues-and-cellular-and-tissue-based-products-for-infection-with-treponema-pallidum-syphilis-guidance-for-industry/9fd76c90-747b-4a80-812b-09cfac7a01e4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/qualification-of-medical-device-development-tools-guidance-for-industry-tool-developers-and-food-and-drug-administration-staff/392746b7-77c7-453d-abc3-dea7880c9864 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-221-recommendations-for-preparation-and-submission-of-animal-food-additive-petitions/953b1e50-77be-4ac0-b2cc-c27d79a23774 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/premarket-notification-510k-submissions-for-bipolar-electrosurgical-vessel-sealers-for-general-surgery-guidance-for-industry-and-food-and-drug-administration-staff/1a366393-d345-405a-a360-ebf32c15bbc9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/cvm-gfi-223-small-entity-compliance-guide-declaring-color-additives-in-animal-foods/53627d69-9e70-4f4d-bd75-7cbfd3e3c895 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/patient-counseling-information-section-of-labeling-for-human-prescription-drug-and-biological-products-content-and-format/91c267ae-e99d-4508-b31c-721b7da25d2b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/global-unique-device-identification-database-gudid-guidance-for-industry-and-food-and-drug-administration-staff/d3c7c927-7b69-451e-b55b-44c244ddbdc9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enforcement-policy-regarding-investigational-new-drug-requirements-for-use-of-fecal-microbiota-for-transplantation-to-treat-clostridium-difficile-infection-not-responsive-to-standard-therapies-guidance-for-industry/1c1d8e06-4c1c-4dc5-8c6a-ebfa9ce68b55 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/registration-for-human-drug-compounding-outsourcing-facilities-under-section-503b-of-the-federal-food-drug-and-cosmetic-act/74d2bf28-3d33-408f-9b37-e47a144fa9bc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medical-device-reporting-for-manufacturers-guidance-for-industry-and-food-and-drug-administration-staff/bdf0f904-24f2-44f0-8046-74c1e429237a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bla-for-minimally-manipulated-unrelated-allogeneic-placentalumbilical-cord-blood-intended-for-hematopoietic-and-immunologic-reconstitution-in-patients-with-disorders-affecting-the-hematopoietic-system-guidance-for-industry/92eb43cc-c22d-4b90-b9cb-77d1adfe8331 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pediatric-study-plans-content-of-and-process-for-submitting-initial-pediatric-study-plans-and-amended-initial-pediatric-study-plans/863eefe3-8c96-4abe-a49e-8317e8bfc2b3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/circumstances-that-constitute-delaying-denying-limiting-or-refusing-a-drug-or-device-inspection-guidance-for-industry/9e51d92c-a107-4e29-ac90-63dedfe2a9c3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bioequivalence-studies-with-pharmacokinetic-endpoints-for-drugs-submitted-under-an-abbreviated-new-drug-application/1da84f16-4374-4eb9-87cd-f13d1d965346 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/human-immunodeficiency-virus-1-infection-developing-antiretroviral-drugs-for-treatment/29bfce2d-7907-435c-b6f8-596f490430cb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/antibacterial-therapies-for-patients-with-an-unmet-medical-need-for-the-treatment-of-serious-bacterial-diseases/7f6befe7-26a9-40de-8b99-346a43431087 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pre-launch-activities-importation-requests-plair-guidance-for-industry/66c1d94d-25c8-49ce-a669-977492f04bbf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-690800-compliance-policy-guide-salmonella-in-food-for-animals/8b76f75c-c3ab-457d-a602-e2859a1d8d9c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/andas-stability-testing-of-drug-substances-and-products-questions-and-answers/4506feda-4fad-4c68-a272-c1ce936ba67d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-submissions-in-electronic-format-postmarket-non-expedited-icsrs-technical-questions-and-answers/16f47a81-0aba-4e45-ab3e-9a1e415cb4d4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/rheumatoid-arthritis-developing-drug-products-for-treatment/f6725d58-9ccd-41cf-8684-52aca25cd029 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-m7r2-assessment-and-control-of-dna-reactive-mutagenic-impurities-in-pharmaceuticals-to-limit-potential-carcinogenic-risk/90470c75-0c9c-4b55-a4dd-bb7a0d572e79 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/safety-considerations-for-container-labels-and-carton-labeling-design-to-minimize-medication-errors/e13010c8-daa7-439e-bd49-fa88d08456a3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-international-standard-iso-10993-1-biological-evaluation-of-medical-devices-part-1-evaluation-and-testing-within-a-risk-management-process-guidance-for-industry-and-food-and-drug-administration-staff/0a520dd9-604d-4769-aa08-2214730129e1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/expanded-access-to-investigational-drugs-for-treatment-use-questions-and-answers-guidance-for-industry/12e2fbc0-e56f-4be2-8fa3-278d7a366326 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/formal-dispute-resolution-sponsor-appeals-above-the-division-level-guidance-for-industry-and-review-staff/1802a54c-173d-4641-9744-9b0ce8679736 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/user-fees-and-refunds-for-premarket-notification-submissions-510ks-guidance-for-industry-and-food-and-drug-administration-staff/327e29e4-6e24-4c3b-9c56-c8dbecde1f94 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/molecular-diagnostic-instruments-with-combined-functions-guidance-for-industry-and-food-and-drug-administration-staff/a574268b-28c8-40e2-8ea4-60887b411baf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/implementation-of-acceptable-full-length-and-abbreviated-donor-history-questionnaires-and-accompanying-materials-for-use-in-screening-donors-of-source-plasma-guidance-for-industry/d9e3abf3-ba62-48f6-92d8-1774e0632a7b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/compliance-policy-guide-sec-390200-determination-by-secretary-that-product-fails-to-comply-or-has-defect-21-cfr-100311/6f05a7c9-686e-476e-9f55-da69eef06462 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-screening-testing-and-management-of-blood-donors-and-blood-and-blood-components-based-on-screening-tests-for-syphilis-guidance-for-industry/55e82ed9-047c-4235-9442-7dc1d1a9a4d0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigational-device-exemption-ide-guidance-for-retinal-prostheses-guidance-for-industry-and-fda-staff/b884a15b-7752-4893-a921-b339d0eb8d5e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-220-use-of-nanomaterials-in-food-for-animals/b9ce364e-3037-4f7a-ae0a-46128ed6c02d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/contract-manufacturing-arrangements-for-drugs-quality-agreements-guidance-for-industry-guidance-for-industry/d69e7f40-c7b7-43d6-9842-3f22446cb427 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/humanitarian-use-device-hud-designations-guidance-for-industry-and-food-and-drug-administration-staff/f69ce18d-0fa9-476d-8bab-21c335878fbf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/types-of-communication-during-the-review-of-medical-device-submissions-guidance-for-industry-and-fda-staff/e94847ca-3957-46e1-b038-20f9f42a560d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/electronic-source-data-in-clinical-investigations-guidance-for-industry/6d72d592-c70b-47f5-810c-0542a685c1b5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency-guidance-for-submitting-hcv-resistance-data-attachment-to-guidance/2f01091c-bdf0-477c-a276-df044ffd9889 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bioresearch-monitoring-technical-conformance-guide/925676a5-7254-4424-9c54-4442ca5be232 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/standardized-format-for-electronic-submission-of-nda-and-bla-content-for-the-planning-of-bioresearch-monitoring-bimo-inspections-for-cder-submissions-guidance-for-industry/c7353b0c-eb15-4733-80c9-4b757e32acef 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacogenomics-premarket-evaluation-in-early-phase-clinical-studies-and-recommendations-for-labeling/74a84cb7-8271-4fc5-b011-1df725ecf2eb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/design-considerations-for-devices-intended-for-home-use-guidance-for-industry-and-food-and-drug-administration-staff/98b59802-0b79-44e6-b189-2e5d473c7347 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-labeling-medical-products-to-inform-users-that-the-product-or-product-container-is-not-made-with-natural-rubber-latex-guidance-for-industry-and-food-and-drug-administration-staff/e969c46d-9917-4ab6-9aea-eea47c7a282c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/generic-drug-user-fee-amendments-of-2012-questions-and-answers-related-to-user-fee-assessments-guidance-for-industry/2ed72247-f375-4181-8610-86ace4008dc0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-420500-interference-with-compendial-tests-revised-11142012/4d2c798b-3bd5-4c58-a7dd-59f246d55258 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/complicated-intra-abdominal-infections-developing-drugs-for-treatment/d6add39a-f308-464b-a6b5-f0161eeea8a0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-nucleic-acid-tests-on-pooled-and-individual-samples-from-donors-of-whole-blood-and-blood-components-including-source-plasma-to-reduce-the-risk-of-transmission-of-hepatitis-b-virus-final-guidance-for-industry/e8fb757d-ba0b-4dd1-9173-494e61da9b48 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submissions-for-postapproval-modifications-to-a-combination-product-approved-under-a-bla-nda-or-pma-draft-guidance-for-industry-and-fda-staff/e6c53755-5cb5-49ce-9d67-07a008f66761 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/immunogenicity-assessment-for-therapeutic-protein-products/04e181cd-8e84-4961-b3ec-443e161c6965 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550050-draft-canned-ackee-frozen-ackee-and-other-ackee-products-hypoglycin-a-toxin/5e8bf2ea-01a5-4aba-a66e-1065f6b2542b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/highly-multiplexed-microbiologicalmedical-countermeasure-in-vitro-nucleic-acid-based-diagnostic-devices-guidance-for-industry-and-food-and-drug-administration-staff/1aa959b8-c546-4122-96a9-3e538a3c1b7f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/safety-reporting-requirements-for-inds-and-babe-studies-guidance-for-industry-and-investigators/5e899308-bd5d-4267-9d7e-71f434a2b8db 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pre-storage-leukocyte-reduction-of-whole-blood-and-blood-components-intended-for-transfusion-final-guidance-for-industry/2237da2a-80aa-4592-b97f-a58f86a9a7ca 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/andas-stability-testing-of-drug-substances-and-products/c3403aba-7f4f-4aa1-9f7b-94ae55a3486f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/completeness-assessments-for-type-ii-api-dmfs-under-gdufa-guidance-for-industry-guidance-for-industry/8789bcc1-8c78-472e-afc7-c1501ce09d7e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/certification-process-of-designated-medical-gases/352e5870-5e87-45f6-8ca5-cd7027d3ac49 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e3-structure-and-content-of-clinical-study-reports-questions-and-answers-r1/5b7e3d17-9b0a-44df-bfcf-df3fae8991ae 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/safety-considerations-for-product-design-to-minimize-medication-errors-guidance-for-industry/8237a0b9-a53f-4a27-a231-874107d935de 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-335300-hypnotherapy-devices-self-hypnotic-tape-recordings/26a6f34d-f3d4-4c27-a4e3-918b42ec4b4d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/self-identification-of-generic-drug-facilities-sites-and-organizations-guidance-for-industry/0f6af607-fb4c-4df3-8f72-edf8eeb27fbe 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/refuse-to-accept-policy-for-510ks-guidance-for-industry-and-food-and-drug-administration-staff/d1d77dff-02ff-4d5b-8b06-be50e0bcbc06 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-204-active-controls-in-studies-to-demonstrate-effectiveness-of-a-new-animal-drug-for-use-in-companion-animals/d9bc3b93-f53a-4229-921d-feae8cf01c81 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/physicochemical-and-structural-q3-characterization-of-topical-drug-products-submitted-in-andas/791aaeaa-9e86-4bc4-8b71-477a833920f1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/organ-specific-warnings-internal-analgesic-antipyretic-and-antirheumatic-drug-products-for-over-the-counter-human-use-guidance-for-industry/14e41e0b-71d2-4b92-a8da-b96b32a988c4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-219-vich-gl51-statistical-evaluation-of-stability-data/0b6795eb-d0d7-42f5-a33b-0e48e4e7867a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pathological-complete-response-in-neoadjuvant-treatment-of-high-risk-early-stage-breast-cancer-use-as-an-endpoint-to-support-accelerated-approval/ad15136b-9f37-470e-a814-e84a9756a3ca 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-213-new-animal-drugs-and-new-animal-drug-combination-products-administered-in-or-on-medicated-feed-or-drinking-water-of-food-producing-animals-recommendations-for-drug-sponsors-for-voluntarily-aligning-product-use-conditions-with-gfi-209/bfc9857a-c105-4a21-999d-b7cf706945a5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/safety-considerations-to-mitigate-the-risks-of-misconnections-with-small-bore-connectors-intended-for-enteral-applications-guidance-for-industry-and-food-and-drug-administration-staff/39cc66e8-e26c-4645-a88a-8c2386369d76 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e2cr2-periodic-benefit-risk-evaluation-report-pbrer/34160d8d-51b7-47bd-a753-e6ad93180322 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pediatric-information-for-x-ray-imaging-device-premarket-notifications-guidance-for-industry-and-food-and-drug-administration-staff/7a347f68-87ec-48b0-b385-4a82d1ebd6a3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/irb-continuing-review-after-clinical-investigation-approval-guidance-for-irbs-clinical-investigators-and-sponsors/7c18de8c-1544-4b72-a67a-3a861d29c31c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/implanted-blood-access-devices-for-hemodialysis-guidance-for-industry-and-food-and-drug-administration-staff/b866ccbc-424b-4a5e-8c9f-784a6c362ea3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/review-of-drug-master-files-in-advance-of-certain-anda-submissions-under-gdufa/bd04aec8-c53e-4d1d-b770-a5c8267fed47 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/early-clinical-trials-with-live-biotherapeutic-products-chemistry-manufacturing-and-control-information-guidance-for-industry/6962bf37-7cfd-4243-ac04-43748353cd63 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/heparin-for-drug-and-medical-device-use-monitoring-crude-heparin-for-quality-guidance-for-industry/28019717-ce5d-43c7-9595-479e33fbe847 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-oversight-of-pet-drug-products-questions-and-answers/3e894e01-dc7a-4e5e-a828-a0b032a0404f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-use-of-histopathology-and-its-associated-methodologies-to-support-biomarker-qualification-guidance-for-industry/9f893e7b-4aa3-4e4f-81bb-b2d74e521f3e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-in-electronic-format-standardized-study-data/814b3542-7010-4e11-9dfa-23b248ce9cbf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/responding-to-unsolicited-requests-for-off-label-information-about-prescription-drugs-and-medical-devices/bffc25a1-1a64-42bf-9751-1502844fa83e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/development-of-therapeutic-protein-biosimilars-comparative-analytical-assessment-and-other-quality-related-considerations-guidance-for-industry/3949c599-c5d4-49ab-bdd6-82c279429c92 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/questions-and-answers-on-informed-consent-elements-21-cfr-5025c-guidance-for-sponsors-investigators-and-institutional-review-boards/f08c5611-e030-4503-853b-be8ace821598 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigational-new-drug-applications-for-positron-emission-tomography-pet-drugs/c3d2d63b-b192-4684-b9ea-880c5065d37b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/preparation-of-ides-and-inds-for-products-intended-to-repair-or-replace-knee-cartilage-guidance-for-industry/23e85975-237a-4552-b819-d0e02d2a7628 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/requalification-method-for-reentry-of-donors-who-test-hepatitis-b-surface-antigen-hbsag-positive-following-a-recent-vaccination-against-hepatitis-b-virus-infection-guidance-for-industry/0e250823-8960-41cb-89b6-e0c03fb60caa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-510k-program-evaluating-substantial-equivalence-in-premarket-notifications-510k-guidance-for-industry-and-food-and-drug-administration-staff/b5031711-1d58-4c45-b081-f570f50bba71 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m3r2nonclinical-safety-studies-for-the-conduct-of-human-clinical-trials-and-marketing-authorization-for-pharmaceuticals-questions-and-answers/04bea7cb-30a1-49e6-94c9-51131e6004d7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/determining-the-extent-of-safety-data-collection-needed-in-late-stage-premarket-and-postapproval-clinical-investigations/4c1e56b3-7744-4a86-b98b-70593f0edb21 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/general-principles-for-the-development-of-vaccines-to-protect-against-global-infectious-diseases-guidance-for-industry/b31a8d12-c66e-47ea-8023-d4945a51137e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/media-fills-for-validation-of-aseptic-preparations-for-positron-emission-tomography/517018b5-dd39-40a9-a516-f826a28553a7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/implementation-of-acceptable-full-length-and-abbreviated-donor-history-questionnaires-and-accompanying-materials-for-use-in-screening-donors-of-blood-and-blood-components-guidance-for-industry/70dc5eba-5a77-4d4f-bf8c-57a2196b9ded 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-decisions-for-investigational-device-exemption-clinical-investigations-guidance-for-sponsors-clinical-investigators-institutional-review-boards-and-food-and-drug-administration-staff/187acde3-b11f-43f1-878d-aabbc39c393a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigational-device-exemptions-ides-for-early-feasibility-medical-device-clinical-studies-including-certain-first-in-human-fih-studies-guidance-for-industry-and-food-and-drug-administration-staff/4cd54e2e-d8ae-4587-9c8b-defde57aa5e1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/tablet-scoringnomenclature-labeling-and-data-for-evaluation/d4b6bb69-1a24-4ebd-be2e-a80b08473b39 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/modifications-to-devices-subject-to-premarket-approval-pma-the-pma-supplement-decision-making-process-guidance-for-industry-and-fda-staff/2fa147f5-4cd9-4ac0-9ae1-09b62dffa25e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/neglected-tropical-diseases-of-the-developing-world-developing-drugs-for-treatment-or-prevention/e681bd27-ed13-423d-b95c-7d701a29f83e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/evaluation-of-sex-specific-data-in-medical-device-clinical-studies-guidance-for-industry-and-food-and-drug-administration-staff/0c5030be-c3f7-445e-872d-0f2f1830e97c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e16-biomarkers-related-to-drug-or-biotechnology-product-development-context-structure-and-format-of-qualification-submissions/dff4ff01-57a3-4145-a118-925a3a80b83c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-trial-imaging-endpoint-process-standards-guidance-for-industry/910804b6-9e1d-47f8-8105-89b586c9622b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/self-selection-studies-for-nonprescription-drug-products/7b20639c-7187-4e71-9943-0ee53848d907 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-214-vich-gl35-pharmacovigilance-of-veterinary-medicinal-products-electronic-standards-for-transfer-of-data/6c70e07d-1ade-47c9-b5d2-3b8d0350101e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessment-of-abuse-potential-of-drugs/6c9a2ccd-021a-4f93-a97e-5444b6de4fef 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/regulatory-classification-of-pharmaceutical-co-crystals/b288c932-6da7-45b6-b036-5876350c1f0f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/policy-for-device-software-functions-and-mobile-medical-applications-guidance-for-industry-and-food-and-drug-administration-staff/db453483-9217-40e9-bd65-eed3323f9e3e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-content-of-investigational-device-exemption-ide-and-premarket-approval-pma-applications-for-artificial-pancreas-device-systems-guidance-for-industry-and-food-and-drug-administration-staff/692e0ca7-0e58-43e0-92f6-1f2f471e307d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/topical-acne-drug-products-for-over-the-counter-human-use-revision-of-labeling-and-classification-of-benzoyl-peroxide-as-safe-and-effective-guidance-for-industry/c1be2f8e-363e-4a2e-8fcb-ff9ccf72373a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/reprocessing-medical-devices-in-health-care-settings-validation-methods-and-labeling-guidance-for-industry-and-food-and-drug-administration-staff/ff9bb589-ce45-48ed-a673-3d3302436dc0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/in-vitro-companion-diagnostic-devices-guidance-for-industry-and-food-and-drug-administration-staff/18915018-e22e-4930-90ea-2f601a510495 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/lookback-for-hepatitis-c-virus-hcv-product-quarantine-consignee-notification-further-testing-product-disposition-and-notification-of-transfusion-recipients-based-on-donor-test-results-indicating-infection-with-hcv-guidance-for-industry/47e1cf90-16d8-4331-8148-46e9e88b7770 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/pet-drugs-current-good-manufacturing-practice-cgmp-small-entity-compliance-guide/26400201-bc4d-4183-a80f-e3cd71291dfb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-527300-dairy-products-microbial-contaminants-alkaline-phosphatase-activity/997fefb7-f607-4bff-84c3-a486b53e8204 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/non-penicillin-beta-lactam-drugs-a-cgmp-framework-for-preventing-cross-contamination-guidance-for-industry/8f4551af-85d4-4a2c-9a05-f4a01a143967 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/donors-of-blood-and-blood-components-notification-of-donor-deferral-small-entity-compliance-guide-guidance-for-industry/99b304c2-023b-4d87-b008-13fe01e38c51 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/how-to-obtain-a-covered-product-authorization/881f0322-95f9-4bfd-b6c3-35f5df950808 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/best-practices-for-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic-healthcare-data-sets/5a792e07-313c-4b6e-a098-39e274850db6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-open-public-hearing-at-fda-advisory-committee-meetings-guidance-for-the-public-fda-advisory-committee-members-and-fda-staff/c9efbd34-43c9-45a4-ab0c-38fd2d0d07bd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/potency-tests-for-cellular-and-gene-therapy-products-final-guidance-for-industry/59c72aad-aad2-413a-82eb-440ea6bc25f8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q11-development-and-manufacture-of-drug-substances/8d1aacb1-7da4-42f7-9a3a-18b2fc871411 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/codevelopment-of-two-or-more-new-investigational-drugs-for-use-in-combination/6a704e0b-f05e-4e65-91b9-7d60ac493505 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dear-health-care-provider-letters-improving-communication-of-important-safety-information/a3ea6356-848d-4286-86e9-8ac6013377e1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia-developing-drugs-for-treatment/44535240-549f-4ab3-a7cb-33d8430de086 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/chronic-hepatitis-c-virus-infection-developing-direct-acting-antiviral-drugs-for-treatment-guidance-for-industry/930fbcbb-8430-4e5f-ad06-452dba6d03ff 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/non-clinical-and-clinical-investigation-of-devices-used-for-the-treatment-of-benign-prostatic-hyperplasia-bph-guidance-for-industry-and-food-and-drug-administration-staff/f9dd9c55-4e33-41f2-a1dc-717e0f0b7988 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/safety-reporting-requirements-for-inds-investigational-new-drug-applications-and-babe-bioavailabilitybioequivalence-studies-guidance-for-industry-and-investigators/9528f5d8-c247-4fdc-8dc2-a32ec6d6afad 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q3c-maintenance-procedures/118d389b-75c5-4f17-981b-0f80521c7270 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigational-new-drug-applications-inds-determining-whether-human-research-studies-can-be-conducted-without-an-ind-guidance-for-clinical-investigators-sponsors-and-irbs/83e34c5d-552a-445c-81e3-be44082f30a8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medication-guides-distribution-requirements-and-inclusion-in-risk-evaluation-and-mitigation-strategies-rems/98ea9f8c-10ac-4377-ab9a-00ed4effd585 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/electronic-submission-of-expedited-safety-reports-from-ind-exempt-babe-studies-guidance-for-industry/0ba6f618-8ff9-42f6-a368-058e7fd53088 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/exculpatory-language-in-informed-consent/b715dc6a-852a-4eb2-b7e7-6f3773d248cc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/cvm-gfi-200-secg-for-designation-of-new-animal-drugs-for-minor-uses-or-minor-species/cc25405a-e0de-43fc-8af5-16c70ae13d0b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-the-ich-regions-annex-14-bacterial-endotoxins-test-general-chapter/98db1203-9518-4653-9880-1131bec30985 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cmc-postapproval-manufacturing-changes-to-be-documented-in-annual-reports/67341cfe-8a48-4fc7-9817-6f9ed89768cf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/qualification-process-for-drug-development-tools-guidance-for-industry-and-fda-staff/f5a3f8af-54f6-44ba-9eea-d3cc587444f7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-188-data-elements-for-submission-of-veterinary-adverse-event-reports-to-the-center-for-veterinary-medicine/9fcc2415-3f73-4ae5-93c3-b076969df761 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/organ-specific-warnings-internal-analgesic-antipyretic-and-antirheumatic-drug-products-for-over-the-counter-human-use-small-entity-compliance-guide/39718e83-6e62-481c-9f54-d26ba46bb38f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-the-ich-annex-13-bulk-density-and-tapped-density-of-powders-general-chapter/17c5137a-e419-426f-8f8c-05a3a1660384 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/information-sheet/frequently-asked-questions-statement-of-investigator-form-fda-1572-guidance-for-sponsors-clinical-investigators-and-irbs/d997c3d8-2f5b-4be6-bdf5-3fcb57d6fe85 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-209-the-judicious-use-of-medically-important-antimicrobial-drugs-in-food-producing-animals/b6b033de-84ae-49f6-b924-4b801de381fd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/program/chapter-48-7348809a-radioactive-drug-research-committee/bfb941da-2647-409d-bbc4-1bdb2311eaf4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nucleic-acid-testing-nat-for-human-immunodeficiency-virus-type-1-hiv-1-and-hepatitis-c-virus-hcv-testing-product-disposition-and-donor-deferral-and-reentry-guidance-for-industry/9abe083b-e500-4bb9-ad6a-22d64bbe75ff 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/requalification-method-for-reentry-of-blood-donors-deferred-because-of-reactive-test-results-for-antibody-to-hepatitis-b-core-antigen-anti-hbc-guidance-for-industry/277daaf6-6b78-49ea-be56-7a9c5a11d75e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-and-industry-procedures-for-section-513g-requests-for-information-under-the-federal-food-drug-and-cosmetic-act-guidance-for-industry-and-food-and-drug-administration-staff/1f5491e2-f651-4c14-97ea-ad2d4653fa58 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-premarket-notifications-for-lamotrigine-and-zonisamide-assays-guidance-for-industry-and-food-and-drug-administration-staff/212a42e4-0689-4ad4-9e7b-5eb382cb15e1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/evaluation-of-therapeutic-equivalence/cd67148c-495a-4ce8-be79-e37f4769b3ae 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pharmacokinetics-in-patients-with-impaired-renal-function-study-design-data-analysis-and-impact-on-dosing/92993772-2585-439d-bdb7-533bf4d9790e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/infusion-pumps-total-product-life-cycle-guidance-for-industry-and-fda-staff/8463ac86-803f-45c8-a325-558ae011327d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-207-vich-gl48-studies-to-evaluate-the-metabolism-and-residue-kinetics-of-veterinary-drugs-in-food-producing-animals-marker-residue-depletion-studies-to-establish-product-withdrawal-periods/a6b23a66-bf8e-407f-9d1d-60d5973a144b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/user-fees-for-513g-requests-for-information-guidance-for-industry-and-food-and-drug-administration-staff/d0402531-87d6-44d4-a378-494302dc85ec 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-206-vich-gl47-studies-to-evaluate-the-metabolism-and-residue-kinetics-of-veterinary-drugs-in-food-producing-animals-comparative-metabolism-studies-in-laboratory-animals/10893ae4-65cd-4018-911b-40e2df090ae1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/irritable-bowel-syndrome-clinical-evaluation-of-products-for-treatment/35ac3629-54d7-4373-91dd-08aadc8f7489 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/helicobacter-pylori-associated-duodenal-ulcer-disease-in-adults-developing-drugs-for-treatment/6e815a93-1ade-4976-a5a1-cf1f0cfcf6d9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-the-ich-regions-annex-12-analytical-sieving-general-chapter/6fb68fc3-1af4-4316-a558-ca92c84d4ff9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-205-vich-gl46-studies-to-evaluate-the-metabolism-and-residue-kinetics-of-veterinary-drugs-in-food-producing-animals-metabolism-study-to-determine-the-quantity-and-identify-the-nature-of-residues-mrk/3d401b22-af7f-412e-94d3-8b8936418dea 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-the-development-of-oligonucleotide-therapeutics-guidance-for-industry/716f5680-73b2-4cf4-a88d-c5ade3c8aecd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-575100-draft-revision-pesticide-chemical-residues-in-food-enforcement-criteria/6e677485-efb8-415c-904e-f7d97f92b37c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/manufacturing-biological-intermediates-and-biological-drug-substances-using-spore-forming-microorganisms-guidance-for-industry/c362d19a-f675-4c2a-8a6b-d79d18b2961c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dosage-delivery-devices-for-orally-ingested-otc-liquid-drug-products/8957963d-c08a-4ab0-b9b5-1b3564a2d4cb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-the-ich-regions-annex-11-capillary-electrophoresis-general-chapter/98ab695d-3452-41c2-992a-926d1ed7f324 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/format-and-content-of-a-rems-document-guidance-for-industry/7d3af53b-d82d-41fe-9a2f-31d366c94701 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-human-prescription-drug-and-biological-products-determining-established-pharmacologic-class-for-use-in-the-highlights-of-prescribing-information/40f1843c-d877-44dc-814b-63c7e743d168 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-blood-establishments-training-of-back-up-personnel-assessment-of-blood-donor-suitability-and-reporting-certain-changes-to-an-approved-application-guidance-for-industry/0b22b08c-0e57-453c-94b8-5d8c5ef6eb1d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-use-of-mechanical-calibration-of-dissolution-apparatus-1-and-2-current-good-manufacturing-practice-cgmp-guidance-for-industry/ef93735a-5356-4653-8ad9-95b2268f53a2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects-guidance-for-industry/dc67997f-c9df-498a-a890-8685c27397e2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/new-contrast-imaging-indication-considerations-for-devices-and-approved-drug-and-biological-products-guidance-for-industry/53827c26-7bc8-4348-a114-e4c7c1bb9ae2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-allogeneic-pancreatic-islet-cell-products-guidance-for-industry/6b1f2a33-5292-47b8-8e57-b821eba6fa0b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/microbiological-data-for-systemic-antibacterial-drug-products-development-analysis-and-presentation/7dedd6ea-e14b-4895-8669-b06331204496 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-of-nonprescription-human-drug-products-marketed-without-an-approved-application-as-required-by-the-dietary-supplement-and-nonprescription-drug-consumer-protection-act-questions-and-answers/ab547dc3-9724-4072-b1cd-f90728d300e3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/information-request-and-discipline-review-letters-under-the-prescription-drug-user-fee-act-guidance-for-industry/5d11a441-b244-476c-b428-3563a82f2f80 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-211-residual-solvents-in-animal-drug-products-questions-and-answers/9781e148-95e8-460b-a7c3-cbef9ad9cd69 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/interpreting-sameness-of-monoclonal-antibody-products-under-the-orphan-drug-regulations/31a4f2ab-649f-4be4-af24-4229e9d753c7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-for-the-evaluation-of-combination-vaccines-for-preventable-diseases-production-testing-and-clinical-studies-guidance-for-industry/c4cd1aec-70c4-4a85-a37c-f9b90e15c425 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pharmaceutical-components-at-risk-for-melamine-contamination-guidance-for-industry/b67e8a1e-249f-4a0f-b5e4-4c87ca550b18 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/frequently-asked-questions-irb-registration-guidance-for-institutional-review-boards-irbs/7a3de4e3-164a-476e-983c-437126be73f7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-198-vich-gl45-bracketing-and-matrixing-designs-for-stability-testing-of-new-veterinary-drug-substances-and-medicinal-products/b2813b0d-4ce6-4f96-9eb8-aac1bd24c6bc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fda-guidance-document-concerning-use-of-pilot-manufacturing-facilities-for-the-development-and-manufacture-of-biological-products/d98f4363-07c5-4cc7-a8ff-82c072cb88b2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-annex-10-polyacrylamide-gel-electrophoresis-general-chapter/8900a464-0070-4075-99d0-5b392f6c2102 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-annex-9-tablet-friability-general-chapter/b478aba0-879f-4d09-8950-143b7ae131fd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-199-animal-generic-drug-user-fees-and-fee-waivers-and-reductions/6fc52a11-514e-4e9d-90b6-c79ef576ec6f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/labeling-otc-human-drug-products-small-entity-compliance-guide-guidance-for-industry/3f5cd376-fd4d-4e8f-9dee-98aab670f72f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-providing-regulatory-submissions-to-cber-in-electronic-format-investigational-new-drug-applications-inds-pdf/8570d177-c5f6-48b3-9e31-b55fcf3ec212 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/technical-considerations-for-pen-jet-and-related-injectors-intended-for-use-with-drugs-and-biological-products-guidance-for-industry-and-fda-staff/ebb20b67-02d8-40a7-918e-388086ac1c10 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/compliance-policy-regarding-blood-and-blood-component-donation-suitability-donor-eligibility-and-source-plasma-quarantine-hold-requirements-guidance-for-industry/069f2c62-fbff-4ee9-af16-027d5e3e75a2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/radioactive-drug-research-committee-human-research-without-an-investigational-new-drug-application/f573b8cb-8d40-4beb-818f-4d2e16361206 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/integrated-summaries-of-effectiveness-and-safety-location-within-the-common-technical-document/d5fec113-5b34-45f5-bbbd-3dfd74cb580b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/label-comprehension-studies-for-nonprescription-drug-products/db55d737-aeaa-4c66-b24c-5295ebc3bf15 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submission-of-summary-bioequivalence-data-for-abbreviated-new-drug-applications/c8804eda-e868-4190-aaf3-700e3b13cf9e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/voting-procedures-for-advisory-committee-meetings-guidance-for-fda-advisory-committee-members-and-fda-staff/6f311baf-9f4e-4bc8-95be-70295fc11923 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/information-sheet/significant-risk-and-nonsignificant-risk-medical-device-studies-guidance-for-irbs-clinical-investigators-and-sponsors/bdf7fe5d-6ac5-437c-ada1-e0c1413282af 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/preparation-and-public-availability-of-information-given-to-advisory-committee-members-guidance-for-industry/7f43f696-9968-424a-adfe-f0d2b562e1d3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/information-sheet/frequently-asked-questions-about-medical-devices-guidance-for-irbs-clinical-investigators-and-sponsors/6df437c3-2cfc-4817-95b7-e25b39645763 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/industry-supported-scientific-and-educational-activities-guidance-for-industry/29bb320f-df04-429b-9a00-dd5726c2b7e6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/irb-review-of-stand-alone-hipaa-authorizations-under-fda-regulations-guidance-for-industry/8363a117-564d-4f47-9897-7aea13a1ef9f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/changes-to-an-approved-application-for-specified-biotechnology-and-specified-synthetic-biological-products/cb3f7a7e-cd25-442c-b55c-ea551ae637f8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-use-of-clinical-holds-following-clinical-investigator-misconduct-guidance-for-industry-and-clinical-investigators/8baa9e6b-d386-4460-927e-2aa353d1ce2b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/information-sheet/fda-institutional-review-board-inspections-guidance-for-irbs-clinical-investigators-and-sponsors/9ff5e55d-57b2-4daf-860d-a115f7c000b9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/information-sheet/fda-inspections-of-clinical-investigators-guidance-for-irbs-clinical-investigators-and-sponsors/592d1927-3441-4de6-a968-71ff4dd6c420 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/information-sheet/waiver-of-irb-requirements-for-drug-and-biological-product-studies-guidance-for-sponsors-clinical-investigators-and-irbs/409bb967-d13b-4e0e-a277-2a2382de216e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-540370-fish-and-fishery-products-decomposition/5001aff7-058f-4ed4-962c-e3c649eef584 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/community-acquired-bacterial-pneumonia-developing-drugs-for-treatment/377d93dd-9e6b-491f-92e9-51b07893cc2b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/data-retention-when-subjects-withdraw-from-fda-regulated-clinical-trials-guidance-for-sponsors-clinical-investigators-and-irbs/3358ed6a-403d-4aaa-b66c-941d2d2630ab 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525425-hops-adulteration-involving-aphid-infestation/6de7af4e-d7f9-4c52-8eeb-a7d07ce19bcf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-300400-contamination-of-devices-labeled-as-sterile/154bf882-2c65-4bfc-9c03-77636e27d7e9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-197-documenting-electronic-data-files-and-statistical-analysis-programs/2907964f-43aa-4edd-abc8-8ef3d94c7f16 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/quality-control-guide-for-sunlamp-products-fda-88-8234/b3011663-c501-41b1-aa76-7faad0ddab28 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/changes-to-an-approved-nda-or-anda-questions-and-answers-guidance-for-industry/35e76fcd-a993-489c-8472-73c4bbb60d94 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-230150-blood-donor-classification-statement-paid-or-volunteer-donor/df993591-aa0e-4f91-8fc9-cee02b4bf336 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-the-submission-of-cabinet-x-ray-system-reports-pursuant-to-21-cfr-102040/58b9ffd0-8de3-436e-a7fe-127025d7542e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-187a-heritable-intentional-genomic-alterations-in-animals-risk-based-approach/068d4f48-5472-4552-9b8d-ac8afa26e0eb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submission-and-review-of-sterility-information-in-premarket-notification-510k-submissions-for-devices-labeled-as-sterile-guidance-for-industry-and-food-and-drug-administration-staff/f615a298-5533-4084-b9bc-068bd55bb558 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-regulatory-requirements-for-medical-devices-fda-89-4203/2529e098-29ec-403e-8ab0-0b4f285bdd9e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/policy-on-warning-label-required-on-sunlamp-products/cf45758a-029e-43cb-8b74-6be30ca148e6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/eligibility-determination-for-donors-of-human-cells-tissues-and-cellular-and-tissue-based-products-guidance-for-industry/0d6f6da3-08eb-4791-955b-cdd563d3459c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-annex-8-sterility-test-general-chapter/57bbe37d-471a-448c-be4d-256b4d649c8b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/potassium-iodide-tablets-shelf-life-extension/29b94bfa-95fe-4703-8a41-83a393bc407b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/180-day-generic-drug-exclusivity-under-the-hatch-waxman-amendments-to-the-federal-food-drug-and-cosmetic-act/99b50bce-632e-41dc-871f-60d4142d9386 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/potassium-iodide-ki-in-radiation-emergencies-questions-and-answers/6106cb9d-2ae0-4039-8532-90c264cc0d57 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/potassium-iodide-as-a-thyroid-blocking-agent-in-radiation-emergencies/37bc2102-9236-47bf-a1a3-6fbb42443ab7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postmarketing-adverse-event-reporting-for-medical-products-and-dietary-supplements-during-a-pandemic/98000d9a-b1f7-4dbc-8bf5-8079e3a4b3a7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-otc-human-drug-products-questions-and-answers/fb79c331-5c94-4c61-a511-0271991af946 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-on-premarket-notification-510k-submissions-for-automated-endoscope-washers-washerdisinfectors-and-disinfectors-intended-for-use-in-health-care-facilities/b1565cbf-b93e-4897-b812-8ef664f08d50 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pharmacogenomic-data-submissions-companion-guidance/26f5c4db-2ae3-46b8-ae62-dbb909250a16 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pharmacogenomic-data-submissions-guidance-for-industry/1d145832-ef9c-4b45-b5aa-8c828660e984 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/user-fee-waivers-for-fdc-and-co-packaged-hiv-drugs-for-pepfar/13c7af5f-84b1-4023-80d0-9ff6cb3357dc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-human-somatic-cell-therapy-and-gene-therapy-guidance-for-industry/b844f825-dbbe-4785-ba4e-22a7419de17b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-deferral-of-donors-and-quarantine-and-retrieval-of-blood-and-blood-products-in-recent-recipients-of-smallpox-vaccine-vaccinia-virus-and-certain-contacts-of-smallpox-vaccine-recipients-guidance-for-industry/c33bb8dd-f8da-49c0-83d6-9512639e68cc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submitting-separate-marketing-applications-and-clinical-data-for-purposes-of-assessing-user-fees-guidance-for-industry/2c9aed18-87e7-4700-8c3b-593f58e268e8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-on-premarket-notification-510k-submissions-for-surgical-gowns-and-surgical-drapes/118e833d-a32a-4db6-ac38-5ca74f146e5d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/levothyroxine-sodium-products-enforcement-of-august-14-2001-compliance-date-and-submission-of-new-applications/2d5e2030-11b1-4414-8987-9ca957a899b5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/user-fee-waivers-reductions-and-refunds-for-drug-and-biological-products/ff74c3d1-95d4-4808-9bba-25a26706e7e4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/statistical-aspects-of-the-design-analysis-and-interpretation-of-chronic-rodent-carcinogenicity-studies-of-pharmaceuticals/f8ef1e83-587f-48eb-8b42-d6a9e1d3b934 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-recommendations-for-the-assessment-of-donor-suitability-and-blood-product-safety-in-cases-of-suspected-severe-acute-respiratory-syndrome-sars-or-exposure-to-sars/c0e0abf6-5a1e-422e-a51d-6fce1784f489 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/sterility-requirement-for-aqueous-based-drug-products-for-oral-inhalation-small-entity-compliance-guide-guidance-for-industry/33082e5b-df1e-4fc3-85e2-71ff153869f4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/for-the-submission-of-chemistry-manufacturing-and-controls-and-establishment-description-information-for-human-blood-and-blood-components-intended-for-transfusion-or-for-further-manufacture-and-for-the-completion-of-the-form-fda-356h-guidance-for-industry/d1bfc306-a5de-418b-9ff7-574608916a68 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/carcinogenicity-study-protocol-submissions/1b1fc892-689b-49f0-b1a2-a339b7cf1bd3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/adverse-event-reporting-to-irbs-improving-human-subject-protection-guidance-for-clinical-investigators-sponsors-and-irbs/8b4e7049-16fc-40f8-b121-81ece765bc26 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s7b-nonclinical-evaluation-of-the-potential-for-delayed-ventricular-repolarization-qt-interval-prolongation-by-human-pharmaceuticals/816481d6-42de-481e-8388-3a53fc8330cc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-on-the-content-and-format-of-premarket-notification-510k-submissions-for-sharps-containers/0151098f-ad84-4c30-9c2a-96d282f9afc8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommended-approaches-to-integration-of-genetic-toxicology-study-results/9df3bcde-34b4-434c-9610-221248544f22 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/hysteroscopes-and-gynecology-laparoscopes-submission-guidance-for-a-510k/c1fc6946-cdb7-49b0-b02f-8dac87105448 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/how-to-comply-with-the-pediatric-research-equity-act/beb13ca3-608c-4121-93d4-787450c752ba 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-studies-for-the-safety-evaluation-of-pharmaceutical-excipients/52563b0e-f99a-4a3b-99a6-14ce0e27cbdb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/good-review-management-principles-and-practices-for-new-drug-applications-and-biologics-license-applications-draft-guidance-for-industry-and-review-staff/d4716fc0-3257-42cf-a1c9-4c6c329dd8d1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/fixed-combinations-and-single-entity-versions-of-previously-approved-antiretrovirals-for-the-treatment-or-prevention-of-human-immunodeficiency-virus-one-under-the-presidents-emergency-plan-for-acquired-immunodeficiency-syndrome-relief/a7806ed2-daae-4932-9169-94ac075dfc10 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/applications-covered-by-section-505b2/5f0df47f-0a4f-498e-9b76-34682f4067f5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pet-drug-applications-content-and-format-for-ndas-and-andas_2011/e18062f8-4070-443b-844c-6a15b3b63ab0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/drug-products-containing-ensulizole-hypromellose-meradimate-octinoxate-and-octisalate-labeling-enforcement-policy/4320b2a8-6f77-4cbf-8a20-7b9631fcf4fe 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-to-reduce-the-risk-of-transfusion-transmitted-malaria-guidance-for-industry/eb835388-a1e0-46db-8c55-61853bcee91b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-evaluation-of-late-radiation-toxicity-of-therapeutic-radiopharmaceuticals/92fb275a-6c59-437b-9f82-274a46b009a0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bone-anchors-premarket-notification-510k-submissions-guidance-for-industry-and-food-and-drug-administration-staff/ecebeef9-bd5e-43bd-9095-8e59eec25be9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-evaluation-of-the-immunotoxic-potential-of-pharmaceuticals/160dff53-faf3-4095-b37e-414e108646cf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/third-party-review-guidance-for-phacofragmentation-system-device-premarket-notification-510k/208fc4aa-f4fa-45a3-807e-5912105bfa60 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-otc-human-drug-products-using-a-column-format/538c56e4-5604-47c8-9451-300e5f66cf8f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/disclosure-of-materials-provided-to-advisory-committees-in-connection-with-open-advisory-committee-meetings-convened-by-the-center-for-drug-evaluation-and-research-beginning-on-january-1-2000/5a2404db-656a-47a4-82ff-0e680fbd2c76 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/implementing-a-collection-program-for-source-plasma-containing-disease-associated-and-other-immunoglobulin-igg-antibodies-guidance-for-industry/4e8d104c-9a57-4ff5-99e6-5470b29e9cfa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/on-the-content-and-format-of-chemistry-manufacturing-and-controls-information-and-establishment-description-information-for-an-allergenic-extract-or-allergen-patch-test-guidance-for-industry/c411f736-f8ed-4ad6-9c31-a59e9cfb753e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/safety-efficacy-and-pharmacokinetic-studies-to-support-marketing-of-immune-globulin-intravenous-human-as-replacement-therapy-for-primary-humoral-immunodeficiency-guidance-for-industry/fdf54353-36d9-4ac5-9115-08d310cb7de6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/time-and-extent-applications-for-nonprescription-drug-products/08491a11-f749-4a9d-82fc-6a6d13776eb7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nucleic-acid-testing-to-reduce-the-possible-risk-of-parvovirus-b19-transmission-by-plasma-derived-products-guidance-for-industry/61270a0b-4323-4d9d-8dab-c2b9ea3aaf2c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-review-and-inspection-of-premarket-approval-application-manufacturing-information-and-operations-guidance-for-industry-and-fda-staff/4055fb7b-9286-4de8-80b0-10744950a3e2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dosage-and-administration-section-of-labeling-for-human-prescription-drug-and-biological-products-content-and-format/e2343785-81a2-4852-aba8-7ffd3a086deb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-studies-section-of-labeling-for-human-prescription-drug-and-biological-products-content-and-format-guidance-for-industry/8675c759-b657-4818-9bed-199de1148828 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-578300-wheat-adulteration-by-insect-and-rodent-filth/e6c99eb1-fc02-48ce-8a9c-ef03fb36cb4d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-578200-corn-meal-adulteration-by-insect-and-rodent-filth/84462c24-bc4e-485c-9d06-c87eeec3f369 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-570425-tree-nuts-adulteration-involving-rejects-insect-infestation-moldy-rancid-otherwise-decomposed-blanks-and-shriveled/d6f87baa-8b59-412a-866f-3382112978e7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-570375-aflatoxins-in-peanuts-and-peanut-products/1974d9fe-d0a5-49cb-9c49-b5549b668e17 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-420100-adulteration-of-drugs-under-section-501b-and-501c-of-the-act-direct-reference-seizure-authority-for-adulterated-drugs-under-section-501b/791ed12f-d37a-45b2-aa57-4f44be4a0bb0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-570300-peanut-butter-adulteration-with-filth-grit/a5fe7e62-92d9-4da0-95e3-0e9a480fa43a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s8-immunotoxicity-studies-for-human-pharmaceuticals/216b9605-e0e0-4dd4-a10b-a51326a268f5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-540590-fish-fresh-and-frozen-as-listed-adulteration-by-parasites/de1aebd7-1e77-48e3-af52-09a3ce1637a5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s7a-safety-pharmacology-studies-for-human-pharmaceuticals/c2197d79-8cb4-464d-8ff4-dbacbcbfef6f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-450100-cgmp-enforcement-policy-otc-vs-rx-drugs/6959da49-928a-4911-a365-25cde7f2ee1a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-448100-reconditioning-of-new-drugs-which-do-not-have-approved-ndasandas/8b00aab0-ef69-48f1-a96d-a601a29bce42 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-555880-guidance-levels-for-radionuclides-in-domestic-and-imported-foods/c1e68336-91a9-4165-a2bc-5bbe7a3f3b90 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-560400-imported-milk-and-cream-federal-import-milk-act/a0e2e142-f655-417e-8794-a65d498bef05 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s4a-duration-of-chronic-toxicity-testing-in-animals-rodent-and-nonrodent-toxicity-testing/274c345e-d541-42de-a26c-85fefde1aa9e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-527200-cheese-cheese-products-adulteration-with-filth/5c824b10-f106-43d8-a29d-0e3ec725c50e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s2b-genotoxicity-a-standard-battery-for-genotoxicity-testing-of-pharmaceuticals/39dc5532-49cc-4723-ab60-cea50fce93fd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550850-strawberries-frozen-whole-or-sliced-adulteration-with-sand-mold/6ad729bc-28d9-4a98-a250-25359ab9d0aa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-555550-foods-standardized-enriched-or-fortified-adulteration-involving-misbranding-potency/7938659e-7420-41c2-bc4c-79b9df757a04 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-555500-all-food-sanitation-including-bacteriological-inspections-classification-of-establishment/603f2391-6ecc-44cb-b182-0f3472a962ff 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525950-whole-plant-unprocessed-sage-and-ground-sage-adulteration-by-insect-and-rodent-filth-mold-mammalian-excreta/e691cc3d-d330-4bf7-9d85-f463c0d4c831 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-615115-extralabel-use-of-medicated-feeds-for-minor-species/a444ce96-2a30-430d-a840-c493ff9189f8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525925-whole-plant-unprocessed-thyme-unground-processed-thyme-ground-thyme-adulteration-by-insect-rodent-filth-mold-mammalian-excreta/53c64c63-e9ec-4a43-9748-9c61248a3c04 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550750-raisins-adulteration-involving-mold-sand-grit-insects/235040a2-27c6-43b7-b03d-c47662ebb3b6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-272-practices-to-prevent-unsafe-contamination-of-animal-feed-from-drug-carryover/335e5317-2d85-4437-9111-0208112a6240 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-555425-foods-adulteration-involving-hard-or-sharp-foreign-objects/7873f9fc-88d9-4fdf-ac49-e430a04720ca 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-555300-foods-except-dairy-products-adulteration-with-salmonella/c1b1253f-3693-45b9-b850-1c3bede1c538 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s1cr2-dose-selection-for-carcinogenicity-studies-of-pharmaceuticals/2a345429-ca02-44f7-82b1-69aca91cb8e5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525850-whole-plant-unprocessed-oregano-crushed-oregano-ground-oregano-adulteration-by-insect-rodent-filth-mold-mammalian-excreta/35dda4bb-e69e-4be0-930f-6a2db02de0d2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-555250-statement-of-policy-for-labeling-and-preventing-cross-contact-of-common-food-allergens/d1787e77-a49d-4eb4-a115-a5c03534ce5f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550700-dried-prunes-dehydrated-low-moisture-prunes-and-pitted-prunes-adulteration-involving-insects-decomposition-dirt-pits-and-pit-fragments/07f747a9-2a10-4398-8835-f8014168ed8c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525350-fennel-seed-adulteration-by-mammalian-excreta-insects/ff88e709-bde7-4993-b383-c6c2abf59580 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585825-sweet-potatoes-dyeing-of-yellow-and-red-varieties/c828b8b3-2157-4107-a8d6-9a7f487abcc9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525330-curry-powder-adulteration-by-insect-and-rodent-filth/ee1ac9b5-74c7-4817-ada7-65cc6e8a1436 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550600-olives-adulteration-involving-pits-rot-insect-infestation/a530ccee-238b-4cb9-93e1-ed252b763cc7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/public-availability-of-labeling-changes-in-changes-being-effected-supplements/0cd869a7-e345-4545-b817-9cde8e7c7438 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-345100-condoms-defects-criteria-for-direct-reference-seizure/d9038b63-111c-4f8c-b202-80355330e839 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585675-popcorn-adulteration-with-rodent-filth-and-field-corn/18be14d7-e020-4121-a3e8-b14a07e7b11e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525225-whole-cassia-or-whole-cinnamon-ground-cinnamon-adulteration-by-insect-and-rodent-filth-mold-mammalian-excreta/49a2ea50-aed6-4d6b-9b7f-97a9583f265d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/changes-to-an-approved-nda-or-anda-guidance-for-industry/be4b40e4-e346-4d56-a97f-7b0099c36302 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550590-cloudberries-multer-berries-canned-adulteration-by-insects/08d3d227-0eb4-4eea-9950-5d496212638f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585575-peas-and-beans-dried-adulteration-involving-storage-insect-damage-rocks/907c122c-9330-4a99-9a91-6c8a038a1fcd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-human-prescription-drug-and-biological-products-implementing-the-plr-content-and-format-requirements/c135cd21-e316-4f76-b282-cd06416c3081 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550500-lingon-berries-canned-adulteration-by-insects/3a30893b-6258-4d8c-a35a-2f15b0808f9e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585475-canned-green-beans-and-canned-wax-beans-misbranding-involving-food-standards/feb03510-ef09-4f07-b2da-3a0eb5618bc2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-355200-electrical-muscle-stimulators/5522cd3d-5f57-4caa-ac5f-214ee7438bc6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/hypertension-indication-drug-labeling-for-cardiovascular-outcome-claims/79efdd86-3643-466c-8fe3-82b6ad2e95ff 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-515100-confectionery-use-of-non-nutritive-substances-as-ingredients/3084ec39-35c8-4959-92e4-76931d956095 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585400-cowpeas-black-eyed-peas-canned-succulent-peas-adulteration-by-insects/0c027b08-f9ad-400f-afb6-9f77f1436566 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-515750-cocoa-beans-adulteration-by-mold-insect-infestation-and-mammalian-excreta/57e4f223-cbaf-4b3e-a5ed-50ac7c9a6e82 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550300-dates-and-date-material-imported-and-domestic-adulteration-involving-mold-insect-excreta-sour-dirty-worthless-and-pits/77ec215a-eef4-46d8-91aa-63a251cf0eb0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-515700-chocolate-chocolate-liquor-adulteration-with-insect-and-rodent-filth/9970f39d-9b7e-4833-a8c3-73ec56eab675 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-335800-clinical-thermometer-adulteration-misbranding-defects/c418493c-65ed-4b0b-aa23-1092344d6c77 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585300-corn-sweet-canned-adulteration-by-corn-ear-worms-corn-borers/71b8b447-a614-4996-b189-80a924837a34 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550250-citrus-fruit-juices-canned-adulteration-with-fly-filth-and-mold/a4da913c-0a9b-4109-a919-9ec8825bf42c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-the-submission-of-510ks-for-solid-state-x-ray-imaging-devices-guidance-for-industry-and-food-and-drug-administration-staff/524eeb43-9618-4c8e-a0f5-4147c634ca2b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550235-cherry-jam-adulteration-with-mold/576c0f4b-6a7e-4854-a7f1-311cda9f0757 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585275-brussels-sprouts-frozen-adulteration-by-insects/8eacecb7-7998-4f5e-8d2b-20480c9e00de 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/off-the-shelf-software-use-in-medical-devices-guidance-for-industry-and-food-and-drug-administration-staff/e6562455-523c-4460-ae34-ee4678a33a70 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585260-broccoli-frozen-adulteration-with-insects/a32faa00-df6f-4668-ab73-9cf328422e7e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550230-cherries-canned-misbranding-involving-food-standards/fc727738-16e7-4491-b6a9-3dc631650166 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-315100-illegal-interstate-commercial-shipment-of-dentures-cpg-retitled-and-revised-5192005/68186d82-83e8-4cde-a99f-9fc618c396af 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q3c-appendix-4/a45d847e-e29f-4d1f-b7b5-a6cdef4c96e4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-545300-foods-rail-car-sanitation-adulteration/6df61982-67a0-4b3f-a450-880304bd60a0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585225-black-eyed-peas-cow-peas-field-peas-dried-adulteration-with-lygus-bug-damage/ea51d680-624d-4984-92ad-27851edbcac2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550200-drupelet-berries-blackberries-raspberries-etc-common-or-usual-names-of-varieties-canned-and-frozen-adulteration-with-rot-and-insects/868a5bdb-c57c-4ee8-bcfa-b0768c351fde 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-510500-green-coffee-beans-adulteration-with-insects-mold/7fa3c426-2a3b-4984-979c-a26d6e31ab1f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550155-apricot-peach-and-pear-nectars-and-purees-adulteration-with-mold/017563e8-fc66-42c5-8777-90969eef5987 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-550100-apple-butter-adulteration-with-mold-rodent-filth-insect/a7fbc756-fe89-4e40-960f-a0908ffe287e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-505500-macaroni-and-noodle-products-adulteration-involving-insect-fragments-and-rodent-hairs/0f418a8d-eaed-44d7-8d95-b6c4eeac2f30 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-document-for-premarket-notification-submissions-for-nitric-oxide-delivery-apparatus-nitric-oxide-analyzer-and-nitrogen-dioxide-analyzer-guidance-for-industry-and-for-fda-reviewers/2a219aad-8a12-4304-ae5a-e38064f0898b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-clinical-evidence-of-effectiveness-for-human-drug-and-biological-products/fd879dfd-f86c-47c3-8e1b-50cf2ede120b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/crohns-disease-developing-drugs-for-treatment/10ab5c94-72ed-489d-b2cc-24cf6914fed5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-545400-pottery-ceramics-import-and-domestic-cadmium-contamination/ebac333e-7752-4c52-95b6-e56250e726ca 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-500500-guidance-levels-for-3-mcpd-3-chloro-12-propanediol-in-acid-hydrolyzed-protein-and-asian-style-sauces/5f3d607b-dc4e-40f4-8ba2-476335a3053d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-250500-plasma-brokers-registration-and-compliance-with-good-manufacturing-practices-is-obsolete-and-was-withdrawn-on-7162018/e7a306c2-1184-4c80-ba98-55a36c16cf96 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-230140-evaluation-and-processing-post-donation-information-reports-is-obsolete-and-was-withdrawn-on-7162018/01acc8fc-6c5e-49f8-8c19-0e72e4fc378f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/developing-and-responding-to-deficiencies-in-accordance-with-the-least-burdensome-provisions-guidance-for-industry-and-food-and-drug-administration-staff/f64095a4-5200-4444-9165-1fce442e2bea 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q3br-impurities-in-new-drug-products-revision-3/a2e10295-fed5-4751-9af6-54da8d5c29c3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q2b-validation-of-analytical-procedures-methodology/582c54c8-1b4b-41ac-9986-b492b25f4794 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q1e-evaluation-of-stability-data/e4413f7a-4a88-4baf-b13c-f5314f2b7f64 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q1d-bracketing-and-matrixing-designs-for-stability-testing-of-new-drug-substances-and-products/b98c22b1-6e33-4f5b-a59c-3fcc41d1104c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/internal-radioactive-contamination-development-of-decorporation-agents/2c9ecc52-8f94-400c-a1be-8bf28a25e1a8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q1b-photostability-testing-of-new-drug-substances-and-products/e6b04732-10d6-4998-b8d0-6dff64f41474 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-560200-country-of-origin-labeling/07f3578e-edb1-4831-abe6-d58fb2148fa3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q1ar2-stability-testing-of-new-drug-substances-and-products/91828b9f-0f69-4b32-8309-b0a7cc4ba7f1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submitting-marketing-applications-according-to-the-ichctd-format-general-considerations/aab838ec-4495-4d46-a53a-ccd911049363 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m5international-conference-on-harmonisation-draft-guidance-on-m5-data-elements-and-standards-for-drug-dictionaries/d4c223eb-7ce8-43b0-9cf7-93a7d505c695 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m4-organization-of-the-common-technical-document-for-the-registration-of-pharmaceuticals-for-human-use-guidance-for-industry/e5a79d19-73aa-4d4c-baa8-342b5ddc7632 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-535100-oleomargarine-misbranding-due-to-insufficient-fat/c91e9a0b-9f80-45f3-a039-9fcde7be0fa0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m4-the-ctd-safety-questions-and-answers/3d7d73b1-cced-46a8-bc54-4914a6e06b8f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m4-the-ctd-quality-questions-and-answers-location-issues/54201b6e-7365-4e4e-afaf-20db7e53cfb8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/tonometers-premarket-notification-510k-submissions-guidance-for-industry-and-fda-staff/7a4f3ea0-cf3f-4b6f-89b0-40797b32e704 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/levothyroxine-sodium-tablets-in-vivo-pharmacokinetic-and-bioavailability-studies-and-in-vitro-dissolution-testing/74b4ee28-e27e-400e-8b87-ba8701d4ea31 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m4-the-ctd-quality/f1d6bf08-fc2b-4ab2-9d7f-10463d955fed 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m4-the-ctd-general-questions-and-answers/84e702f8-2534-4e9e-a14b-d644b13bd0d2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/investigational-device-exemptions-ides-for-devices-indicated-for-nocturnal-home-hemodialysis-guidance-for-industry-and-fda-staff/7c63ae38-9eff-4af8-8dcd-c0612c8198e2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pharmacogenetic-tests-and-genetic-tests-for-heritable-markers-guidance-for-industry-and-fda-staff/2f7c5ab1-2d7a-491f-af6a-ba14f6a18f4f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q10-pharmaceutical-quality-system/8532cdab-836f-4123-9c43-575d6d0cd0d9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/m3r2-nonclinical-safety-studies-for-the-conduct-of-human-clinical-trials-and-marketing-authorization-for-pharmaceuticals/fab84a39-1f07-487f-ae13-2eb2b1884d18 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q5d-quality-of-biotechnologicalbiological-products-derivation-and-characterization-of-cell-substrates-used-for-production-of-biotechnologicalbiological-products-availability/aefa81fa-3759-44d3-89fb-1df4d46b4346 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/estrogen-and-estrogenprogestin-drug-products-to-treat-vasomotor-symptoms-and-vulvar-and-vaginal-atrophy-symptoms-recommendations-for-clinical-evaluation/729d676c-05c7-4f9b-bfcd-77ed841b485f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-recommendations-for-single-use-devices-reprocessed-by-third-parties-and-hospitals-final-guidance-for-industry-and-fda/ca510d51-2927-4aef-9724-b0f778a2572a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pharmacokinetics-in-patients-with-impaired-hepatic-function-study-design-data-analysis-and-impact-on-dosing-and-labeling/578ee829-2b5f-40bd-8dca-59c140a08ef9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/population-pharmacokinetics-guidance-for-industry/acd44982-2fd1-4119-a9f0-697ef34947f3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e12a-principles-for-clinical-evaluation-of-new-antihypertensive-drugs/a715b1f0-1946-46b1-8a7f-cd01a428224d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/sterilized-convenience-kits-for-clinical-and-surgical-use-final-guidance-for-industry/846db4af-4bb9-4918-8029-7ccc1b1b1d8a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e11-clinical-investigation-of-medicinal-products-in-the-pediatric-population/22e34547-3d8e-42d2-a67f-98b794654491 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pharmacokinetics-in-pregnancy-study-design-data-analysis-and-impact-on-dosing-and-labeling/08e99d11-48f5-4d96-a72c-c66cde9d04ca 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/obesity-and-overweight-developing-drugs-and-biological-products-for-weight-reduction/d3075b32-e4bf-4368-aa3d-a04e7457ded0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/andas-impurities-in-drug-products-guidance-for-industry/1729c807-7b92-415c-a307-05a491b55e63 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/quality-assurance-guidelines-for-hemodialysis-devices/3ba771d9-7f22-406c-abae-c98b652a56fa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e9-statistical-principles-for-clinical-trials/d427b5ed-dd16-417e-adc2-9f35d3a3df23 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-on-the-department-of-defense-exemption-from-the-fda-performance-standard-for-laser-products-guidance-for-industry-and-fda/79d5dd39-c8e1-45cb-a96e-12b6a7dba5bf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/alternate-source-of-the-active-pharmaceutical-ingredient-in-pending-andas-guidance-for-industry/8a3da1bc-1ebb-48aa-a3ea-7662562c4370 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e7-studies-in-support-of-special-populations-geriatrics/c911e3e2-106e-4e5a-88dd-39137953f07a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/complicated-urinary-tract-infections-developing-drugs-for-treatment/018382d5-5be6-4149-a89a-c2c59b0c9ad4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-annex-4c-microbiological-examination-of-non-sterile-products-acceptance-criteria-for-pharmaceutical-preparations-and-substances-for-pharmaceutical-use-general-chapter/37fd4de1-74d0-4064-8a99-bce4a2f3600f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cancer-drug-and-biological-products-clinical-data-in-marketing-applications/46d12435-8972-4d63-a8eb-3c3d753c0178 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency-guidance-for-submitting-hcv-resistance-data/3b53e257-72e5-402a-9e6e-a5abd8c1a7a8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/human-gene-therapy-products-incorporating-human-genome-editing-guidance-for-industry/176eb36a-08ad-4533-8261-d03967d6aef6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/development-and-use-of-risk-minimization-action-plans-guidance-for-industry/0c2f3726-2538-48fb-815a-44b28e56a090 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-annex-4b-microbiological-examination-of-non-sterile-products-tests-for-specified-micro-organisms-general-chapter/a3b06fde-b682-4b31-b079-32820415d5aa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency-guidance-for-submitting-influenza-resistance-data/88713cca-c233-4559-9c7c-6699ccbcfc65 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-evaluation-and-recommendation-of-pharmacopoeial-texts-for-use-in-the-international-conference-on-harmonisation-regions/ed4cda87-18d7-4f82-acd8-1d3fee51bdc8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-annex-4a-microbiological-examination-of-non-sterile-products-microbial-enumeration-tests-general-chapter/43eb7a00-2df4-4386-ba3e-ebe72023f2e3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/developing-medical-imaging-drug-and-biological-products-part-3-design-analysis-and-interpretation-of-clinical-studies/560bad6d-d575-4a09-84e7-a396f541a476 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency-guidance-for-submitting-hiv-resistance-data/8e09b2a7-3993-4541-b20f-ea130a547e62 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-annex-3-test-for-particulate-contamination-subvisible-particles-general-chapter/cb170fcf-d00e-41cf-bc04-eee9003e8914 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e2d-postapproval-safety-data-management-definitions-and-standards-for-expedited-reporting/34c1364c-ea36-4314-8bc7-bb62b5e1de2f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/developing-medical-imaging-drug-and-biological-products-part-2-clinical-indications/b799f895-2a25-481d-85aa-d8b5f1322a85 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency/81122360-623f-492b-84a2-d1ef7e31728f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/spl-standard-for-content-of-labeling-technical-qs-as/9b83f17b-5c76-4f6d-b007-379c81321c8b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/writing-dear-doctor-letters-for-recalls-of-implantable-cardioverter-defibrillators-icds-guidance-for-industry-and-fda-staff/b201ddec-7524-4c88-83c1-06dd21028263 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/content-and-format-of-investigational-new-drug-applications-inds-for-phase-1-studies-of-drugs-including-well-characterized-therapeutic-biotechnology-derived-products-guidance-for-industry/ecc5878c-4062-49df-90cc-6ac91b3adb4c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/user-labeling-for-devices-that-contain-natural-rubber-21-cfr-801437-small-entity-compliance-guide-guidance-for-industry/d15d7f42-6f5a-4854-a5fd-0034f22ff9e2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/decorative-non-corrective-contact-lenses-guidance-for-industry-fda-staff-eye-care-professionals-and-consumers/236bd2e1-e002-4963-91a8-13ae3707a29c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585200-beets-canned-adulteration-with-rot/c1d2c0b2-3e29-411f-bcc0-89307102a4a2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/biological-indicator-bi-premarket-notification-510k-submissions-guidance-for-industry-and-fda-staff/51018101-f28f-48a6-9a97-175cb14cee50 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/osteoarthritis-structural-endpoints-for-the-development-of-drugs/8fba9dbf-fb3b-42a9-8837-a2ce4870eba1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-in-electronic-format-content-of-labeling/23ae1483-3f18-4d5b-b4f8-4d2b84de3d6e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submission-of-abbreviated-reports-and-synopses-in-support-of-marketing-applications/0fb9e1c4-cf27-43e2-b137-274ade81a207 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-on-informed-consent-for-in-vitro-diagnostic-device-studies-using-leftover-human-specimens-that-are-not-individually-identifiable-guidance-for-sponsors-institutional-review-boards-and-food-and-drug-administration-staff/11476245-87f7-47f1-9524-579d0dd12cae 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/clinical-study-designs-for-catheter-ablation-devices-for-treatment-of-atrial-flutter-guidance-for-industry-and-fda-staff/2a32ad89-221f-44a9-9ef1-e5f95274621c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-electronic-anti-theft-systems-guidance-for-industry/bb4a941b-e1d9-48db-b2d3-d5e87921c34c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/integration-of-dose-counting-mechanisms-into-mdi-drug-products/b523d7a1-3c0a-423e-ac27-f899492e96ff 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/administrative-procedures-for-clia-categorization-guidance-for-industry-and-food-and-drug-administration-staff/f0ea1c64-f301-46d7-871d-775a1df357e5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q3ar-impurities-in-new-drug-substances/7e49ddae-0c3a-43e8-9c8a-ae972f01bd2b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/frequently-asked-questions-about-the-reprocessing-and-reuse-of-single-use-devices-by-third-party-and-hospital-reprocessors-final-guidance-for-industry-and-fda-staff/45a4854e-150d-4415-8273-25536f7884bd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/formal-dispute-resolution-scientific-and-technical-issues-related-to-pharmaceutical-cgmp/55274916-c795-40ce-a3f2-ca31e54f8053 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/expiration-dating-of-unit-dose-repackaged-solid-oral-dosage-form-drug-products-guidance-for-industry/4c952faf-8edd-43d6-961a-2d9c085959f9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/current-good-manufacturing-practice-for-phase-1-investigational-drugs-guidance-for-industry/179f8504-7c99-4bec-826e-e67ad9ce1f79 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/supac-ir-immediate-release-solid-oral-dosage-forms-scale-up-and-post-approval-changes-chemistry-manufacturing-and-controls-in-vitro-dissolution-testing-and-in-vivo-bioequivalence-documentation/d92f2615-a9dd-43a1-bed0-97946ea41dbf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/proposed-approach-to-regulation-of-cellular-and-tissue-based-products/d4c69ac2-d93b-4834-9b6f-c6a4c0387ab9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nasal-spray-and-inhalation-solution-suspension-and-spray-drug-products-chemistry-manufacturing-and-controls-documentation-guidance-for-industry/39c6d463-15aa-443b-847e-8eb8baa08474 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/metered-dose-inhaler-mdi-and-dry-powder-inhaler-dpi-drug-products-quality-considerations/c62dfac7-e8d8-48bb-833a-3c127bd90939 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-191-changes-to-approved-nadas-new-nadas-vs-category-ii-supplemental-nadas/33b97e61-bc96-497e-9004-842c9543f2f4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/inds-for-phase-2-and-phase-3-studies-chemistry-manufacturing-and-controls-information-guidance-for-industry/f47444ad-ffd7-42ea-816d-1d6da8a15bf1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/drug-master-files-for-bulk-antibiotic-drug-substances-guidance-for-industry/2638fcb2-869c-4214-8f7d-6403c9f7b75e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-95-vich-gl12-effectiveness-of-anthelmintics-specific-recommendations-for-bovines/f2399729-41b9-42ca-a631-0bb129d7963f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/container-closure-systems-for-packaging-human-drugs-and-biologics-questions-and-answers-guidance-for-industry/65c49013-89c0-4092-8da3-edd988fe933a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/container-closure-systems-for-packaging-human-drugs-and-biologics-guidance-for-industry/d244272d-47ee-46c6-acc3-fc70c8998f36 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/charging-for-investigational-drugs-under-an-ind-questions-and-answers/e6ac16bc-3e90-4996-b2e5-b9671d33c720 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/reporting-amount-of-listed-drugs-and-biological-products-under-section-510j3-of-the-fdc-act/f4a6fb80-fa17-454a-9560-0d01b8cf687d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-assessment-of-donor-suitability-and-blood-and-blood-product-safety-in-cases-of-possible-exposure-to-anthrax-guidance-for-industry/3c6a09c1-24ab-442b-b40a-2ab825c7ee4a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-menu-labeling-supplemental-guidance-edition-2/80b67880-b5b1-4ffd-9cca-b281c7923801 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/dissolution-testing-of-immediate-release-solid-oral-dosage-forms/8cc84e15-f9e6-4319-afe6-f59a882e535c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/premarket-notification-submissions-for-blood-and-plasma-warmers-guidance-for-fda-reviewers/96dda803-173e-4c80-8ebd-9cbbb5a52a80 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/premarket-notification-submissions-for-empty-containers-for-the-collection-and-processing-of-blood-and-blood-components-guidance-for-fda-reviewers/75446840-7ce2-4478-b4a8-0f84dbeae534 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cooperative-manufacturing-arrangements-for-licensed-biologics-guidance-for-industry/c6b65fcf-378f-4aaf-bb82-b1c028898fea 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q2r2-validation-of-analytical-procedures/2fb8b117-5251-4360-87db-a581ceb120a0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/certain-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-recovered-from-donors-who-were-tested-for-communicable-diseases-using-pooled-specimens-or-diagnostic-tests-guidance-for-industry/2badf630-8585-45e0-8caf-a8078914403e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/cvm-gfi-69-small-entities-compliance-guide-for-feeders-of-ruminant-animals-with-on-farm-feed-mixing-operations/b4a29fb3-4166-4e20-9545-c49a8385e5fe 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/bioanalytical-method-validation-guidance-for-industry/2bd6e05d-59f0-445b-b5b1-9e6c4f25eeef 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/regulation-of-human-cells-tissues-and-cellular-and-tissue-based-products-hctps-small-entity-compliance-guide-guidance-for-industry/9f906950-df1b-468e-8e0c-1d4c4112552c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/identifying-trading-partners-under-the-drug-supply-chain-security-act/bf7b7d12-8a7e-47af-a970-6443dabf401e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/streamlining-the-donor-interview-process-recommendations-for-self-administered-questionnaires-guidance-for-industry/95ab0caf-de0b-424e-aea5-e52dd17d1cbb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-63-vich-gl1-validation-of-analytical-procedures-definition-and-terminology/b4b727c0-7b34-4fa8-922a-70806e086f7e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q4b-annex-5-disintegration-test-general-chapter/47d28fb4-91e4-46f4-94a8-fa4640dfcd88 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/informed-consent-recommendations-for-source-plasma-donors-participating-in-plasmapheresis-and-immunization-programs-guidance-for-industry/d7ebe62f-a512-4294-94c1-821faa558520 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/revised-recommendations-regarding-invalidation-of-test-results-of-licensed-and-510k-cleared-bloodborne-pathogen-assays-used-to-test-donors-guidance-for-industry/0cda0e13-b5d9-4c9c-874d-d7dd38e5de33 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-181-blue-bird-medicated-feed-labels/d2ce9c00-b40e-4add-baa1-692e1149f7fc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-183-animal-drug-user-fees-fees-exceed-costs-waiverreduction/3661d690-1900-46d0-b667-e685213e3d17 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-57-preparation-and-submission-of-veterinary-master-files/bad3bbd6-5ab6-420f-8120-5b7f2a41f542 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/cvm-gfi-195-small-entities-compliance-guide-for-rendererssubstances-prohibited-from-use-in-animal-food-or-feed/eb148907-d7f6-499a-8036-6a7e87b0cfaf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-100-vich-gl18-r2-impurities-residual-solvents-in-new-veterinary-medicinal-products-active-substances-and-excipients-revision-2/c0564c1d-25bb-407e-ac8b-f7bc0de58f8c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/statistical-approaches-to-establishing-bioequivalence/ecbc1c62-e39f-4980-b654-baa7788c2171 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-111-vich-gl19-effectiveness-of-anthelmintics-specific-recommendations-for-canines/c40335a4-0fcc-44de-bfb2-d9420b088dd7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-110-vich-gl16-effectiveness-of-anthelmintics-specific-recommendations-for-porcines/ebde517a-e0df-4a94-afa8-631fb5675ea3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-98-dioxin-in-anti-caking-agents-in-animal-feed-and-feed-ingredients/187c630f-535e-442c-90ed-3e7bd66f71d8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-99-vich-gl17-testing-of-new-biotechnologicalbiological-products/f8abde3f-dcab-4e25-ac8e-bde8728ec8fd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-97-vich-gl14-effectiveness-of-anthelmintics-specific-recommendations-for-caprines/30cbefce-fa87-4d4d-aadd-5fbf9f2d4495 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-96-vich-gl13-effectiveness-of-anthelmintics-specific-recommendations-for-ovines/d4061972-50cb-47aa-93df-e738e355e373 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-3-general-principles-for-evaluating-the-human-food-safety-of-new-animal-drugs-used-in-food-producing-animals/4591bf3d-2cba-401f-9c9a-d99516e803b4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-142-vich-gl29-pharmacovigilance-of-veterinary-medicinal-products-management-of-periodic-summary-update-reports-psus/70412378-9015-4b2c-a35a-736a47368179 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-92-vich-gl10r-impurities-in-new-veterinary-drug-substances/9b1e0fd4-5cd0-40ca-b252-b3c6e3e53a37 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-91-vich-gl8-stability-testing-for-medicated-premixes/1ecd34dd-4f26-4c0d-93ea-50ebebe3b06a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-90-vich-gl7-effectiveness-of-anthelmintics-general-recommendations/bdd01522-5754-4a9b-80be-e769d7a0a6d8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-89-vich-gl6-eias-for-veterinary-medicinal-products-phase-i/bfe16fea-1197-4297-bf4a-28377243ff1e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-135-validation-of-analytical-procedures-for-type-c-medicated-feeds/c2b03161-928c-40e8-bf9e-4a3fbf218f45 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-83-chemistry-manufacturing-and-controls-changes-to-approved-nadaanada/93c6c574-e597-4c4b-a10e-f61c19036d9e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-voluntary-disclosure-of-sesame-as-an-allergen/e1efbca3-a42a-4895-a429-828133dcf75d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-82-development-of-supplemental-applications-for-approved-new-animal-drugs/d7302553-b643-4c3e-a567-6ed05b3a9a0c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-79-dispute-resolution-procedures-for-science-based-decisions-on-products-regulated-by-cvm/d157bda4-3e4f-4670-a1c2-1b7a788831a0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/cvm-gfi-76-questions-and-answers-bse-feed-regulations/5760c249-1af3-473d-809b-c053e1e3810a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-74-vich-gl4-stability-testing-of-new-veterinary-dosage-forms/d5953016-b574-40c1-a966-48bc03da9ddd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-150-concerns-related-to-the-use-of-clove-oil-as-an-anesthetic-for-fish/63f9f5f4-4182-4222-9561-599b806a8caf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-73-vich-gl3r-stability-testing-of-new-veterinary-drug-substances-and-medicinal-products/8fc0cd10-9593-429b-b0da-43022b41d439 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/cvm-gfi-70-small-entities-compliance-guide-for-feeders-of-ruminant-animals-without-on-farm-feed-mixing-operations/aa4b227c-a75f-4122-8672-49c6d4672984 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/cvm-gfi-68-small-entities-compliance-guide-for-protein-blenders-feed-manufacturers-and-distributors/6a856bf1-a9d4-4c97-8459-bd1ea6072165 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postapproval-changes-to-drug-substances-guidance-for-industry/78d470cd-b4c0-45be-b582-1163b9b97017 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/cvm-gfi-67-small-entities-compliance-guide-for-renderers/e3b254f0-928f-4a82-a703-c74cffc0dbe1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-123-development-of-data-supporting-approval-of-nsaids-for-use-in-animals/2fba31c6-6379-465a-99a2-39516024bfdd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-64-vich-gl2-validation-of-analytical-procedures-methodology/11d298b3-90fc-475a-be61-b97fa813f23a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-122-manufacture-and-labeling-of-raw-meat-foods-for-companion-and-captive-noncompanion-carnivores-and-omnivores/d513f440-d56d-4ba6-b88c-144983eff95f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-119-how-cvm-intends-to-handle-deficient-submissions-filed-during-the-investigation-of-a-new-animal-drug/1b8e8657-1290-49ce-9cc3-89d1651ee37b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-61-special-considerations-incentives-and-programs-to-support-the-approval-of-new-animal-drugs-for-minor-uses-and-for-minor-species/7cbf17f7-6c8b-4e68-9f84-7be2176b22f0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-56-protocol-development-guideline-for-clinical-effectiveness-and-target-animal-safety-trials/a782e95a-0f8a-49bd-ab5f-5dd224fff904 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-116-vich-gl23-r2-studies-to-evaluate-the-safety-of-residues-of-veterinary-drugs-in-human-food-genotoxicity-testing-revision-2/fc7c106a-c8b0-441e-a55f-abe2934e7915 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-555450-foods-adulteration-involving-infestation-and-1080-rodenticide/28092786-6ffc-40e1-9187-9ff12a7cb575 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-115-vich-gl22-studies-to-evaluate-the-safety-of-residues-of-veterinary-drugs-in-human-food-reproduction-toxicity-testing-revision-1/d8ab6dff-e03d-4a0c-8b80-38ec453d081b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-extension-and-clarification-of-compliance-dates-for-certain-provisions-of-four-implementing-rules-of-the-fda-food-safety-modernization-act/b6f3f0ac-fed1-4b45-afcb-13ea53b4d1e9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-35-bioequivalence-guidance/5305fcaa-1866-47bc-a5f8-4a9a269847ad 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-113-vich-gl20-effectiveness-of-anthelmintics-specific-recommendations-for-felines/df2377d3-f4a9-41c1-9ecf-ae67e430f8bb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-108-registering-with-cvms-electronic-submission-system/0d7c2793-fe10-4cf0-88bb-79ddbad93779 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-106-the-use-of-published-literature-in-support-of-new-animal-drug-approvals/8b239628-7b08-4fd5-a96c-440f51741fee 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cpg-sec-490100-process-validation-requirements-for-drug-products-and-active-pharmaceutical-ingredients-subject-to-pre-market-approval/b94c2509-66e7-4f39-b0f9-fad032bc48c3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-104-content-and-format-of-effectiveness-and-target-animal-safety-technical-sections-and-final-study-reports-for-submission/5ddd89cc-0ad4-40f9-8b49-7207b27eb13a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-126-bacpac-i-intermediates-in-drug-substance-synthesis-bulk-actives-postapproval-changes-chemistry-manufacturing-and-controls-documentation/b81e8e56-c453-49c6-880d-62c5dc8c17d6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-136-protocols-for-the-conduct-of-method-transfer-studies-for-type-c-medicated-feed-assay-methods/c0f0eaa6-adf0-4347-a20a-2e2af8c1cc44 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-141-vich-gl28-studies-to-evaluate-the-safety-of-residues-of-veterinary-drugs-in-human-food-carcinogenicity-testing/be0a3cd7-ca67-4cf4-b23a-a399acd7dee2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/gastroparesis-clinical-evaluation-of-drugs-for-treatment-guidance-for-industry/4b7bc445-8e11-4ce8-a6d6-3439f06daab5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-143-vich-gl30-pharmacovigilance-of-veterinary-medicinal-products-controlled-list-of-terms/319e39e8-53fc-42fb-8112-db8f1fc13d0c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-144-vich-gl27-pre-approval-information-for-registration-of-new-veterinary-medicinal-products-for-food-producing-animals-with-respect-to-antimicrobial-resistance/a842b044-b78d-4522-bf2b-f161e44ad7b0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-foreign-supplier-verification-programs-for-importers-of-food-for-humans-and-animals/a774e5ce-04b8-4e53-8e90-409b4041ee1d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-147-vich-gl31-studies-to-evaluate-the-safety-of-residues-of-veterinary-drugs-in-human-food-repeat-dose-90-day-toxicity-testing/94547ce7-85c2-4565-97c0-78f2776bac38 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-80-evaluation-the-utility-of-anti-salmonella-chemical-food-additives/f7dc4287-e8ca-4f8d-a188-da9518aaae03 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-148-vich-gl32-studies-to-evaluate-the-safety-of-residues-of-veterinary-drugs-in-human-food-developmental-toxicity-testing/179d449a-5e11-49b3-8311-446f15207c24 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-149-vich-gl33-studies-to-evaluate-the-safety-of-residues-of-veterinary-drugs-in-human-food-general-approach-to-testing/f04ce418-4260-4eb9-9049-603c88b33ae4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-regulatory-framework-for-substances-intended-for-use-in-human-food-or-animal-food-on-the-basis-of-the-generally-recognized-as-safe-gras-provision-of-the-federal-food-drug-and-cosmetic-act/1059256b-1a05-4199-b9f4-b1c04c0cc2fa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-5-drug-stability-guidelines/405e879d-abb8-401b-aff7-3efd49d4acab 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-156-comparability-protocols-chemistry-manufacturing-and-controls-information-for-new-animal-drugs/3b46eda7-635e-4041-aff7-92c21da620bb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-158-use-of-material-from-deer-and-elk-in-animal-feed/bb082cd6-a4ca-47f3-85b0-5fa49b88cada 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-160-vich-gl37-studies-to-evaluate-the-safety-of-residues-of-veterinary-drugs-in-human-food-repeat-dose-chronic-toxicity-testing/9d67fa28-7f44-4e28-86a6-d13200f79e96 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-seafood-haccp-and-the-fda-food-safety-modernization-act/e7ce40b4-e627-4fc0-b56f-8947af3276ed 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/format-and-content-for-the-cmc-section-of-an-annual-report/7fdfa926-06f8-4702-a349-78fa20f388b6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enforcement-policy-for-certain-marketed-tobacco-products-draft-guidance-for-industry/12b958b4-9a40-4285-8318-024bd4612801 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-recognition-of-acceptable-unique-facility-identifier-ufi-for-the-foreign-supplier-verification-programs-regulation/5a36b80d-62d2-49d6-89f9-c6fc510de4c5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-scientific-evaluation-of-the-evidence-on-the-beneficial-physiological-effects-of-isolated-or-synthetic-non-digestible-carbohydrates-submitted-as-a-citizen-petition-21-cfr-1030/e1b9ec05-bb0d-4a32-a3a0-af54f74c17b7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/civil-money-penalties-relating-to-the-clinicaltrialsgov-data-bank-guidance-for-responsible-parties-submitters-of-certain-applications-and-submissions-to-fda-and-fda-staff/0e9dc583-3ef6-4205-9302-de301840b935 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-prior-notice-of-imported-food-contingency-plan-for-system-outages/3f564023-1516-4f3d-8fe6-3e20f0933cd3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-highly-concentrated-caffeine-in-dietary-supplements/c93ff3ad-eb4a-41ca-917a-67758f87980f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-application-of-the-foreign-supplier-verification-program-regulation-to-the-importation-of-live-animals/181464e0-0118-4c5e-99e9-0ab5f3664a71 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/meetings-with-the-office-of-orphan-products-development-guidance-for-industry-researchers-patient-groups-and-food-and-drug-administration-staff/a7eb2116-3f03-46a5-85e2-feb125bfa39a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-in-electronic-format-orphan-drug-and-humanitarian-use-device-designation-requests-and-related-submissions-draft-draft-guidance-for-industry/cac61e0f-25c5-4efc-9f40-f3703a350a46 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-standards-for-the-growing-harvesting-packing-and-holding-of-produce-for-human-consumption/04b9b4b3-e95d-4eee-a3ea-068c4689750b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/testicular-toxicity-evaluation-during-drug-development/04182421-d0d9-46c1-ac57-10b10ca62d0c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-determining-the-number-of-employees-for-purposes-of-the-small-business-definition-in-parts-117-and-507/7f1e04f2-de5b-44f1-b0be-eb482f4f5514 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/opioid-use-disorder-developing-depot-buprenorphine-products-for-treatment/f53ca142-5456-4eec-9cc0-358980e372cd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/postmarketing-safety-reporting-for-combination-products-guidance-for-industry-and-fda-staff/a8271d36-1dc5-4263-81ed-b9326b983403 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-standards-for-the-growing-harvesting-packing-and-holding-of-sprouts-for-human-consumption/925b5473-b453-4f83-819f-3213f19976e7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cytomegalovirus-in-transplantation-developing-drugs-to-treat-or-prevent-disease/070d95a8-6704-4190-b2d6-8b1e6b7a5a2e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-declaration-of-added-sugars-on-honey-maple-syrup-other-single-ingredient-sugars-and-syrups-and-certain-cranberry-products/b56856ad-648e-487f-8e3d-4bc3bf733b4f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-serving-sizes-of-foods-that-can-reasonably-be-consumed-at-one-eating-occasion-dual-column-labeling-updating-modifying-and-establishing-certain-reference-amounts-customarily-consumed-serving-size-for-breath-mints/75f43649-1564-4b87-847c-c10b413c516b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-considerations-for-determining-whether-a-measure-provides-the-same-level-of-public-health-protection-as-the-corresponding-requirement-in-21-cfr-part-112-or-the-preventive-controls-requirements-in-part-117-or-507/685d11e2-d3e8-4e1f-84cf-764560f7bb47 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-application-of-the-foreign-supplier-verification-program-regulation-to-importers-of-grain-raw-agricultural-commodities/dc64d8c3-96f9-488b-bb6f-1b2dbcc7de6e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/tobacco-product-master-files-guidance-for-industry/a5cf400c-2b17-4147-b717-a4c1787d8521 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-policy-regarding-certain-entities-subject-to-the-current-good-manufacturing-practice-and-preventive-controls-produce-safety-andor-foreign-supplier-verification-programs/359de594-e390-46e5-912b-94846497c735 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-246-hazard-analysis-and-risk-based-preventive-controls-for-food-for-animals-supply-chain-program/225a8d48-087b-4d82-95f6-60f59960d3a8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/human-gene-therapy-for-hemophilia-guidance-for-industry/bceafce9-c9f0-4137-9ca5-071464212a06 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-refusal-of-inspection-by-a-foreign-food-establishment-or-foreign-government/4f68c704-9217-4805-b5a9-fc01e4b59952 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-sanitary-transportation-of-human-and-animal-food-what-you-need-to-know-about-the-fda-regulation/13d92d4b-c3d3-408d-83bd-a29f076d4c08 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-a-labeling-guide-for-restaurants-and-retail-establishments-selling-away-from-home-foods-part-ii/3b73b762-51db-4272-97d5-ceab1c524500 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-supply-chain-program-requirements-and-co-manufacturer-supplier-approval-and-verification-for-human-food-and-animal-food/244440d6-2277-4766-9b9f-63f06593dd81 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-standards-for-the-growing-harvesting-packing-and-holding-of-produce-for-human-consumption/07beb73a-19e9-4172-8ac7-7af67ce90c3c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-clarification-on-food-establishment-waiver-from-requirements-of-the-sanitary-transportation-of-human-and-animal-food-rule/dabcc9ed-bbea-4238-98ce-07afd4deacfe 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/requalification-of-donors-previously-deferred-for-a-history-of-viral-hepatitis-after-the-11th-birthday-guidance-for-industry/24540605-9960-4591-9063-9a97daf273cf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-ultrafiltered-milk-in-the-production-of-standardized-cheeses-and-related-cheese-products/472234e1-538a-4259-bf9d-97cb05ef91b0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/demonstrating-the-substantial-equivalence-of-a-new-tobacco-product-responses-to-frequently-asked-questions-revised-guidance-for-industry/ca63d7b0-fa21-46f9-95d7-598412c447c9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-low-acid-foods-packaged-in-hermetically-sealed-containers-lacf-regulation-and-the-fda-food-safety-modernization-act/31a596f6-e571-4f94-a13a-8756a70e8b95 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-juice-haccp-and-the-fda-food-safety-modernization-act/7fc6cdb3-7422-4b12-b315-28132712fbf7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-mitigation-strategies-to-protect-food-against-intentional-adulteration/a49d6b4b-db17-4194-aa47-ea2817a042c7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-compliance-with-providing-an-acceptable-unique-facility-identifier-for-the-foreign-supplier-verification-programs-for-food-importers-regulation/1698894b-b28e-4fd8-a1e2-0bed1c6d8cdf 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/microdose-radiopharmaceutical-diagnostic-drugs-nonclinical-study-recommendations-guidance-for-industry/487ab7a5-87bb-4424-9c4b-4b2f31f320a6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/refuse-to-file-nda-and-bla-submissions-to-cder-guidance-for-industry/9d29f151-eed6-4c49-afde-4bcd7fa65bf7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-food-allergen-labeling-exemption-petitions-and-notifications/6bf56775-0c0d-4f4f-bbce-ee11812f721f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-reference-amounts-customarily-consumed-list-of-products-for-each-product-category/279642b7-a0e5-44c1-97c7-174b5e5a9cd3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/how-to-prepare-a-pre-request-for-designation-pre-rfd-guidance-for-industry/cc79c332-6e12-4bdf-8c0a-a8993430308a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/prohibition-of-distributing-free-samples-of-tobacco-products-guidance-for-industry/f4b010da-e178-4179-a7c3-b4e2981e320c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/interpretation-of-and-compliance-policy-for-certain-label-requirement-applicability-of-certain-federal-food-drug-and-cosmetic-act-requirements-to-vape-shops-guidance-for-industry/48a6c16c-087f-4f62-857e-8542d107a7ae 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-best-practices-for-convening-a-gras-panel/36f92b90-91bc-4dae-89ce-c6e1df1bad42 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-considerations-regarding-substances-added-to-foods-including-beverages-and-dietary-supplements/dea1f9c8-682b-4f0e-9660-252c7dc396e3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-what-you-need-to-know-about-current-good-manufacturing-practice-hazard-analysis-and-risk-based-preventive-controls-for-human-food/8eab9a27-0ea8-4e69-9afe-c456a698ae7a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/e2cr2-periodic-benefit-risk-evaluation-report-questions-and-answers/9735c0c5-468e-4e9b-a4c9-a7bad1eb9d94 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-preparation-of-food-contact-notifications-for-food-contact-substances-in-contact-with-infant-formula-andor-human-milk/3b8ccd5c-b098-4340-b371-47555e80e443 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/assessing-adhesion-with-transdermal-and-topical-delivery-systems-for-andas-draft-guidance-for-industry/2987a560-17ed-4e62-b674-1c17e17f5298 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-describing-a-hazard-that-needs-control-in-documents-accompanying-the-food-as-required-by-four-rules-implementing-fsma/5f2fe0c2-1bd3-4569-99e2-59523a73515a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/special-protocol-assessment-guidance-for-industry/2565ab98-6128-47ba-b033-f84934855d60 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-classification-of-activities-as-harvesting-packing-holding-or-manufacturingprocessing-for-farms-and-facilities/9fd0715e-03d5-438e-ab26-a821182dd667 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/program/nepa-final-guidance/d6eae006-feeb-4131-8ca6-30f5d3291446 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/institutional-review-board-irb-written-procedures-guidance-for-institutions-and-irbs/064df3a6-12f1-4790-b540-5750ce3b8107 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-hazard-analysis-and-risk-based-preventive-controls-for-human-food/5fd68db1-ed0f-475c-b909-1096823b9420 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/gifts-to-fda-evaluation-and-acceptance-guidance-for-the-public-and-fda-staff/d6ee96a7-7a73-4a85-b433-866db04c35ac 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-calorie-labeling-of-articles-of-food-in-vending-machines/251ecb4b-837a-4f88-a7a0-2eac8d73ad6c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-calorie-labeling-of-articles-of-food-in-vending-machines/d911622b-8a5a-49a5-8c28-d059ca18c7bc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-substantiation-for-structurefunction-claims-made-in-infant-formula-labels-and-labeling/1047f88e-5834-4f74-b931-62bfe623d843 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/fda-deems-certain-tobacco-products-subject-to-fda-authority-sales-and-distribution-restrictions-and-health-warning-requirements-for-packages-and-advertisements-guidance-for-industry/a2f3677d-e0c6-43c6-b7df-a698233927ae 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/premarket-tobacco-product-applications-for-electronic-nicotine-delivery-systems-ends-guidance-for-industry/9f728f85-21da-4d36-a8c7-aa6288755a2e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-voluntary-sodium-reduction-goals-target-mean-and-upper-bound-concentrations-for-sodium-in-commercially-processed-packaged-and-prepared-foods/22515ce7-0408-494e-b49e-da075f39b85b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-alpha-linolenic-acid-eicosapentaenoic-acid-and-docosahexaenoic-acid-omega-3-fatty-acids-nutrient-content-claims/3914d483-0832-404e-9331-f1ce1e57ca46 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-action-level-for-inorganic-arsenic-in-rice-cereals-for-infants/7d825f8c-7e76-482a-9b00-654ecd2bffeb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/minutes-of-institutional-review-board-irb-meetings-guidance-for-institutions-and-irbs/4b56f900-1718-406d-8e07-7ef1b122f0f3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-submitting-forms-for-food-canning-establishment-registration-and-food-process-filing-to-fda-in-electronic-or-paper-format/3bd65a00-b449-408a-8362-bf36330c31ec 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-questions-and-answers-on-fdas-fortification-policy/d91c8ecf-730e-4a56-b3fc-3d4b22c9c1e5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-voluntary-labeling-indicating-whether-food-has-or-has-not-been-derived-from-genetically-engineered-atlantic-salmon/08c76892-cf4a-4b9e-b195-7964e95bd743 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/use-of-investigational-tobacco-products-draft-guidance-for-industry-and-investigators/73d43a3c-66bd-494f-9d5e-275ab9cb4ed6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-and-fda-staff-model-accreditation-standards-for-third-party-certification-body-accreditation-for-food-safety-audits/755b020a-6f45-4b98-a422-7c54a7156e69 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/modified-risk-tobacco-product-applications-draft-guidance-for-industry/df69ce54-7478-4c7e-9c86-b9adc4722478 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/civil-money-penalties-and-no-tobacco-sale-orders-for-tobacco-retailers-revised-guidance-for-industry/b9429af4-6e07-4717-a63d-80d08bf4af75 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/determination-of-the-period-covered-by-a-no-tobacco-sale-order-and-compliance-with-an-order-guidance-for-tobacco-retailers/f1cb2ea3-3f86-4860-a3e2-1a2b0420996d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-and-fda-staff-questions-and-answers-regarding-mandatory-food-recalls/13481b4a-408a-408e-a752-397a816d17ea 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/establishing-that-a-tobacco-product-was-commercially-marketed-in-the-united-states-as-of-february-15-2007-revised-guidance-for-industry/0ef82b66-b714-484c-96d0-3986f85238a8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/informed-consent-guidance-for-irbs-clinical-investigators-and-sponsors/282489cf-c0a6-44c7-acff-58b3373fd179 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/live-case-presentations-during-investigational-device-exemption-ide-clinical-trials-guidance-for-institutional-review-boards-industry-clinical-investigators-and-food-and-drug-administration-staff/4c3659fc-d668-4bdf-ad3c-6eae3e5cb9ff 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/rare-pediatric-disease-priority-review-vouchers-draft-guidance-for-industry/c961e6ec-0020-4d39-9efc-529439e82e7e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/considering-whether-an-fda-regulated-product-involves-the-application-of-nanotechnology-guidance-for-industry/bdd390a3-d77a-4962-bb49-7d12b6eb2bce 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/surveying-leveling-and-alignment-laser-products-guidance-for-industry-and-food-and-drug-administration-staff/324fece2-b301-4f29-816e-36fcc0cec011 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-evaluation-of-endocrine-related-drug-toxicity/3925c81a-41d1-4ab8-a0da-0aec3f634c05 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-exempt-infant-formula-production/d3576928-6af1-4b2e-aa67-51e933bb0a52 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/enforcement-policy-for-certain-provisional-tobacco-products-that-fda-finds-not-substantially-equivalent-guidance-for-industry-and-tobacco-retailers/d5cec392-5fbe-45a8-bb91-683e01bf1d9b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-establishing-and-maintaining-a-list-of-us-milk-and-milk-product-seafood-infant-formula-and-formula-for-young-children-manufacturersprocessors-with-interest-in-exporting-to-china/7241119c-3450-4d37-b080-e365b571a9f0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/supac-manufacturing-equipment-addendum/a362d5e9-2422-4c5a-bb5b-e13556f3eaa2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-390100-definition-of-commerce-21-cfr-10003d-2/87f68cc6-7a28-40c7-93fe-704539519534 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-distinguishing-liquid-dietary-supplements-from-beverages/7a29fdc7-ce03-46be-a2b4-d0ef853afe4d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/regulatory-requirements-for-hearing-aid-devices-and-personal-sound-amplification-products-guidance-for-industry-and-food-and-drug-administration-staff/2b7de2e1-3d66-44ef-9d00-0966a1342ad1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-acrylamide-in-foods/e5b192f4-4b89-487f-beb4-da30e55f23a4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/glass-syringes-for-delivering-drug-and-biological-products-technical-information-to-supplement-international-organization-for-standardization-iso-standard-11040-4-draft-guidance-for-industry-and-fda-staff/06b5cbc1-04b4-49e0-bfa3-e384112aad06 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/combined-food-and-drug-administration-and-sponsor-oncologic-drugs-advisory-committee-briefing-document/acf14472-e5b8-47ba-a5bd-76d6bae8bd27 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pyrogen-and-endotoxins-testing-questions-and-answers/516412d4-f8e5-4f44-9ad9-64ecc7a52326 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-proper-labeling-of-honey-and-honey-products/e8e71a15-2a16-4a8d-8bfe-f96f9585162b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pulse-oximeters-premarket-notification-submissions-510ks-guidance-for-industry-and-food-and-drug-administration-staff/be0145bd-7ce8-475d-a092-cc4cf7fef3f0 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-questions-and-answers-regarding-food-facility-registration-seventh-edition/ec4232b3-bcd5-4398-9def-e5f1891f6511 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/small-entity-compliance-guide-establishing-an-allowable-level-for-di-2-ethylhexylphthalate-in-bottled-water/ff5388a3-eae7-4dec-9a28-a16d8a230ad2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-acute-bacterial-sinusitis-developing-drugs-for-treatment/7da00031-ea5b-4089-9e6f-f3d05d4121bd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-acute-bacterial-otitis-media-developing-drugs-for-treatment/9ac0e00e-ecae-4bd4-b721-1cb22881e2cb 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-necessity-of-the-use-of-food-product-categories-in-food-facility-registrations-and-updates-to-food-product-categories-2016-edition/e7840310-54e6-493d-826f-f642b2b910b8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/size-of-beads-in-drug-products-labeled-for-sprinkle-rev1-guidance-for-industry/e91280a2-a51b-4821-8bdc-f85a7743af01 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-assessing-the-effects-of-significant-manufacturing-process-changes-including-emerging-technologies-on-the-safety-and-regulatory-status-of-food-ingredients-and-food-contact-substances-including-food-ingredients-that-are-color-additives/826bd2b8-54bd-4366-9795-e0f9fc361569 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-testing-for-salmonella-species-in-human-foods-and-direct-human-contact-animal-foods/8e6ed641-d6ff-4a6e-b9c7-4934933f38a8 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-questions-and-answers-regarding-establishment-and-maintenance-of-records-by-persons-who-manufacture-process-pack-transport-distribute-receive-hold-or-import-food-edition-5/186ce42e-6766-4a46-b3ee-8bf2062745b7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-fda-records-access-authority-under-sections-414-and-704-of-the-federal-food-drug-cosmetic-act/985fd89f-3e79-4e8a-8b48-a727d2758e47 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/medication-guides-adding-a-toll-free-number-for-reporting-adverse-events/55bf6f85-07ac-436b-bb1a-804570352668 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submission-of-warning-plans-for-cigarettes-and-smokeless-tobacco-products-draft-guidance-for-industry/75bffede-ae53-4d67-a3e9-a4d05d1dac96 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/draft-guidance-for-industry-new-dietary-ingredient-notifications-and-related-issues/8b64ce86-61fd-4886-9c38-f1bd929022f6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/harmful-and-potentially-harmful-constituents-in-tobacco-products-as-used-in-section-904e-of-the-federal-food-drug-and-cosmetic-act-guidance-for-industry-and-fda-staff/ab952930-b5d8-425d-8255-006e5cc27f68 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/premarket-approval-application-and-humanitarian-device-exemption-modular-review-guidance-for-industry-and-fda-staff/101d4214-dbce-4b60-b778-d03444e69316 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/useful-written-consumer-medication-information-cmi/f8bbda8e-e6e7-4551-8991-096c13ba9c6c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-microbiological-considerations-for-antimicrobial-agents-used-in-food-applications/eb7ce8b5-11af-4d25-b8f0-48a594c3b011 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/tropical-disease-priority-review-vouchers/5a29b7d1-5c71-4f17-b7d0-4c04b9df5ed1 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/tobacco-health-document-submission-revised-guidance-for-industry/f7052ba8-ca6d-4d93-ae55-6ac247ee3546 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pdes-for-triethylamine-and-for-methylisobutylketone/c3d4c7db-7f2f-4f5c-a410-e930c81766c9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-scope-of-the-prohibition-against-marketing-a-tobacco-product-in-combination-with-another-article-or-product-regulated-under-the-federal-food-drug-and-cosmetic-act-draft-guidance-for-manufacturers-retailers-importers-and-fda-staff/2231f427-b610-4246-8ca7-a5be42f0053d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/national-uniformity-for-nonpresciption-drugs-ingredient-listing-for-otc-drugs/9d832005-d340-46af-95c2-1e3fa3b3ab8b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-580100-food-storage-and-warehousing-adulteration-filth-domestic-and-import/80b921b9-d4fe-465e-abf7-0e5a05a8e833 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-570500-aflatoxins-in-pistachio-nuts/eddde45b-4853-4eee-a8fe-dd92e008e831 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/s6-preclinical-safety-evaluation-of-biotechnology-derived-pharmaceuticals/b4092e3c-509e-4d7e-9f1c-4d7274985cc7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/non-clinical-information-for-femoral-stem-prostheses-guidance-for-industry-and-fda-staff/b39c20b9-4453-4880-847a-c355c99e6160 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-570350-peanuts-shelled-and-unshelled-adulteration-with-filth-and-reject-nuts/e2bf2e89-60c5-4454-af89-69f9f7d8695e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-527100-butter-adulteration-involving-insufficient-fat-content/0a49a400-16cc-4777-b3bc-450bef9220ca 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/listing-of-ingredients-in-tobacco-products-guidance-for-industry/c4d8bccc-555b-490c-8ca1-f36b0fd5d4b2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585900-tomato-products-adulteration-with-mold/06e1ded6-2425-4e81-8c57-5dd80ebfb459 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-525375-whole-ginger-adulteration-with-insect-filth-mold-mammalian-excreta/1f9bef54-dbad-410c-b73e-04bcc17811d5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q8-q9-and-q10-questions-and-answers/143dddaa-3858-4f11-a750-8ff7806e5dcd 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-585150-asparagus-canned-or-frozen-adulteration-with-insect-filth/e16b291f-ef0d-4abf-b6ed-860d011a1b47 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/q1c-stability-testing-for-new-dosage-forms/460409ad-4511-4ee7-b945-5c24194cbe0c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-300500-reprocessing-of-single-use-devices/28181350-237f-452b-8357-1ba22d523014 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/metal-expandable-biliary-stents-premarket-notification-510k-submissions-guidance-for-industry-and-food-and-drug-administration-staff/f2e2118b-f14f-4d6e-a1e0-477e6c113acc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/the-abbreviated-510k-program-guidance-for-industry-and-food-and-drug-administration-staff/8b6c9460-8612-4c4d-9a8a-305c9b7540b9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/determination-of-intended-use-for-510k-devices-guidance-for-cdrh-staff-update-to-k98-1/5bf830b5-ab1f-45b6-ba8f-b8c4628d709d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/rems-document-technical-conformance-guide/34e140c1-4889-43f1-ac2c-9da4138b615d 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/procedures-for-renewal-and-amendment-of-certain-laser-light-show-variances-laser-notice-55/32aa4267-eba5-4b26-988e-f15adc380930 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/radiation-safety-considerations-for-x-ray-equipment-designed-for-hand-held-use/90e80c37-cd3e-42a7-9264-212a86e37af2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-over-the-counter-otc-human-chorionic-gonadotropin-hcg-510ks-guidance-for-industry-and-fda-reviewersstaff/ea717772-1510-4c48-82e6-81e153b5f603 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/commercially-distributed-analyte-specific-reagents-asrs-frequently-asked-questions-guidance-for-industry-and-fda-staff/37944373-0a83-4fc7-9961-694d5581f5ea 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/prescription-drug-marketing-act-donation-of-prescription-drug-samples-to-free-clinics/703c91fa-8616-445a-8a1e-5ad08e94d3f4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/reviewers-guidance-checklist-for-orthopedic-external-fixation-devices-version-5/3a981763-0742-4791-9d38-5c25b07acd3f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-document-for-testing-orthopedic-implants-with-modified-metallic-surfaces-apposing-bone-or-bone-cement/cd87e0b3-b8d0-49e8-9177-1f26d322488a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/information-for-keratome-manufacturers-regarding-lasik-final-guidance-for-industry/e5b189cc-d972-4a93-8dc5-b39ad36a40e3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-preparation-of-food-contact-substance-notifications-toxicology-recommendations/bd2c6e57-6c26-426a-a890-5742750b7b33 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pet-drug-products-current-good-manufacturing-practice-cgmp/23c6bcb5-9ee0-43d5-8d11-19c962b97eb5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-on-the-content-and-organization-of-a-premarket-notification-for-a-medical-laser/4a66f2cb-239a-46ae-b702-c0c4c53ce6fc 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-preparation-of-food-contact-substance-notifications-administrative/7af89891-2acd-4858-ad0d-45699a0e7e18 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/slit-lamp-guidance-guidance-for-industry/f2197301-1c14-4b32-930c-c953cd55131c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/uniform-contraceptive-labeling-guidance-for-industry/86f0292a-d41b-478b-97a5-b201b271e67e 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-document-for-the-preparation-of-premarket-notification-510k-applications-for-mechanical-and-powered-wheelchairs-and-motorized-three-wheeled-vehicles/aee97122-abcf-459c-b155-ff5d597bb820 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/revised-procedures-for-adding-lens-finishing-laboratories-to-approved-premarket-approval-applications-for-class-iii-rigid-gas-permeable-contact-lenses-for-extended-wear-guidance-for-industry-and-fda-staff/4f981a97-3a70-49c3-a49a-7658408b4291 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/pediatric-expertise-for-advisory-panels-guidance-for-industry-and-fda-staff/64e434d8-3d9c-45cc-ae8a-11155709b0a9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-document-for-the-preparation-of-premarket-notification-510k-applications-for-heating-and-cooling-devices/0e6cd838-ebdc-46a1-9353-767d2f7702f3 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/biological-product-deviation-reporting-for-blood-and-plasma-establishments-guidance-for-industry/6c58653c-8367-4da8-9b28-4e92356ee9c7 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/changes-or-modifications-during-the-conduct-of-a-clinical-investigation-final-guidance-for-industry-and-cdrh-staff/5b7509ef-77c6-44d7-95e0-64a535377ae9 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-document-for-the-preparation-of-premarket-notification-510k-applications-for-exercise-equipment/f521588c-4862-46f0-bd2b-76328358be86 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-and-fda-establishing-and-maintaining-a-list-of-us-dairy-product-manufacturersprocessors-with-interest-in-exporting-to-chile/9feda04f-0032-4000-9113-f778b05e0b7f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-prior-notice-of-imported-food-questions-and-answers-edition-4/414092aa-2312-42f0-8c11-f23e0b4bd39c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-document-for-the-preparation-of-premarket-notification-for-ceramic-ball-hip-systems/17ae91a7-3d49-49e7-a9e8-976f23f368f4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance/critical-path-innovation-meetings/ee45485e-83c8-41f9-a2ca-d085119c7179 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-540525-scombrotoxin-histamine-forming-fish-and-fishery-products-decomposition-and-histamine-cpg-710824/f76b6e00-a37c-4aeb-80ac-60d4d55f90aa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/advanced-manufacturing-technologies-designation-program/e585c7bf-51f3-465f-a829-2981682ae1a4 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-665300-use-of-type-a-medicated-article-proprietary-names-in-the-names-of-medicated-feeds/11240fe5-1c72-489f-bad2-8a132d1ee759 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-sec-651100-ethylenediamine-dihydroiodide-eddi/fa820bd9-fb6c-4fcf-bd11-0a39e94ae344 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-document-for-powered-suction-pump-510ks-guidance-for-industry-and-fda-reviewersstaff/303165bb-ef2b-4616-b960-cba6d0963b01 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-document-for-nonprescription-sunglasses-guidance-for-industry/28ead139-126c-49c6-9f8a-477ae40a1a0a 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/noise-claims-in-hearing-aid-labeling-guidance-for-industry/b7655856-38a7-4590-882f-e15a85ff8c1c 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/compliance-policy-guide-cpg/cpg-section-110800-post-detention-sampling-guidance-for-industry/fdca87c0-4986-42fe-b753-86608cd9b75f 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/submission-of-warning-plans-for-cigars-guidance-for-industry/d43f70cb-3f07-4445-99be-ad8d730c4a02 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-menu-labeling-supplemental-guidance/c3f9b658-f413-4937-b214-faa1c0fbb690 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-labeling-of-infant-formula/ed9336ef-868d-45b1-9238-506698156661 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/small-entity-compliance-guide/small-entity-compliance-guide-gluten-free-labeling-of-foods/1da78022-f103-47b9-9231-92b8451760aa 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-guidelines-for-evaluation-of-hysteroscopic-sterilization-devices/3f079303-f5ce-440c-bbc5-3421722a5563 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-document-for-testing-non-articulating-mechanically-locked-modular-implant-components/5c304757-5bd1-4487-9c2a-9b348dad9556 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/blood-establishment-computer-system-validation-in-the-users-facility-guidance-for-industry/0d458283-d7d4-4dbf-b665-009d53641a92 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-and-food-and-drug-administration-staff-assemblers-guide-to-diagnostic-x-ray-equipment/c579c0cd-7c2c-468c-863f-e3fb87583ca6 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/collection-of-race-and-ethnicity-data-in-clinical-trials-guidance-for-industry-and-food-and-drug-administration-staff/a71158cb-a49f-4de9-8a2f-48f8df76abe5 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/process-to-request-a-review-of-fdas-decision-not-to-issue-certain-export-certificates-for-devices-guidance-for-industry-and-food-and-drug-administration-staff/491e3ac2-292e-440a-bace-69cf6847ae95 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/minimizing-risk-for-childrens-toy-laser-products-guidance-for-industry-and-food-and-drug-administration-staff/6373b533-1574-4697-a792-a773996abeed 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-117-vich-gl24-management-of-adverse-event-reports-aers/85cb1a62-a46b-4390-a406-c37214267d87 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/surveillance-and-detention-without-physical-examination-of-surgeons-andor-patient-examination-gloves-guidance-for-industry-and-fda-staff/85c848e7-d9db-4b6b-b4e2-bff601e35d9b 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/cvm-gfi-72-gmps-for-medicated-feed-manufacturers-not-required-to-register-and-be-licensed-with-fda/75587c5a-83bd-48d8-bcee-aa60829ef7c2 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/guidance-for-industry-fdas-voluntary-qualified-importer-program/68fe9b6b-2b76-40df-9574-e2c8c0a60c52 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/public-availability-of-advisory-committee-members-financial-interest-information-and-waivers-guidance-for-the-public-fda-advisory-committee-members-and-fda-staff/88d3e93e-8c53-4bbb-a7f5-e8ffb0e2a655 2025-12-15 monthly 0.7 https://www.globalkeysolutions.net/guidances/guidance-document/development-of-non-opioid-analgesics-for-chronic-pain-draft-guidance-for-industry/38dd6b2d-d805-429f-bd38-3ebf08581d86 2025-12-15 monthly 0.7